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Neuroblastoma is a highly metastatic and invasive tumour with poor 
prognosis. Despite recent advances in the treatment of neuroblastoma, 
mortality is still high due to uncontrolled metastatic disease, and novel 
therapeutic approaches for the treatment of neuroblastoma are therefore 
desperately needed.  
A potential novel approach for therapy of neuroblastoma relates to the 
polysialic acid decoration of the neural cell adhesion molecule (PSA-
NCAM). PSA-NCAM is selectively re-expressed in a number of tumours 
including neuroblastoma, where it is thought to modulate tumour 
dissemination. Expression is strongly associated with poor clinical 
prognosis and an aggressive tumour phenotype. Inhibition of the 
enzymes responsible for synthesis of PSA, the polysialyltransferases 
(polySTs) presents a novel and selective therapeutic opportunity. 
The aims of the studies described in this thesis are to evaluate PSA-
NCAM expression and function in neuroblastoma, and to develop and 
utilise cell-based models to pharmacologically investigate novel polyST 
inhibitors. 
PSA-NCAM was seen to be highly expressed in neuroblastoma clinical 
specimens and associated with phenotypes of tumour aggressiveness. A 
screening panel consisting of cell lines with a range of PSA-NCAM 
expression types was established and utilised to develop assays for 
pharmacologically assessing novel polyST inhibitors. Using cytidine 
monophosphate (CMP), a naturally-occurring inhibitor of polySTs, the 
robustness of the assays was confirmed before progression to evaluate 
novel molecules. From 16 compounds identified in an in vitro screen of 
polyST inhibition, three promising polyST inhibitors were identified. 
These promising polyST inhibitors modulated PSA-NCAM expression on 
the tumour cell surface and led to a significant reduction in cell migration. 
Therefore the work presented in this thesis suggests that targeting 
polySTs is a promising novel therapeutic strategy for neuroblastoma and 
further research in this area is warranted. 
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1. Introduction 
1.1. Overview of cancer 
1.1.1. What is cancer? 
Cancer is a term that describes a group of diseases where there is 
abnormal and uncontrolled growth of cells caused by disruption in the 
normal controlling mechanisms that govern the balance between cell 
division, cell death and cell differentiation [1]. This abnormal growth or 
mass of tissue is called a tumour (or neoplasm). Tumours can be either 
benign or malignant. Benign tumours are non-cancerous, rarely 
dangerous and grow locally. In contrast, malignant tumours are life-
threatening and have the potential to invade locally, spread regionally 
and metastasize to distant sites in the body [2]. In terms of tissue origin, 
cancers are pathologically classified into several types. Carcinomas arise 
from the epithelial cells of organs such as the lungs, breast and colon. 
Sarcomas originate from connective or supportive tissue cells such as 
bone, cartilage and muscles. Leukaemias develop from blood forming 
tissues such as bone marrow. Lymphomas develop from cells of the 
immune system [3].   
1.1.2. The hallmarks of cancer       
Cancer arises from a multistage process in which cells undergo several 
genetic alterations enabling them to grow uncontrollably, invade locally 
and metastasize to other sites. As a tumour develops from small benign 
lesions to highly malignant and metastatic cancers, cells composing 
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these tumours acquire new features that differentiate them from normal 
cells. Hanahan and Weinberg proposed six crucial alterations, known as 
the “Hallmarks of cancer”: self-sufficiency in growth signals, insensitivity 
to growth-inhibitory (anti-growth) signals, evasion of programmed cell 
death (apoptosis), limitless replicative potential, neoangiogenesis and 
finally tissue invasion and metastasis (Figure 1.1) [4]. A decade on from 
this and a further two hallmarks are emerging; de-regulation of cellular 
metabolism and evasion of immune destruction though these are not yet 
generalized and validated in all cancers. Furthermore, two enabling 
characteristics have also been added; instability and mutability of 
genome as well as tumour-promoting inflammation. These enabling 
characteristics are essential for tumours to acquire the original set of 
hallmarks [5]. 
 
Figure 1.1. Hallmarks of cancer. Adapted from [5]. 
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1.1.3. Cancer mortality statistics  
Cancer is one of the main causes of death worldwide. According to the 
International Agency for Research on Cancer (IARC), the latest statistics 
available for 2008 show that 12.7 million new cancer cases and 7.6 
million cancer deaths were reported worldwide [6]. Furthermore, it is 
estimated that by 2030 there will be 20 million cases of cancer and 12.9 
million deaths from cancer. In Europe, there were an estimated 1.8 
million deaths from cancer and approximately 3.4 million new cancer 
cases [7]. In the United Kingdom, the most recent figures date back to 
2008 for cancer incidence and 2009 for cancer mortality and show that 
408,381 new cancer cases and 156,090 cancer deaths were reported [8]. 
In the United States, cancer is the second leading cause of death after 
heart disease. The estimated number of new cancer cases was about 
1.44 million, with 565,650 deaths from cancer in 2008 [6]. 
The main cause of cancer mortality is complications associated with 
metastatic disease. The vast majority of cancer patients have advanced 
stage of disease at the first diagnosis and approximately 90% die from 
uncontrolled metastasis. In this context, the metastatic process and the 
available therapeutic options for the treatment of metastatic disease will 
now be discussed. 
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1.1.4. Metastasis 
For the tumour to progress and grow at sites away from the primary site 
the final hallmark of cancer, invasion and metastasis is required [5]. 
Cancer cells acquire molecular and cellular changes enabling them to 
detach from the primary tumour and travel and spread via the circulation 
to reach distant sites where they seed and grow to form secondary 
tumours. These changes include alterations in cellular shape, cell-cell 
adhesion, cell-extracellular matrix (ECM) interactions and proteolysis. 
Cancer cells gain these alterations by undergoing a de-differentiation 
process called epithelial-mesenchymal transition (EMT). In this process, 
non-malignant epithelial cancer cells are transformed into malignant 
fibroblast-like cancer cells (mesenchymal). This phenotypic change 
enables the cancer cells to migrate, invade and resist apoptosis [5].  
The process of metastasis follows a series of sequential rate-limiting 
steps that start when individual cancer cells detach from the primary 
mass and invade the surrounding healthy tissues (Figure 1.2) [9]. At this 
stage, cancer cells detach from each other through the suppression of 
homotypic cell-cell adhesion (E-cadherin adhesion molecule), followed 
by attachment to stromal cells and ECM structural components through 
up-regulation of other adhesion molecules (N-cadherin, integrins and 
immunoglobulins) [10]. During this attachment, cells degrade the ECM 
and basement membrane surrounding blood vessels by the production of 
several lytic enzymes such as matrix metalloproteinases (MMPs)  
resulting in pathways that facilitate cancer cell migration [5, 9, 11]. 
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Following the invasion and migration of cancer cells through the ECM 
and basement membrane, cancer cells attach to the endothelial cell 
layers of either blood or lymph vessels and penetrate the vessel wall by 
degrading it with proteolytic enzymes, a process called intravasation. 
Once cancer cells enter the circulation they often aggregate with 
platelets and leukocytes and travel via blood vessels to distant sites. 
Once cells reach a target organ, their progress is halted in the narrow 
capillaries of the organ where they either embolise or directly attach to 
the endothelium of the blood vessel through expression of adhesion 
molecules such as integrins and selectins. Cells then penetrate the 
endothelium and basement membrane and then the tissue parenchyma 
[9, 10]. Cancer cells then migrate to a nearby site where they may form 
micrometastases. These micrometastases may remain dormant until the 
stimulation of angiogenesis. After the initiation of blood vessels, which 
provides nutrients and growth promoting cytokines a rapid vigorous 
growth of the cells can occur with further subsequent dissemination in 
many cases [5, 10, 11]. 
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Figure 1.2. Basic steps in the metastatic cascade. Epithelial cells are transformed to 
carcinoma in situ. Cancer cells detach from each other, degrade the basement 
membrane, migrate and invade the surrounding tissues. Cells intravasate into blood 
and lymph vessels where they travel in the circulation to distant sites. Once arrested in 
the capillary, they extravasate through the vessel wall and migrate to nearby tissue 
where they may form micrometastases. Adapted from [9]. 
Whenever metastatic disease occurs the disseminating cancer cells from 
the primary mass remain the main reason for increasing cancer morbidity 
and mortality. This is due to uncontrolled metastasis that restricts the 
normal organ function and therefore causes death. 
Treatment of metastatic disease remains difficult and represents a major 
challenge for health care systems. Cancer therapy relies on three 
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treatment modalities; surgery, radiotherapy and chemotherapy. Once 
cancer has disseminated from the primary tumour, chemotherapy is the 
most widely used treatment modality as localised therapies (surgery and 
radiation) are often no longer effective. Despite major advances in the 
efficacy of chemotherapeutic agents many cancers are difficult to treat 
and remain incurable because of uncontrolled metastasis. Moreover, the 
lack of selectivity and resistance to chemotherapeutic agents remains an 
important issue [12, 13].  
In the last decade, important progress has been made in understanding 
the concepts and molecular mechanisms underlying the metastatic 
process. This has shifted the emphasis of anticancer drug development 
from anti-proliferative treatment to more targeted therapies for controlling 
metastasis, leading to the discovery of new targets and development of 
new strategies to curb metastasis. Emerging anti-metastatic therapies 
include anti-vascular agents and MMP inhibitors. These anti-metastatic 
therapies are extensively focused on inhibiting angiogenesis and 
production of MMPs in tumours. Although these emerging anti-metastatic 
therapies have shown some promise in combating metastasis they are 
mainly tumour-type specific. Therefore more novel targeted strategies 
are needed and essential to limit or disrupt specifically molecular 
mechanisms underlying the metastatic dissemination of other tumour 
types [12].  
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1.2. Neuroblastoma 
The focus of this thesis is the disease, neuroblastoma, a childhood 
cancer where uncontrolled metastasis is the major cause of death. 
Neuroblastoma is an embryonic, extracranial solid tumour and is the 
second most common paediatric tumour accounting for 10% of paediatric 
tumours and for 15% of childhood fatalities [14]. In the UK, about 100 
new neuroblastoma cases are diagnosed every year [8], and about 650 
children are newly diagnosed in the USA every year [15].  
Neuroblastoma is derived from neural crest cells of the sympathetic 
nervous system [13, 14], with most primary tumours arising in the 
abdomen, where the adrenal gland is the most common site. Other 
primary locations include the neck, chest and pelvis (Figure 1.3) [16]. 
Common metastatic sites are the lymph nodes, bone marrow, bones, 
liver, skin and the testes in males [17].                  
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Figure 1.3. Location of neuroblastoma primary tumours. Neuroblastoma primary 
tumours arise in the neck, chest, abdomen, and pelvis (black objects). Adapted from 
[18].  
1.2.1. Pathology 
Neuroblastoma originates from multipotent progenitor cells. The 
appearance and aggressiveness of the tumour can depend upon the 
differentiation of the cells into neuroblastic, ganglionic and Schwann cells 
[14].  
On the basis of histopathological features and grade of cellular 
differentiation within the tumour, neuroblastic tumours are classified into 
neuroblastoma, ganglioneuroblastoma and ganglioneuroma [14]. 
Neuroblastoma shows poor differentiation with abundant neuroblasts 
while ganglioneuromas are fully differentiated benign tumours with a 
dense stroma around mature ganglion cells. Ganglioneuroblastomas are 
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partially differentiated tumours having intermixed characteristics of both 
neuroblastoma and ganglioneuromas [13]. In order to predict the clinical 
behaviour and prognosis of neuroblastomas, the International 
Neuroblastoma Pathology Classification (INPC) has classified peripheral 
neuroblastic tumours according to their histopathological features. This 
classification has been developed by incorporating age-dependent 
histopathological features of neuroblastomas such as degree of 
neuroblastic differentiation, Schwannian stromal content and Mitosis-
Karyorrhexis Index (MKI) (Table 1.1) [14, 19]. In terms of disease 
diagnosis and staging, the International Neuroblastoma Staging System 
(INSS) has been established. This system assesses the tumour stage 
and the pattern of the tumour spread in order to predict tumour prognosis 
and treatment outcomes (Table 1.2) [13]. 
Table 1.1. International Neuroblastoma Pathology Classification (INPC). Adapted 
from [20]. 
Tumour type/ 
Subtypes by age 
Histology/MKI Prognostic group 
Neuroblastoma (Stroma-poor)  
<18 months 
Poorly differentiated or differentiating and       
low  or intermediate MKI 
Favourable 
Undifferentiated tumour or high MKI Unfavourable 
>18 months 
Differentiating tumour and low MKI Favourable 
Undifferentiated/ Poorly differentiated tumour    
or intermediate/high MKI 
Unfavourable 
>5 Years All tumours Unfavourable 
Ganglioneuroblastoma 
Intermixed tumour (stroma-rich) Favourable 
Nodular (composite stroma-rich/stroma-
dominant and stroma-poor) 
Unfavourable 
Ganglioneuroma 
Maturing, well differentiated (stroma-
dominant) 
Favourable 
Mature Favourable 
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Table 1.2. International Neuroblastoma Staging System (INSS). Adapted from [20].  
Stage 1 
Localised tumour with complete gross excision, with or without 
microscopic residual disease; representative ipsilateral lymph nodes 
negative for tumour microscopically (nodes attached to and removed with 
the primary tumour may be positive). 
Stage 2A 
Localised tumour with incomplete gross excision; representative ipsilateral 
non adherent lymph nodes negative for tumour Microscopically. 
Stage 2B 
Localised tumour with or without complete gross excision, with ipsilateral 
non adherent lymph nodes positive for tumour. Enlarged contralateral 
lymph nodes must be negative microscopically. 
Stage 3 
Unresectable unilateral tumour infiltrating across the midline (vertebral 
column) with or without regional  lymph node  involvement; or  localized 
unilateral tumour with contralateral regional lymph node   involvement; or 
midline tumour with bilateral extension by infiltration (unresectable) or by 
lymph node  involvement. 
Stage 4 
Any primary tumour with dissemination to distant lymph nodes, bone, bone 
marrow, liver, skin and/or other organs (except as defined for stage 4S). 
Stage 4S 
Localised primary tumour (as defined for stage 1, 2A or 2B), with 
dissemination limited to skin, liver and/or bone marrow (limited to infants 
<1 year of age). 
1.2.2.   Biology and prognosis 
Many factors have been found to influence the clinical behaviour and 
treatment outcomes in neuroblastomas (Table 1.3). These include: 
Table 1.3. Neuroblastoma prognostic factors. Adapted from [21]. 
Prognostic factor Favourable Unfavourable 
Age < 1year > 1year 
DNA ploidy Hyperdiploid Diploid 
Chromosome 1p Normal Deletion 
Chromosome 17q Normal Gain 
TRkA High Low 
TRkB - High 
TRkC High Low 
N-MYC Normal copy Amplified 
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1.2.2.1. Patient age at diagnosis 
At first diagnosis children younger than 1 year old have a good prognosis 
for all stages compared to those who are older [14].  
1.2.2.2. DNA ploidy 
DNA ploidy is predictive for treatment response and survival. Patients 
with a DNA diploid karyotype have poor prognosis and respond less to 
therapy, while patients with DNA hyperdiploidy have a better prognosis 
[22].  
1.2.2.3. Chromosomal abnormalities  
Many cytogenetic abnormalities identified in neuroblastomas have 
prognostic significance. Allelic deletion of chromosome 1p and allelic 
gain of chromosome 17q in neuroblastoma are significantly correlated 
with poor prognosis [13]. 
1.2.2.4. Neurotrophin receptors 
The expression of the three tyrosine kinase receptors (TrkA, TrkB and 
TrkC) plays an important role in neuroblastoma prognosis. Highly 
expressed TrkA or TrkC in neuroblastoma leads to either differentiation 
or apoptosis and a more favourable prognosis [23]. On the other hand, 
high expression of full length TrkB and its corresponding ligand, Brain-
Derived Neurotrophic Factor (BDNF) is associated with unfavourable 
prognosis [24, 25]. TrkB expression is believed to induce drug resistance 
and metastasis leading to unfavourable outcomes [16].  
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1.2.2.5. N-MYC oncogene 
The N-MYC oncogene is a key prognostic genetic marker for 
neuroblastoma, with its amplification associated with poor prognosis. N-
MYC is a transcription factor located on the short arm of chromosome 
2p. It is widely expressed in the neural crest cells where it regulates cell 
proliferation, cell death and differentiation [18]. N-MYC amplification is 
found in 25% of primary untreated neuroblastoma cases where it is 
strongly correlated with disease metastasis and unfavourable prognosis. 
More than 40% of metastatic neuroblastoma cases show N-MYC 
amplification compared to a less than 10% frequency in localised 
tumours [26]. N-MYC amplification is therefore considered to be a 
significant predictor for advanced stage of disease, rapid disease 
progression and poor prognosis [13, 22]. 
1.2.3. Treatment 
Current treatment for neuroblastoma relies on the combined therapeutic 
approaches of surgery, chemotherapy and radiotherapy. The therapeutic 
approach adopted depends upon the stage of the tumour and patient age 
at diagnosis [13].  
1.2.3.1. Surgery 
Surgical modality provides a means for diagnosis, accurate staging of 
disease and treatment by complete tumour resection. The surgical 
approach is considered the most appropriate option in the treatment of 
low-stage neuroblastoma with survival rates of more than 95% [21]. In 
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the case of advanced disease surgery is only useful as a diagnostic tool, 
where fine needle biopsies can be taken and used for diagnosis and 
prognosis by molecular pathology techniques [13, 22].  
1.2.3.2. Radiotherapy 
Radiotherapy either alone or in conjugation with surgery and 
chemotherapy is an effective modality to reduce local relapse rates of 
neuroblastoma. Radiotherapy has been utilized to improve resectability 
of bulky tumours and management of disseminated disease [13, 22]. 
1.2.3.3. Chemotherapy 
Chemotherapy plays a crucial role and remains the predominant 
treatment in the management of intermediate and high-risk 
neuroblastoma. Several chemotherapeutic agents have been utilised 
alone or in combinations for the treatment of neuroblastoma. These 
agents are generally cytotoxic in nature and include iphosphamide, 
cyclophosphamide, melphalan, vincristine, cisplatin, carboplatin, 
doxorubicin, etoposide and teniposide [13, 22]. Polychemotherapy has 
produced better response rates and improved survival rates in 
neuroblastoma patients (Table 1.4) [27]. However these are still poor and 
it is estimated that more than half of the children with advanced-stage 
disease will relapse because of drug-resistant residual disease [28]. 
Furthermore, long-term toxicity of chemotherapy remains an essential 
issue [13]. 
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Table 1.4. Survival rates for combination chemotherapy regimens used for the 
treatment of high-risk neuroblastoma. Adapted  from [29].      
Regimen 
Patient 
number 
Event free 
survival 5-
year (%) 
Overall 
survival 5-
year (%) 
1.Cyclophosphamide,doxorubicin,vincristine,cisplatin 
and etoposide 
47 46(3y) 55(3y) 
2.Cyclophosphamide, doxorubicin, cisplatin and 
teniposide 
60 9 24 
3.Vincristine,cisplatin, etoposide and cyclophosphamide 130 18 19 
5.Carboplatin, etoposide.,vincristine. cisplatin and 
cyclophosphamide 
125 31 40 
6. Ifosfamide and etoposide 135 14 20 
7. Vincristine, actinomycin, ifosfamide and doxorubicin 206 27 33 
8. Peptichemio, vincristine, ciclophosphamide and 
cisplatin 
65 17 23 
9. Deferoxamine, cyclophosphamide, thiothepa, 
carboplatin 
159 17 28 
 
Novel therapeutic approaches are therefore needed for the treatment of 
neuroblastoma. One potential approach would be to modulate the 
expression of molecules on the surface of neuroblastoma cells which are 
involved in the process of tumour dissemination. A strategy here would 
be to investigate modulation of cell surface molecules involved in the 
adhesion and migration processes. One such set of molecules is the 
glycans.  
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1.3. Glycans and tumour progression 
Glycans are endogenous carbohydrates consisting of covalently-linked 
assemblies of monosaccharides. Glycans are known to decorate the 
surface of cells, settle in the ECM, and couple with soluble signalling 
molecules. This allows them to play important roles in biological 
processes where they either mediate or modulate cell-cell, cell-ECM and 
cell-molecular interactions [30-32].  
There are several classes of glycans based on the nature of the linkage 
to the non-carbohydrate portion of the molecule (Figure 1.4). Glycans 
coupled with proteins (glycoproteins) are either attached to an 
asparagine (Asn) residue to form N-linked glycans or to serine or 
threonine residues to form O-linked glycans (Figure 1.4 a and b). In 
glycolipids, oligosaccharides are covalently attached to ceramide to form 
glycolsphingolipids (Figure 1.4 c). Examples of these are the sialylated 
glycolsphingolipids, gangliosides (GM1, GM3, GD2 and GD3). Moreover, 
another class of glycolipids is the Glycosylphosphatidylinositol (GPI 
anchored) (Figure 1.4 d). Here, a protein is anchored to the outer leaflet 
of the cell membrane by a glycan covalently attached to 
phosphatidylinositol. Glycosaminoglycans are another class of glycans 
that can either occur in free form like hyaluronan (Figure 1.4 e) or 
covalently attached to proteoglycans (Figure 1.4 f) like chondroitin 
sulphate and heparan sulphate. Additionally, some nuclear and 
cytoplasmic proteins are decorated with N-acetylglucosamine by O- 
glycosylation of serine residue (Figure 1.4 g) [30].   
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Figure 1.4.  Structure and location of common types of glycans. Glc, glucose; Gal, 
galactose; Man, mannose; GlcNAc, N-acetylglucosamine; GalNAc, N-
acetylgalactosamine; GlcA, glucuronic acid; Fuc, fucose; Xyl, xylose; Sia, sialic acid. 
Adapted from [30].  
Numerous studies have demonstrated that tumour progression is 
associated with diverse and complex alterations in glycan expression 
[30]. These alterations comprise the loss of expression and under- and 
over- expression of existing glycans as well as the neoexpression of 
oncofoetal antigens. The latter represents expression of antigens in 
tumours when expression of these antigens is normally limited to 
embryonic tissues. This set of changes in glycan expression often arise 
from alteration of glycosyltransferase levels (affecting glycosylation) in 
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the Golgi apparatus of tumour cells leading to malignant transformation 
[32]. 
As a characteristic of tumour phenotype, altered glycosylation enables 
neoplastic cells to mediate cell adhesion, cell motility, and receptor 
activation. These alterations facilitate tumour progression by enhancing 
neoplastic proliferation, invasion, angiogenesis, and metastasis outlined 
in Figure 1.5 [30].  
As illustrated in Figure 1.5, the alteration of glycan expression enhances 
tumour proliferation by activating several types of growth-factor 
receptors. For example, in lipid rafts, gangliosides mediate 
oligomerization of respective receptor tyrosine kinase receptors leading 
to phosphorylation and growth signalling [30, 32]. Moreover, gangliosides 
(for example GM1) enhance heterodimerization of growth-factor 
receptors like ERBB2–ERBB3 leading to growth signalling [30]. In tumour 
invasion, the altered glycan expression enables tumour cells to detach 
from primary tumour, degrade the basement membrane and ECM, and 
migrate to surrounding tissues [30]. Tumours express sialylated glycans 
like Sialyl Tn antigen that have a repulsive effect on cell-cell and cell-
ECM interactions and therefore facilitate the detachment of tumour cells 
from the primary tumour [30, 32].  
Altered glycan expression on the surface of tumour cells promotes 
tumour metastasis via the bloodstream. Host platelets and lymphocytes 
facilitate tumour dissemination by enhancing embolisation and arrest at 
distant sites where tumour cells extravasate [30]. The formation of emboli 
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requires adhesion between tumour cells, platelets and lymphocytes. This 
adhesion is mediated by selectins where P-, L- and E-selectins 
expressed on platelets, leukocytes and endothelial cells respectively all 
bind to glycan receptors of sialyl Lewis X and A (SLeX and SLeA) 
expressed on the surface of tumour cells ( labelled ‘P,’ ‘L’, and ‘E’ in the 
figure) [30, 33]. In tumour angiogenesis, the formation of new blood 
vessels is required for growth of the primary cancer and its metastases. 
A number of pro-angiogenic growth factors that induce tumour 
angiogenesis bind to glycans on the surface of tumour cells [30]. Such as 
heparan sulphate which binds to Fibroblast Growth Factor (FGF) and 
Vascular Endothelial Growth Factor (VEGF). These growth factors are 
then released by heparanase produced from endothelial cells where they 
activate endothelial receptor tyrosine kinases to support the 
neovasculature [30]. 
One of these N-linked glycans is the polymeric form of sialic acid known 
as polysialic acid (Figure 1.6). Polysialic acid (PSA) decorates the 
surfaces of cells of embryonic tissues and tumours as described below, 
usually expressed on the Neural Cell Adhesion Molecule (NCAM). 
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Figure 1.5. Examples of glycans contribution to major events of tumour 
progression. Adapted from [30].  
 
Figure 1.6. Chemical structures of sialic acid and its polymeric form polysialic 
acid. 
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1.3.1. Molecular structure of PSA-NCAM 
PSA is a glycan that is mainly found attached to the cell surface protein 
NCAM. Before considering PSA decoration on NCAM it is necessary first 
to examine NCAM molecular structure. 
1.3.1.1. NCAM 
NCAM is a polypeptide member of the immunoglobulin super family. It 
exists in three isoforms characterized by molecular weight namely 
NCAM-120, NCAM-140, and NCAM-180. All these isoforms arise from 
alternative splicing of a single gene. These isoforms share the same 
extracellular domain comprising five immunoglobulin-like domains (Ig 1-
5), two fibronectin type III repeats (FN1 and FN2) and six N- 
glycosylation sites. NCAM-140 and NCAM-180 are connected to the 
intracellular cytoskeleton through the transmembrane domain, while 
NCAM-120 is membrane GPI-anchored (Figure 1.7 A and B) [34, 35].  
NCAM is involved in a variety of cis/trans- homophilic and heterophilic 
interactions which accounts for its adhesive properties. In homophilic 
interactions, NCAM cis-dimers are formed by the binding of the IgI and 
IgII domains of neighbouring NCAM molecules on the same cell 
membrane. For NCAM trans-dimers (binding of NCAM molecule on one 
cell membrane with an NCAM molecule on an opposing cell membrane), 
the formation of NCAM cis-dimers is a pre-requisite, as two types of 
NCAM trans dimers are formed; flat zipper and compact zipper. The flat 
zipper type involves the binding between IgII and IgIII domains of one 
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NCAM molecule with the IgII and IgIII domains in another NCAM 
molecule on the opposing cell membrane (Figure 1.7 C). The compact 
zipper involves the binding between IgI–IgIII domains of one NCAM 
molecule with the IgII–IgII domains in another NCAM molecule on the 
opposing cell membrane [34, 36]. 
In heterophilic interactions, NCAM binds molecules other than NCAM at 
the cell membrane. NCAM interacts with other members of the 
immunoglobulin family, such as axonin-1 and laminin-α1. Moreover, 
NCAM can bind with ECM members such as the proteoglycans 
chondroitin sulphate and heparan sulphate as well as structural proteins 
like collagen, fibronectin and laminin. Additionally, NCAM can interact 
and activate growth factor receptors like FGFR and glutamate receptors 
[34, 36]. 
 
Figure 1.7. NCAM molecular structure. (A) Diagram showing the identifiable domains 
(left) and the post-translational modifications (right) of NCAM. (B) The 3 different NCAM 
isoforms. (C) Models of NCAM interactions. As depicted, the red circle shows the 
linkages for NCAM cis dimers, whilst the green circle shows the linkages for NCAM 
trans interaction (flat zipper interaction). Adapted from [34]. 
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1.3.1.2. PSA 
PSA is a unique carbohydrate synthesized as a post-translational 
modification of NCAM. PSA consists of a linear homopolymer of α-2,8-
linked N-acetyl neuraminic acid (sialic acid), typically up to 100 residues 
[37]. PSA is biochemically characterized by its high polyanionic (negative) 
charge and its large hydration volume resulting from carboxyl groups at 
physiological pH [34]. PSA is synthesised in the Golgi apparatus by the 
addition of multiple α-2,8-linked sialic acid residues to the 5th Ig-like 
domain via two N-glycosylation sites (via asparagine residues) in all 
NCAM isoforms. NCAM polysialylation is catalysed by two distinct 
polysialyltransferases (polySTs) namely STX and PST (see section 
1.3.2). The expression of PSA-NCAM is developmentally regulated in a 
stage and tissue-specific manner [35]. PSA is highly expressed during 
embryogenesis where its peak expression is in the perinatal phase. 
During development, PSA expression is abundant in both neural and 
non-neural tissues [38]. However, its expression is progressively 
decreased by adulthood where it is confined to certain areas in the brain. 
PSA is continuously expressed in areas of the brain where neurogenesis 
or plasticity persists, specifically the olfactory bulb, hippocampus and 
hypothalamus [35].  
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1.3.2. PolySTs 
PSA biosynthesis on NCAM is catalyzed by two selective Golgi localized 
polyST enzymes: STX (ST8Sia II) and PST (ST8Sia IV). These are 
members of the α-2,8-sialyltransferase family of enzymes which in turn 
belong to the wider glycosyltransferase family (Table 1.5). PolySTs are 
unique in their catalytic ability to transfer multiple α-2,8-linked sialic acid 
residues from the donor substrate CMP-sialic acid to N-terminal 
structures on the 5th Ig- like domain  of all NCAM isoforms [38]. 
Table 1.5. Functions of the various α-2,8-sialyltransferases. Adapted from [37]. 
ST8Sia enzyme Function 
ST8Sia I Mono or oligo- sialylation of glycolipids 
ST8Sia II Polysialylation of NCAM 
ST8Sia III Formation of disialylated and oligosialylated 
structures on glycoprotiens and glycolipids 
ST8Sia IV Polysialylation of NCAM 
ST8Sia V Mono or oligo- sialylation of glycolipids 
 
Analysis of polySTs demonstrated that these enzymes are differentially 
expressed (tissue- and cell-specific) and are independently capable of 
forming PSA on NCAM [39]. Both polyST enzymes levels are high during 
embryogenesis and their levels progressively decline overall soon after 
birth except in certain areas of the brain. Here, STX levels are low 
whereas PST expression is predominant. Since both enzymes are 
simultaneously expressed they are believed to act co-operatively, 
resulting in higher levels of PSA-NCAM than if synthesized by either 
enzyme alone [37, 38]. 
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A comparison of the amino acid sequences of both PST and STX reveals 
that these enzymes have high homology, sharing 59% amino acid 
sequence identity [37, 38]. Like other sialyltransferases, polySTs have a 
common type II transmembrane protein topology characterised by the 
presence of a short N-terminal cytoplasmic segment, a transmembrane 
domain (TMD) and a large intraluminal domain that includes a stem 
region and catalytic domain (Figure 1.8) [40]. All sialyltransferase 
enzymes share consensus sequences, which are found in the catalytic 
domain of all mammalian STs. These are known as sialyl motifs L (large; 
48 amino acids), S (small; 23 amino acids), VS (very small; 6 amino 
acids) and Motif III (4 amino acids) [41]. The large sialyl motif (L) is 
involved in binding with the donor substrate CMP-sialic acid, while the 
small sialyl motif (S) is thought to participate in binding both the donor 
and acceptor substrates [40, 42].  
 
Figure 1.8. Type II transmembrane topology of polysialyltransferases. TMD= 
Transmembrane domain.  Adapted from [38]. 
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NCAM is the abundant major carrier of polysialic acid where its 
polysialylation is specifically regulated by polySTs. As a glycoprotein, the 
oligosaccharide structure of the N-glycan attached to NCAM is the rate-
limiting step for NCAM polysialylation. PolySTs critically require the N-
glycan structure of NCAM to be sialylated by α-2,3- or α-2,6-linkages in 
order to synthesize PSA. In contrast, the non-sialylated oligosaccharide 
structures cannot serve as acceptors for polySTs [37]. Moreover, 
polySTs crucially require N-glycan core fucosylation for the 
polysialylation of NCAM (Figure 1.9) [43, 44]. Another requirement for 
NCAM polysialylation is polyST-binding to the NCAM FN1 domain. 
Studies have shown that the acidic surface patch of NCAM FN1 domain 
is necessary for polyST recognition and essential for N-glycan 
polysialylation on neighbouring 5th Ig domain. This suggests that NCAM 
FN1 acts as a recognition and docking site for polyST which accounts for 
NCAM polysialylation specificity [45]. 
 
Figure 1.9. Core oligosaccharide structure of N-glycan. Adapted from [44]. 
Moreover, polySTs are structurally unique from other sialyltransferases in 
having two distinctive polybasic motifs termed the polysialyltransferase 
domain (PSTD) and polybasic region (PBR). These structural differences 
also play a crucial role in the specificity of polySTs for NCAM 
polysialylation. The PSTD consists of 32 amino acids and is located 
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upstream and adjacent to the S sialyl motif. The overall positive charge 
of the PSTD is essential for polysialylation activity. It functions to facilitate 
the processivity of polysialylation by electrostatic binding with growing 
polyanionic PSA chains [46]. The PBR consists of 35 amino acids and is 
equidistant from sialyl motif L and the TMD. This region is also important 
for catalytic activity [47, 48]. Both these regions are therefore key to the 
specific nature of NCAM polysialylation. Replacement of key amino acids 
in the PBR strongly reduces NCAM substrate recognition [48], further 
confirming that polysialylation of NCAM is a highly substrate-specific 
reaction for polySTs. 
1.3.3. PSA biosynthesis 
As described above, PSA is synthesized by two polyST enzymes, STX 
and PST. These two enzymes are unique in their catalytic ability of 
adding multiple α-2,8-linked sialic acid residues to NCAM [38]. 
N-acetylneuraminic acid (Neu5Ac) is the monosaccharide monomer that 
makes up PSA. Neu5Ac synthesis starts in the cytosol with the 
hydrolysis of uridine disphosphate-N-acetylglucosamine (UDP-GlcNAc) 
by UDP-N-acetylglucosamine 2-epimerase to form N-acetyl-
mannosamine (ManNAc, see Figure 1.10 step 1). ManNAc undergoes 
phosphorylation at carbon-6 by N-acetylmannosamine-kinase to give N-
acetylmannosamine 6-phosphate (ManNAc-6-phosphate) (Figure 1.10 
step 2) [49]. On condensation with phosphoenolpyruvate by N-
acetylneuraminic acid 9-phosphate synthase (Neu5Ac9-phosphate 
synthase), ManNAc 6-phosphate is converted to N-acetylneuraminic 
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acid-9-phosphate (ManNAc-9-phosphate) (Figure 1.10 step 3). The N-
acetyl-neuraminic 9-phosphate undergoes de-phosphorylation by N-
acetyl neuraminic 9-phosphatase (Neu5Ac 9- phosphatase) to produce 
Neu5Ac (Figure 1.10 step 4) [50]. 
Neu5Ac is then activated in the nucleus by N-acetylneuraminyl 
cytidyltransferase (CMP- Neu5Ac synthase) which catalyses the transfer 
of cytidine monophosphate (CMP) from cytidine triphosphate (CTP) to 
Neu5Ac producing N-acetylneuraminic acid cytidine monophosphate 
(CMP-Neu5Ac) (Figure 1.10 step 5). The CMP-Neu5Ac is then 
translocated to Golgi apparatus. These monomers are then added by 
polySTs in an α-2,8-linkage to an α-2,3-linked terminal Neu5Ac on N-
glycan sites bound to an Asn residue of NCAM [38, 50]. 
 
Figure 1.10. The sequential biosynthesis of sialic acid. 
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1.3.4. PSA physical properties 
The ability of PSA to decrease NCAM-mediated membrane-membrane 
adhesion originates partly from its physical properties. On the basis of 
the size and structure of this macromolecule, it is believed that PSA acts 
by exerting broad steric forces on the molecular and cellular interactions. 
Due to the charge and hydration properties of PSA, it sterically alters the 
intercellular space between opposing cells and decreases the adhesive 
properties of NCAM [51-53]. Electron microscopy imaging demonstrated 
that PSA presence increases the intercellular space by 10-15 nm [51]. 
This intercellular hindrance may have resulted from increased 
intercellular repulsion or inactivation of adhesive properties of proteins. 
By impeding membrane-membrane contact, PSA could alter the 
efficiency of receptor-receptor interactions on opposing cells [51, 52]. 
Further evidence supporting the anti-adhesive properties of PSA came 
from quantitative measurements of molecular forces [53]. These 
measurements showed that NCAM polysialylation increases the extent of 
steric repulsion between opposing membranes. In addition, such ionic 
strength–dependent steric repulsion is sufficient to overcome the effect of 
homophilic and heterophilic NCAM interactions, consequently abolishing 
inter-membrane adhesion [53]. 
In this context, the effects of PSA on molecular and cellular interactions 
are defined by two mechanisms referred to as trans and cis mechanisms. 
These two mechanisms are illustrated schematically in Figure 1.11. In 
the trans mechanism, PSA impedes interactions between NCAM and 
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receptors on the opposing membranes (Figure 1.11, upper). In cis 
mechanisms, PSA alters cellular interactions on the same cell membrane 
by modifying NCAM-NCAM and NCAM-receptor interactions (Figure 
1.11, lower). These alterations result in reducing adhesion and modifying 
the intercellular signalling [52].  
 
Figure 1.11. Schematic diagram showing PSA steric effect on cellular 
interactions. Effect of PSA (sphere of influence circled) on cis and trans NCAM-NCAM 
and NCAM-receptor interactions. NCAM = darker shapes; other receptors = lighter 
shapes. Adapted from [52]. 
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1.3.5. Biological roles of PSA 
1.3.5.1. Neuronal cell migration 
Several lines of evidence suggest PSA is involved in neural cell migration 
of the developing brain and in restricted areas of the adult brain (mainly 
the olfactory bulb and hippocampus) [54]. PSA is found to be a promoter 
of both axophilic and cooperative cell migration with several animal 
studies having established this link between PSA and cell migration [55, 
56]. Using enzymatic removal of PSA by endoneuraminidase (endoN), 
migration and dissociation of migrating neuroblasts from rostral migratory 
stream (a route through which newly generated neuroblasts in 
subventricular zone are migrated to olfactory bulb) are impaired leading 
to a smaller olfactory bulb and thicker rostral migratory stream as 
observed in NCAM-deficient mice [57, 58]. Furthermore, aberrant defects 
in both radial and tangential neuronal migration have been reported as a 
result of concomitant genetic deletion of STX and PST [55, 56]. 
Regarding PSA mechanisms affecting cell migration, it is proposed that 
PSA enhances the detachment of cells from their primary sites and 
promotes cell motility by enhancing locomotion (adhesion/de-adhesion 
process) of cells along a substrate [54, 55]. Another possible mechanism 
is that PSA regulates directed migration towards concentration gradients. 
In other words, PSA can modify the sensitivity of cells for adequate 
sensing to the growth factors ingredients [56]. 
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1.3.5.2. Axonal and dendritic pathfinding 
PSA plays a permissive role in regulating axon fasciculation (clustering of 
developing axons to form bundles and fascicules) and nerve branching. 
PSA in both central and peripheral nervous systems exerts a 
defasciculative effect on growing axons allowing them to respond 
effectively to extrinsic signals and to appropriately reach their targets 
such as limb motorneuron axons, corticospinal axons and optic 
projections. PSA appears to exert its action by the attenuation of axon-
axon interactions as well as the interactions with other receptors such as 
adhesion molecule L1 [35, 55]. Enzymatic removal of PSA during the 
axon outgrowth period results in axon pathfinding errors and innervation 
of inappropriate targets [34]. 
1.3.5.3. Synaptic plasticity 
Extensive evidence indicates that PSA plays an important role in 
synaptic plasticity. Before synaptic formation, PSA expression continues 
on axons and dendrites. However, it rapidly disappears once synaptic 
contacts are stabilised [35]. PSA involvement in synaptic plasticity was 
established in animal studies examining the plastic modifications of 
synaptic transmission. Several reports indicated that both Long Term 
Potentiation (LTP) and Long Term Depression (LTD) are impaired by 
either enzymatic or genetic removal of PSA. It was suggested that the 
elimination of PSA does not influence basal synaptic transmission but 
does influence the efficiency of synaptic transmission [34, 55]. 
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Regarding plausible mechanisms by which PSA induces synaptic 
plasticity, it is proposed that PSA attenuates synaptic cell adhesion 
resulting in the membrane expansion that leads to plasticity. 
Furthermore, PSA may also modulate intracellular signalling leading to 
synaptic plasticity [34, 35]. 
It is possible to conclude that PSA functions as a dynamic regulator of 
the stability and plasticity of neuronal networks. PSA enhances cell 
migration, promotes axonal and dendritic pathfinding, and induces 
synaptic plasticity. A plausible mechanism by which PSA exerts these 
effects is that it serves as a physical spacer, decreasing adhesion forces 
and altering stability of other adhesion systems. Therefore, it can be 
considered as a negative regulator for cell-cell interactions.  
PSA clearly plays a key role in neuronal development and has also been 
identified as playing an important role in tumour progression. Indeed, 
there is now a growing body of literature evidence that recognizes PSA 
neoexpression in many tumour types as a modulator of malignant 
transformation. PSA can be considered as an oncodevelopmental 
antigen [59-61]. This evidence will be explored in the next section. 
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1.4. PSA-NCAM neoexpression and malignant 
transformation 
Several lines of evidence have reported PSA-NCAM re-expression in a 
number of tumour types (summarised in Tables 1.6 & 1.7). In both neural 
and non-neural crest derived tumours, PSA-NCAM was detected in 
Wilm’s tumour [62], small cell lung carcinoma (SCLC) [63], non-small cell 
lung carcinoma (NSCLC) [64], pancreatic cancers [65], pituitary tumours 
[66], medullary thyroid carcinoma [67], multiple myeloma [68], 
rhabdomayosarcoma [69], medulloblastoma [70] and neuroblastoma 
[71]. These tumours are all generally characterised as highly aggressive 
in behaviour because of their ability to readily invade and metastasize, 
forming secondary tumours [38].  
PSA-NCAM expression is believed to contribute significantly to the 
metastatic cascade by facilitating detachment from the primary tumour 
and migrating to the metastatic site, forming metastatic foci [61]. 
Therefore, PSA-NCAM expression may represent an oncodevelopmental 
antigen, which plays an important role in tumour progression, invasion 
and metastasis [38].  
This section reviews the direct evidence for PSA-NCAM expression in 
both clinical tumours and experimental tumours in animal models and its 
possible role in tumour progression, invasion and metastasis. All tumour 
types are initially considered before focusing on the evidence for 
neuroblastoma.  Moreover, it covers the recent limited work that has 
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been performed to elucidate the role of PSA modification on NCAM 
signalling in the modulation of tumour malignancy. 
1.4.1. Evidence of PSA-NCAM expression in malignancies and its 
possible contribution to tumour progression 
1.4.1.1. Clinical samples 
Table 1.6 is a summation of all the clinical studies that have been 
identified from the literature which describe PSA-NCAM expression in 
cancer patients. For each study, the number of patient samples have 
been totalled and recorded the proportion expressing PSA-NCAM as a 
percentage. 
Immunohistochemical investigation of Wilm’s tumours found that poorly 
differentiated tumours express PSA-NCAM more extensively than the 
more differentiated tumours. Similar PSA molecular mass (≈200 KDa) 
was determined for PSA expressed in both Wilm’s tumours and in human 
embryonic kidney and brain. These results suggest neoexpression of 
PSA in Wilm’s tumour and its role as an oncodevelopmental antigen [62].  
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Table 1.6. Summary of clinical studies on the possible role of PSA-NCAM in 
tumour progression, invasion and metastasis. 
Tumour type Clinical 
sample type  
Sample 
size 
PSA positivity/ 
PSA levels 
Results Ref 
 
 
 
Neuroblastoma 
 
 
 
 
Tumour & 
serum 
 
14 
 
100% 
Advanced: high 
Limited: low 
 
Marker for neuroblastoma 
management 
 
[71] 
Tumour & 
 serum 
17 100% 
Differential marker of paediatric 
tumours 
[72] 
Tumour & 
 serum 
24 63% Prognostic marker [73] 
Tumour 136 100% 
STX as marker for metastatic 
neuroblastoma 
[74] 
Tumour 36 58% 
Favourable prognostic marker 
in advanced stage 
[75] 
Wilm’s Tumour 9 100% Oncodevelopmental marker [62] 
 
 SCLC 
Tumour 25 100% 
distinguishing SCLC from other 
carcinoid 
[76] 
Tumour 70 92% 
correlates with aggressive 
tumour behaviour 
[63] 
Tumour 17 60% prognostic factor [77] 
Tumour 50 100% 
correlates with metastatic 
potential 
[61] 
Pituitary Tumour 82 47% 
tumour invasion & marker of 
aggressiveness 
[66] 
Medullary thyroid Tumour 33 100% Oncodevelopmental marker [67] 
Glioma Tumour 30 30% Mediates tumour invasion [78] 
Astrocytoma Tumour 30 77% 
Significant PSA expression in 
high malignant tumours 
Grade III: 28% 
Grade IV: 45% 
[79] 
Glioblastoma Tumour 59 70% 
prognostic marker for 
glioblastoma 
[80] 
Pancreatic (neural 
lesion) 
Tumour 15 67% Correlates with neural invasion [65] 
Colorectal cancer Tumour 39 74.4% 
Promotes colorectal cancer 
dissemination 
[81] 
NSCLC 
Tumour 57 49% 
PSA with metastasis 
STX with progression 
[64] 
Tumour 237 19% Clinical marker [82] 
Medulloblastoma CSF 29 100% 
Marker for management of 
medulloblastoma patients 
[70] 
Multiple Myeloma 
 
Serum 92 61% Prognostic marker [68] 
Rhabdomyosarcoma 
  Tumour 
 
  Serum 
11 
 
7 
 
100% 
S-IV: high 
S-II &III: low 
Diagnostic and prognostic 
marker 
[83] 
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The presence of PSA-NCAM expression was also investigated in high 
grade SCLC neuroendocrine lung tumours. Komminoth and co-workers 
showed that all SCLC primary tumours and metastatic tumour deposits 
were immunoreactive for long PSA chains regardless of histological type 
[76]. As part of a separate study, the pattern of PSA-NCAM expression 
was examined across a range of neuroendocrine lung tumours. PSA-
NCAM expression was markedly higher in SCLC than in other 
neuroendocrine lung tumours indicating its aggressive metastatic 
behaviour [63]. In agreement with these findings, PSA-NCAM expression 
was detected in 60% of all NCAM positive SCLC patients. Moreover, 
PSA-NCAM negative patients were characterised with higher survival 
rates as compared to PSA-NCAM positive patients [77]. In contrast, 
Scheidegger and co-workers demonstrated heterogeneous PSA-NCAM 
expression in 50 samples of human primary and metastatic SCLC 
tumours [61]. Despite the heterogeneity of PSA-NCAM expression in all 
samples, there was consistency in the pattern of PSA-NCAM expression 
between primary and metastatic tumours [61]. As PSA-NCAM is 
expressed in both primary and metastatic tumours, it appears that PSA-
NCAM expression plays an important role in tumour progression and 
metastasis. 
Across the spectrum of human pituitary adenomas, PSA-NCAM 
expression was detected in 47% of tumours. Furthermore, there was a 
strong correlation between PSA-NCAM expression and tumour invasion, 
regardless of tumour subtype, suggesting PSA-NCAM expression can be 
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seen as a clinical marker of tumour aggressiveness as opposed to a 
specific sub-type [66]. 
Across the spectrum of human thyroid carcinomas, PSA-NCAM 
membranous immunoreactivity was strongly exhibited in 33 of 79 thyroid 
lesions, where all PSA-NCAM positive lesions were aggressive 
medullary thyroid carcinomas. The quantitative difference in PSA-NCAM 
expression was shown to discriminate thyroid carcinomas suggesting 
PSA-NCAM expression as a marker for medullary thyroid carcinoma and 
c-cell hyperplasia [67]. 
Suzuki and co–workers investigated PSA-NCAM involvement in glioma 
progression and invasion in the brain [78]. PSA-NCAM expression was 
detected in 30% of patients where NCAM was detected, with expression 
significantly higher in diffuse astrocytoma cells (40%) than in other 
tumour cell types. Diffuse astrocytoma was characterised with extensive 
spreading and obvious disease reoccurrence [78]. Recently and in 
agreement with the glioma study, PSA-NCAM expression was 
immunohistochemically investigated in 30 patients diagnosed with 
different grades of astrocytomas. It was more strongly expressed in 
grade III (28%) and grade IV (45%) astrocytoma cells than in grade I and 
II (4%) [79]. 
Moreover, PSA-NCAM expression was also investigated in 56 
glioblastoma patient samples, including 48 patients with relapsed 
disease [80]. PSA-NCAM expression was detected in 70% of patients 
where it was associated with poor prognosis and was adversely 
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correlated with overall survival and disease free survival of glioblastoma 
patients. PSA-NCAM expression was also found to regulate the 
expression of transcription factor for gliomagenesis, olig2. Therefore, 
PSA-NCAM was suggested to be a valuable prognostic marker for 
glioblastoma [80]. 
In pancreatic cancer, PSA-NCAM expression was detected in 67% of 
NCAM positive cases. In all instances, PSA-NCAM expression was 
found where the tumours exhibited extensive neural invasive lesions and 
was associated with higher proliferation activity in neural invasive lesions 
than in primary and/or PSA-NCAM negative tumours [65].  
The first evidence of PSA-NCAM expression in colorectal cancers came 
recently from a study performed by Fernandez-Briera et al. [81] PSA-
NCAM and NCAM expression was immunohistochemically investigated 
in 39 patient samples. PSA-NCAM expression was detected in 74.4% of 
all NCAM positive patients. Expression of NCAM and PSA-NCAM was 
exhibited as cytoplasmic staining. There was a significant correlation 
between PSA-NCAM expression and number of lymph node metastases, 
suggesting the involvement of PSA-NCAM in dissemination of colorectal 
cancers [81]. However, the expression of PSA-NCAM in colorectal 
cancers demonstrated in this study should be regarded with caution as 
firstly, colorectal cancers are non-neuroendocrine tumours and secondly, 
the pattern of PSA-NCAM immunostaining is different to other studies 
discussed here, where the common pattern of PSA-NCAM 
immunoreactivity is localized at the cytoplasmic membrane. Therefore, it 
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is possible that these variable immunostaining results may arise from 
poor antibody specificity, or may suggest an alternative, as yet 
undiscovered role for PSA-NCAM. This is an area worthy of future study. 
In non-neuroendocrine lung tumours, evidence of PSA-NCAM 
expression in NSCLC seems to be compelling. Although Lantuejoul and 
co-workers reported that all cases of NSCLC were negative for PSA-
NCAM expression [63], PSA-NCAM expression was detected in 50% of 
different graded NSCLC tumours in the other studies [64]. Here, PSA 
was highly expressed in the more aggressive cases of stage IV (79%) 
and stage III (70%) and less expressed in stage I (only 21%). Most of the 
patients positive PSA expression were in cases of lymph node 
metastasis (70%) or in distance metastasis (79%) rather than being in 
the cases of local extent of the primary tumour (40%). The extent of 
PSA-NCAM expression was significantly higher in moderately (75%) to 
poorly (67%) differentiated tumours than in the case of well-differentiated 
tumours (20%). Although PSA-NCAM expression was detected in all 
NCAM positive tumours, it was also expressed in 40% of NCAM negative 
tumours suggesting that PSA may be expressed on proteins other than 
NCAM assuming the antibody staining is sound [64]. Despite the 
presence or absence of NCAM expression, the negative PSA-NCAM 
expressing patients showed higher survival rates (72%) than positive 
PSA expressing patients (53%) in all stages. This suggests the 
significance of PSA-NCAM expression as an unfavourable prognostic 
marker in NSCLC [82]. However, several reports have indicated an 
absence of PSA-NCAM expression in NSCLC. With respect to tumour 
41 
 
origin, NSCLC is non-neural crest derived tumour [63, 84]. It is therefore 
possible that these variable results may arise from incorrect diagnoses. It 
is perhaps possible that NSCLC was misdiagnosed, whereas in fact it 
was a neuroendocrine lung tumour such as large cell neuroendocrine 
carcinoma or SCLC or had elements of more than one cell type. 
1.4.1.1.1. Soluble PSA-NCAM 
Several studies have reported the presence of PSA-NCAM in the 
cerebrospinal fluid (CSF) and in the serum of cancer patients and this is 
referred to here as soluble PSA-NCAM. Soluble PSA-NCAM was 
suggested as a diagnostic and prognostic marker for many tumours 
(Table 1.6). Soluble PSA-NCAM was quantitatively measured in high 
levels in CSF of medulloblastoma patients [70] and in the serum of 
patients with multiple myeloma [68], rhabdomyosarcoma [83] and 
neuroblastoma [71]. Higher PSA-NCAM levels were measured in CSF 
containing metastatic cells than in other groups (abnormal imaging or 
normal group). In agreement with clinical status and cytology, PSA-
NCAM measurements correlated with CSF metastasis of 
medulloblastoma indicating its possible usefulness as a marker in the 
management of medulloblastoma patient [70]. 
In the serum of patients with multiple myeloma, soluble PSA-NCAM 
levels were significantly elevated in 61% of patients where high PSA-
NCAM content was associated with advanced disease stages. 
Furthermore, patients with high PSA-NCAM levels had a shorter survival 
time than patients with lower PSA-NCAM levels implying the possible 
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utilisation of soluble PSA-NCAM measurement as a prognostic marker 
for this tumour [68]. Similarly to multiple myeloma, high PSA-NCAM 
levels were found in the serum and tumour specimens of patients 
diagnosed with rhabdomyosarcoma. Here, serum levels of PSA-NCAM 
were higher in patients with extensive disease than in others. In 
agreement with these results, advanced disease tumours (stages III and 
IV) and those at the metastatic stage were found to express high PSA-
NCAM than tumours with lower stages [83].  
1.4.1.2. Functional studies in experimental models  
Evidence for the contribution of PSA-NCAM to tumour invasion and 
metastasis has been evaluated in several tumour animal models and has 
been summarised in Table 1.7.  
Table 1.7. Summary of experimental studies on PSA-NCAM possible role in 
tumour progression, invasion and metastasis. 
 
 
 
 
 
 
 
Tumour type Experimental Sample 
size 
PSA 
Positivity 
Results Ref. 
 
Neuroblastoma 
 
SCID mice 
(LAN-1, LAN-5, 
SK-N-SH and Kelly) 
 
- 
 
LAN-1 and 
LAN-5 
 
decreases adhesiveness of 
cells and promotes 
dissemination and 
metastasis 
 
[85] 
 
 
Small cell lung 
(SCLC) 
 
 
 
Nude mice 
 
 
50 
 
100% 
 
correlates with metastatic 
potential 
 
[61] 
 
Nude mice 
(NCL-H146, PC-12) 
 
- 
 
 
 
100% 
 
 
Transfected cells showed 
reduced tumourigencity 
[84] 
Pituitary 
 
Rat model 
(SMtTW2,SMtTW3, 
SMtTW10, SMtTW4) 
42 
 
Varies 
 
 
High PSA expressing   
SMtTW4 enhanced 
invasion and metastasis 
[59] 
Glioma Mice model (C6) - 100% Mediates tumour invasion [78] 
 
Rhabdomyo-
sarcoma 
 
Nude mice (TE671) 
 
 
25 
 
 
100% 
 
 
Induces  metastasis 
 
[69] 
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In attempting to elucidate the metastatic potential of PSA-NCAM in 
SCLC, two different sublines derived from the human SCLC cell line NCI-
H69, namely E2 (PSA-NCAM negative) and E3 (PSA-NCAM positive) 
were inoculated subcutaneously into nude mice [61]. Interestingly, PSA-
NCAM expressing tumour cells (E3) showed high metastatic potential by 
producing significant intracutaneous metastasis compared to PSA-NCAM 
negative tumour cells (E2). In the light of these results, PSA-NCAM 
expression appears to enhance the development of invasive and 
metastatic potentials of tumour cells [61]. 
By using human pituitary tumours in animal models, PSA-NCAM 
expression has been investigated and correlated to invasion and 
metastasis [59]. In all four benign and malignant transplantable pituitary 
lineages (SMtTW), Daniel and co-workers demonstrated that highly PSA-
NCAM expressing tumours (SMtTW4) grown subcutaneously invaded the 
kidney and exhibited metastatic nodules. In contrast, tumours (SMtTW2 
and SMtTW3) expressing naked NCAM (no PSA) were non-invasive and 
did not metastasize [59]. In this context, PSA-NCAM expression appears 
to potentiate tumour invasion and metastasis. 
The role of PSA-NCAM in glioma invasion was explored by using PST or 
STX-transfected rat C6 glioma cells. In contrast to previous studies in 
neuroblastoma cells, PSA-NCAM expression did not modulate the 
growth rate in vitro. However, when the C6 glioma cells were inoculated 
into mouse brains PSA-NCAM positive glioma cells aggressively invaded 
the corpus callosum, whereas the PSA-NCAM negative tumour cells 
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rarely did so [78]. It is possible to speculate that polysialylation enhances 
glioma cell invasion. 
By using an animal model of human rhabdomyosarcoma lung 
metastasis, Daniel and co-workers studied the role of PSA-NCAM 
expression in the metastatic process [69]. Intraperitoneal administration 
of the highly PSA-NCAM-expressing rhabdomyosarcoma cell line TE671 
induced lung and liver metastasis while the intramuscular administration 
led to lung metastasis only. Moreover, enzymatic removal of PSA-NCAM 
expression by intraperitoneally injected endoN  diminished metastasis in 
the lung and liver and delayed the formation of  ascites [69]. These 
results provide further evidence for PSA-NCAM involvement in 
malignancy. It can be concluded PSA-NCAM expression seems to 
promote tumour cell migration and metastasis. 
PSA-NCAM expression has been investigated in a large panel of both 
neural and non-neural crest originating tumour cell lines [84]. PSA-NCAM 
membranous immunoreactivity was frequently exhibited in neural crest-
derived tumour cells (neuroblastoma and SCLC) but rarely detected in 
non-neural crest-derived tumour cells except for rhabdomyosarcoma 
[84], multiple myeloma [68], and Wilm’s tumours [62]. Although PSA-
NCAM expression did not exert any significant effect on growth rate 
between positive and negative PSA-NCAM expressing tumour cells, 
PSA-NCAM transfected tumour cells grew poorly. As a result, it is likely 
that PSA-NCAM expression decreased tumourigencity by modulation of 
cell interactions in this model [84]. In contrast, tumour cell growth was 
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markedly inhibited by enzymatic removal of PSA-NCAM in both human 
neuroblastoma cells SH-SY5Y [86] and rhabdomyosarcoma cells TE671 
compared to PSA-NCAM negative cells [87], suggesting a further role for 
PSA-NCAM expression in tumour progression. 
1.4.2. PSA-NCAM expression in neuroblastoma 
1.4.2.1. Neuroblastoma clinical samples 
Several lines of evidence report PSA-NCAM expression in the sera and 
tumour specimens of neuroblastoma patients (Table 1.6). The utilisation 
of soluble PSA-NCAM levels corresponding to expression in tumour 
specimens as a diagnostic and prognostic marker for neuroblastoma was 
evaluated in many studies [71-73]. Gluer and co-workers investigated 
PSA-NCAM expression in the serum and tumour specimens of 14 
neuroblastoma patients with different disease grades and stages. In 
agreement with the level of PSA-NCAM expression in tumour specimens, 
significantly higher PSA-NCAM serum levels were found in patients with 
undifferentiated and advanced stages of disease compared with lower or 
normal serum levels in differentiated and limited disease. Moreover, 
PSA-NCAM levels were reduced during successful chemotherapy 
reflecting correlation of PSA-NCAM with neuroblastoma progression and  
suggesting its usefulness in management of neuroblastoma therapy [71]. 
Among various paediatric tumours, the applicability of using soluble PSA-
NCAM levels as a marker in differentiating malignant embryonic tumours 
was tested. Here PSA-NCAM expression was useful in differentiating 
neuroblastoma, rhabdomyosarcoma and Wilm’s tumours from other 
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malignant paediatric tumours such as Ewing sarcoma, lymphoma, kidney 
sarcoma and nephroma [72]. In patients with ganglioneuroma and 
neuroblastoma, PSA-NCAM expression was positive in 15 of 24 tumour 
specimens where it corresponded to high PSA-NCAM levels in the serum 
of 13 of 20 patients. In correlation with clinical stage and tumour 
differentiation, PSA-NCAM was highly expressed in advanced stage 
undifferentiated tumours (neuroblastoma) as opposed to decreased or no 
expression in differentiated low stages tumours, correlating with normal 
serum levels. Therefore, PSA-NCAM expression was suggested to be a 
marker for neuroblastoma with poor prognosis [73]. 
On the basis of its expression and key responsibility for PSA synthesis in 
certain malignancies, mRNA expression of STX was studied in 39 
neuroblastoma tumours and 8 neuroblastoma cell lines. STX was highly 
expressed in all stages and different phenotypes of neuroblastoma 
tumours. High STX expression was associated with unfavourable 
prognosis in metastatic stages suggesting its utility as a prognostic 
marker for metastatic neuroblastoma [74]. 
Data on the diagnostic and prognostic value of PSA-NCAM expression in 
neuroblastoma seems to be compelling. Recently, the pattern of PSA-
NCAM expression was evaluated in 36 neuroblastoma patients (31 
primary tumours). PSA-NCAM expression was detected in 58% of patient 
samples where its expression was associated with advanced (metastatic) 
disease. In contrast to the majority of studies, PSA-NCAM positive 
patients were shown to have higher survival rates than PSA-NCAM 
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negative patients in the advanced disease group. Consequently, PSA-
NCAM expression was deemed to be a favourable prognostic factor in 
advanced stage neuroblastoma [75]. These results conflict with previous 
studies which associate PSA-NCAM expression with poor prognosis in 
neuroblastoma [71, 73, 74]. The reasons behind these conflicting results 
are unclear but there are several possible explanations. The tumour 
specimens used in this study were primary tumours (not metastatic 
samples) and the sample size used was too small (only 23 samples were 
used for survival analysis) to demonstrate the viability of results obtained. 
1.4.2.2. Neuroblastoma experimental models 
The contribution of PSA-NCAM to neuroblastoma dissemination and 
metastasis was evaluated in a human neuroblastoma cell xenograft 
model (Table 1.7) [85]. In this study, the expression of NCAM, PSA-
NCAM and polySTs was investigated across a panel of human 
neuroblastoma cell lines (LAN-1, LAN-5, SH-SY5Y, SK-N-SH and Kelly) 
before and after engraftment in mice. The in vitro results showed that 
PSA was found to decorate NCAM-140 and NCAM-180 at the surface of 
LAN-1, LAN-5 and SH-SY5Y cells where the level of polysialylation on 
NCAM was correlated with the mRNA levels of polySTs. Moreover, 
neither SK-N-SH nor Kelly cell lines expressed NCAM, PSA-NCAM or 
polySTs. In agreement with the in vitro results, similar expression profiles 
of NCAM, PSA-NCAM and polySTs were exhibited in the respective cell 
lines in vivo except for SH-SY5Y which was unable to grow. Following 
the inoculation of cell lines in to mice, it was determined that PSA-NCAM 
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expressing cell lines (LAN-1 and LAN-5) progressed and disseminated to 
develop numerous micrometastases while PSA-NCAM negative cell lines 
(SK-N-SH and Kelly) only grew as primary tumours [85]. These results 
indicate that PSA-NCAM decoration promotes the detachment of tumour 
cells and enhances tumour dissemination and metastasis. 
Evidence of NCAM, PSA-NCAM and polySTs expression in the SK-N-SH 
and Kelly cell lines from the above study [85] seems to conflict with prior 
studies as previously NCAM, PSA-NCAM and polySTs were all shown to 
be expressed in SK-N-SH [84, 88-90] and Kelly cell lines [87]. The likely 
reason behind this conflicting result is the cellular heterogeneity of all 
neuroblastoma cell lines. This issue is discussed further in Chapter 4. 
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1.4.3. PSA decoration controls NCAM functions from adhesion to 
signalling  
Despite the growing evidence for the contribution of PSA-NCAM to 
tumour malignancy, the underlying mechanisms at the cellular level 
remain unclear. As we have discussed, it has been observed that PSA-
NCAM expression facilitates tumour cell detachment from the primary 
tumour and enhances migration of tumour cells to metastatic sites, 
forming metastatic foci [61]. Physically, PSA decoration on NCAM acts 
as dynamic spacer that decreases the adhesion between the cells and 
therefore impedes the cell-cell contacts [53]. Besides this anti-adhesive 
effect, PSA steric hindrance may also favour interaction between  NCAM 
and other receptors and therefore, control NCAM interactions [91]. 
However, the potential impact of polysialylation on NCAM signalling in 
tumour malignancy has not yet been fully explained. This section 
considers the recent limited work that has been carried out to investigate 
the role of PSA in promoting tumour malignancy by controlling NCAM 
signalling. 
The impact of polysialylation on NCAM signalling in modulating tumour 
malignancy was studied by Seidenfaden et al. [87]. PSA decoration was 
found to interfere with NCAM signalling, affecting control of growth, 
survival and differentiation of tumour cells. In naturally PSA-NCAM 
expressing neuroblastoma (Kelly, LAN-5 and SH-SY5Y) and 
rhabdomyosarcoma (TE671) cell lines EndoN treatment to remove PSA 
from NCAM led to cell growth inhibition but had no effect on PSA-NCAM 
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negative neuroblastoma (LS) cells. Moreover, PSA removal from the cell 
surface promoted neuroblastoma cell survival and neuronal 
differentiation. These were highly significant findings as it is suggested 
that PSA removal significantly enhances the heterophilic NCAM 
interactions at the site of tumour cell contacts, leading to induction of 
NCAM signalling. This was reflected by the activation of extracellular 
signal-regulated kinase 1/2 (ERK1/2) that led to MAPK-dependent 
survival and differentiation of neuroblastoma cells. Based on these 
results, it was suggested that NCAM polysialylation promotes tumour 
progression by controlling the NCAM heterophilic interactions at cells 
contact sites [87]. 
Another original mechanism to promote tumour growth is the direct 
interaction of PSA with growth factors. PSA-NCAM has been shown to 
promote neuroblastoma cell growth by regulation of Brain-Derived 
Neurotrophic Factor-TrKB(BDNF-TrKB) signalling via direct binding to 
BDNF [92]. At physiological conditions, PSA is shown to interact directly 
with BDNF to form large complexes (PSA-BDNF) at the cell surface. The 
formation of these complexes was greatly dependent on the degree of 
polymerization of PSA, where the minimum chain length required for 
binding BDNF was 12 residues. Moreover, these large complexes were 
able to release BDNF molecules to the high affinity receptor, TrKB where 
they interact. In neuroblastoma cells that naturally express PSA-NCAM 
and TrKB, it was shown that exposure to the PSA-BDNF complex leads 
to a significant increase in cell growth and survival. On this basis, it was 
suggested that PSA-NCAM acts as a reservoir for BDNF where it inhibits 
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the diffusion of BDNF away from cell surface, maintaining local 
concentrations sufficient to enhance activation of TrKB receptors [92]. 
In an attempt to elucidate the mechanisms underlying the contribution of 
PSA-NCAM to tumour metastasis, Li et al. demonstrated that PSA-
NCAM enhances cell migration via activation of FGFR regardless of cell 
adhesion capacities [93]. It was found that cells stably engineered to 
over-express PSA-NCAM show an increase in migratory and invasive 
potential compared to mock-transfected cells. This PSA-NCAM-mediated 
migration was not affected by cell adhesion to different substrates. 
Moreover, PSA-NCAM expression differentially modulated the adhesion 
of cells to different substrates. Adhesion of mock cells to fibronectin was 
high, moderate to vitronectin, laminin and collagen IV, and poor to 
heparin. In contrast, PSA-NCAM expressing cells were poorly adherent 
to fibronectin, highly adherent to heparin and adhesion to vitronectin, 
laminin and collagen IV remained unchanged. Significantly, these PSA-
NCAM triggered effects were reversed by treatment with EndoN or a 
specific FGFR inhibitor, namely SU5402. Embarking from the latter 
observation, the involvement of FGFR in PSA-NCAM driven migration 
was investigated. It was found that PSA-NCAM promotes migration 
possibly by activating the FGFR signalling pathway through 
phosphorylation of PLC-γ, focal adhesion kinase (FAK) and extracellular 
signal regulated kinase (ERK) 1/2. On the other hand, PSA-NCAM driven 
cell adhesion to different substrates might be regulated by 
phosphorylated Fyn. Overall, it was concluded that PSA-NCAM 
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potentiates FGFR signal transduction, promoting cell migration and 
independently regulates cell adhesion by Fyn (Figure 1.12). 
 
Figure 1.12. NCAM regulated signalling to adhesion and migration. NCAM 
mediates signalling pathways through two tyrosine kinases FGFR and Fyn. Adapted 
from [94]. 
In a recent study, it was shown that polysialylation regulates NCAM 
triggered tumour cell migration and controls focal adhesion at the cell-cell 
contacts [95]. PSA removal from NCAM by EndoN significantly reduced 
neuroblastoma (SH-SY5Y and Kelly) and rhabdomyosarcoma (TE-671) 
cells migration. This reduction in migration potential was due to NCAM 
enrichment at cell-cell contacts which led to upregulation of focal 
adhesion of tumour cells. This was achieved via NCAM dependent 
signalling in which Fyn association to the focal adhesion protein scaffold 
paxillin was promoted in response to PSA removal. Such an effect was 
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compromised by pre-treatment with kinase inhibitor PP2. In contrast, pre-
treatment with an FGFR specific inhibitor (PD173074) did not alter focal 
adhesions suggesting that FGFR activity was not involved in focal 
adhesion upregulation at the cell contacts [95]. This is in agreement with 
the previously described study by Li et al. where PSA-NCAM driven cell 
adhesion was mediated by Fyn and PSA-NCAM triggered cell migration 
was mediated via the FGFR signalling pathway [93]. Collectively, it was 
concluded that PSA-NCAM plays a key role in controlling tumour cell 
migration through the regulation of cell-cell and cell-matrix interactions 
[95]. 
In summary, PSA-NCAM is highly expressed in several tumour types 
notably, including neuroblastoma. Several lines of strong evidence 
indicate a role for PSA-NCAM expression in neoplastic progression, with 
PSA-NCAM expression strongly correlated with tumour cell detachment 
from primary sites, cell migration and the formation of metastatic foci. 
Therefore, PSA-NCAM expression is potentially a modulator of tumour 
invasion and metastasis. Apart from its physical properties, PSA 
decoration enhances tumour progression and metastasis through 
masking NCAM signalling and crosstalking with other signalling 
receptors, including TrKB and FGFR. Furthermore, PSA-NCAM 
expression is associated with an unfavourable prognosis in many 
tumours and is suggested to be a marker for many metastatic tumours 
such as neuroblastoma.  
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On this basis, PSA-NCAM represents a unique and novel therapeutic 
opportunity to develop a new strategy for the treatment of 
neuroblastoma. This strategy, which is considered in the next section, is 
to interfere with PSA-NCAM synthesis by designing small molecules that 
selectively inhibit polySTs, in order to reduce cell surface PSA-NCAM 
expression, thereby modulating the processes associated with tumour 
cell dissemination. 
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1.5. Development of a novel therapeutic strategy to 
target PSA-NCAM in neuroblastoma  
As discussed in the previous section, there are several lines of evidence 
for the role of PSA-NCAM expression in tumour progression, invasion 
and metastasis. This highlights the potential for developing small 
molecules that selectively inhibit the polySTs and therefore modulate the 
biosynthesis of PSA-NCAM at the surfaces of tumour cells for 
therapeutic purposes.  
Before considering approaches to generate molecules that target PSA-
NCAM, this section will review general approaches which have been 
utilised in the development of anticancer drugs. This will then lead on to 
considering the limited work reported so far on targeting polySTs in PSA-
NCAM expressing cells. 
1.5.1. Anticancer drug development strategies 
Two key approaches to the discovery and development of new cancer 
therapeutics are empirical compound- oriented screening and target-
oriented screening. The empirical approach seeks to identify the 
inhibitory effects of compounds or natural products against proliferating 
tumours either in vitro or in vivo. In contrast, target-oriented screening 
focuses on identifying specific molecular targets or pathways that are 
responsible for tumourigenesis and designing selective compounds that 
alter or inhibit those defined targets or pathways [96, 97]. 
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The majority of anticancer drugs on the market today have been 
developed through the empirical approach, which has historically been 
the major approach taken. As a greater understanding of tumour biology 
has become apparent however, a more target-oriented approach has 
been adopted.  
1.5.1.1. Empirical compound oriented approach 
The National Cancer Institute (NCI), established in 1955 in the United 
States of America has been the world leader in the development of 
empirical screening strategies [97].  The NCI was set up to provide a 
large scale screening capability that enabled the discovery and 
assessment of chemicals and natural products as potential anticancer 
drugs [97, 98]. For such purposes, several in vitro and in vivo models 
have been utilized to identify novel and most efficient anticancer drug 
[99]. 
Figure 1.13 is a summary of the current strategy for NCI screening and 
drug development. 
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Figure 1.13. The NCI current screening strategy. The current strategy for NCI 
screening and drug development consists of several in vitro and in vivo models that 
enables identification of novel and the most efficient anticancer drug. Adapted from 
[100]. 
Compounds are initially screened against a panel of three highly 
sensitive cell lines consisting of MCF-7 (breast carcinoma), NCI-H460 
(lung carcinoma) and SF-268 (glioma). Compounds showing a significant 
anti-proliferative effect are then progressed to screening in the NCI60 cell 
line panel. This in turn results in generating 60 separate dose response 
curves for each compound [97, 101]. These dose response curves are 
then analysed using the COMPARE algorithm [102]. Compounds 
demonstrating a unique mode of action and disease specificity are then 
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progressed for testing using the hollow fibre assay [96]. Compounds 
showing a 50% decrease or greater in net cell growth are subsequently 
evaluated in xenograft models. Once the compound demonstrates 
efficacy in a xenograft model further in vivo pharmacokinetic and 
pharmacodynamic studies are carried out. Upon successful progress 
through all the above screening stages, a candidate compound is then 
further developed in terms of toxicology and formulation before being 
entered into clinical trials [97, 101]. 
1.5.1.2. Target-oriented approaches 
As the underlying mechanisms of cancer pathogenesis are increasingly 
understood, anticancer drug development is shifting from the empirical 
approach to more target-oriented approaches to drug discovery with the 
aim to develop novel drugs that selectively interfere with targets 
important for disease progression (angiogenesis, invasion, metastasis, 
cell cycle and apoptosis) [103]. The discovery of anticancer drugs using 
the rational approaches is based on target-oriented and structure-based 
drug design (Figure 1.14).  
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Figure 1.14. Rational approaches for anticancer drug development. Adapted from 
[104]. 
Target identification describes the process of characterising a drug target 
that is differentially expressed between normal and tumour tissues [103].  
It is based on three approaches. The first approach involves the 
characterisation of genes or proteins whose expression or post-
translational medication is altered in cancers. This is followed by 
identifying the genes, proteins or pathways which directly contribute to 
cancer initiation, maintenance and progression. The last approach is the 
characterisation of the relevant genes whose disturbance result in 
phenotype alteration in tumour cells [105]. 
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Following the discovery of a drug target, target validation is an important 
part of the drug discovery process. By using the mechanistic studies the 
functional role of the target in tumourigenesis is validated. This can be 
achieved by utilising in vitro assays or techniques using tumour cell line 
models. In tissues (xenograft or clinical), the constitutive expression of 
the target is often characterised by immunohistochemistry [10, 104].  
The second phase of an anticancer drug discovery programme is the 
identification of hit and lead compounds. This can be achieved by using 
structure-based drug design and/or a target oriented strategy. In the case 
of structure-based drug design, lead compounds are often designed 
depending on the known structure of a substrate or cofactor. Generally, 
hit compounds are identified through virtual screening of large chemical 
libraries against the three dimensional structure of the target, often in 
silico. Knowledge of the target structure can be obtained by using 
structural biological techniques such as x-ray crystallography and nuclear 
magnetic resonance (NMR). Homology model development is also a well 
validated approach. Libraries of compounds can then be screened by 
computer using structural information to identify “virtual hits” which are 
then examined in vitro [104, 106].  
In contrast, the aim of the target-oriented approach is to identify 
compounds that have the ability to modulate the activity of the target of 
interest, usually without specific information about the likely compound 
structure. To achieve this, chemicals are screened using the biochemical 
assays utilising recombinant proteins or genetically engineered cells. To 
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accelerate the process, high throughput screening techniques using 
large chemical libraries are often employed to identify compound hits. 
Both of these approaches are often complementary to each other with 
their primary aim to identify lead compounds that can eventually be 
transformed into drug candidates [103, 104]. 
Following hit identification, these agents are optimised by an iterative 
process of compound synthesis and refinement, reliant on feedback from 
biological evaluation. Ultimately, compounds are then selected for animal 
studies to evaluate the pharmacokinetic and pharmacodynamic 
properties of lead compounds [103]. As the project reaches the final 
stages of drug development, at least two in vivo models are preferably 
required to demonstrate the activity of the lead compounds and to 
provide a means of prioritising and nominating candidate compounds for 
future clinical development [104].  
Following lead-optimisation, the candidate drug development phase 
starts with preclinical toxicology studies and early clinical trials. These 
studies are aimed at assessing the safety of these candidate drugs for 
human use. Preclinical toxicology studies are then performed by using 
rodent-only programmes [107]. Promising drug candidates are then 
progressed to early clinical trials where ultimately a decision is made as 
to whether or not the candidate drug with the desired activity is as 
effective in treating patients as in the animal models [103, 104]. 
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1.5.1.3. PolyST inhibitors 
In this context, the target oriented and structure based drug design 
approaches have been used for the discovery and development of 
polyST inhibitors. The following section will review the work that has 
been published in this novel area, before outlining the strategy employed.  
1.5.2. Small molecule inhibitors of polySTs 
The inhibition of polyST enzymes to modulate PSA-NCAM synthesis as a 
therapeutic strategy is a novel area. Examining the literature for starting 
points for the design of polyST inhibitors reveals that there are only two 
reports describing such molecules. One approach involves the use of N-
acylmannosamines and the other describes CMP-based sialyltransferase 
inhibitors. Neither approach was an attempt to develop a cancer 
therapeutic. 
1.5.2.1. N-acylmannosamines 
In an attempt to inhibit PSA-NCAM biosynthesis, researchers have 
exploited the permissiveness of polySTs to interfere with PSA decoration 
on NCAM.  A small series of related studies describe how the sialic acid 
biosynthesis pathway was utilised to chemically modulate NCAM 
polysialylation [108-111]. This was achieved by incubating the cells with 
unnatural sugars (analogues of N-acetyl-D-mannosamine (ManNAc)) 
(Figure 1.15), a precursor in the sialic acid biosynthetic pathway.  
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Figure 1.15. Chemical structures of N-acylmannosamines. 
Carter et al. utilized the permissiveness of polySTs for successful 
generation of modified PSA chains, through incubation with modified N-
acylmannosamines [108]. The N-acyl modification present in the 
mannosamine derivative is transferred and incorporated into subsequent 
molecules in the pathway, each being accepted by the enzyme in 
question, ultimately resulting in N-acyl-modified PSA. In this study, the 
ketone-containing synthetic sugar N-levulinoylmannosamine (ManNLev) 
was incubated with NT2 (human embryonic carcinoma cell line) cells. 
Cells accepted this unnatural sugar in the pathway to biosynthesize the 
respective sialoside N-levulinoyl sialic acid (SiaLev), which was then 
incorporated into the growing PSA chain. Evidence of incorporation of 
SiaLev into the growing PSA chain was demonstrated by resistance to 
degradation by sialidases as monitored by fluorescence microscopy. 
Importantly, this study indicated the ability of polySTs to tolerate CMP-
modified sialosides biosynthesized from unnatural sugars [108]. 
The importance of other ManNAc analogues as modulators of PSA-
NCAM expression was studied by Mahal et al. [111]. Here, NT2 cells 
were incubated with N-proponylmannasomine (ManNProp) and N-
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butanoylmannasomine (ManNBut) at a range of concentrations up to and 
including 10 mM. PSA-NCAM expression was concentration-dependently 
inhibited by ManNBut while no effect was observed with ManNProp 
treatment. Similar effects were demonstrated in other cell lines including 
SH-SY5Y cells (human neuroblastoma), H345 cells (human small cell 
lung carcinoma) and also Hela cells (human cervical carcinoma) 
engineered with NCAM and the STX enzyme. Moreover, it was 
determined that polySTs utilised the CMP-sialic acid derivatives bearing 
the same modifications (that would be synthesised from the N-acyl 
derivative inside the cell) when these were administered directly. CMP-
SiaNBut was utilised less efficiently than CMP-SiaNProp and CMP-Sialic 
acid and therefore, CMP-SiaNBut terminated the extension of PSA 
chains. The inhibitory effects of ManNBut were reversible since PSA-
NCAM expression was re-established in Hela cells 24 hours after 
removal of the agent [111]. 
The differential effects of ManNAc analogues on the polysialylation of 
NCAM was further assessed by treating NT2 and Hela cells (stably 
engineered with NCAM and either STX or PST) with N- 
pentanoylmannasomine (ManNPent) in addition to ManNProp and 
ManNBut [109]. The millimolar treatments with ManNBut and ManNPent 
led to concentration-dependent inhibition of PSA biosynthesis on NCAM, 
with the ManNBut treatment proving most effective. PSA-NCAM 
expression was reduced upon treatment with ManNProp in 
concentration-dependent manner, in contrast to the previous study.  
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When these ManNAc analogues were acetylated similar effects to the 
unprotected analogues were exhibited, but with significantly greater 
potency than observed with the parent analogues. This demonstrated 
that acetylation of these analogues enhanced cell permeability by 
increasing lipophilicity improving the inhibitory potency by at least 30-fold 
[109].  
A key recent study by the Horstkorte group further assessed the effects 
of ManNAc analogues on NCAM polysialylation [110]. It was 
demonstrated that ManNProp, ManNBut and ManNPent each blocked 
PSA-NCAM expression by selective inhibition of the STX enzyme but 
had no effect on the PST enzyme, which remained permissive. Here, 
different cell lines including HL-60 (promyelocytic leukemia), NT-2 
(human embryonic carcinoma) and PST-engineered PC12 cells were 
incubated with ManNProp, ManNBut and ManNPent, each at 5 mM for 
48 h. ManNAc analogues inhibited PSA-NCAM expression in NT-2 cells 
whilst no effect was observed on the other cell lines. These results were 
explained by the differences in transcription levels of the polySTs, where 
NT-2 cells predominately expressed STX and other cell lines exclusively 
expressed PST. These results were further confirmed by treating CHO 
(Chinese hamster ovary) cells stably transfected with either STX or PST. 
It was determined that treatment of ManNAc analogues led to complete 
inhibition of PSA-NCAM expression in CHO-STX cells whilst PSA-NCAM 
expression was unaffected in CHO-PST cells. Therefore it was 
concluded that ManNAc analogues abrogated PSA-NCAM expression by 
selective inhibition of STX [110]. 
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1.5.2.2. CMP-based sialyltransferase inhibitors 
Another strategy to modulate the PSA-NCAM expression at the surface 
of cells has been based on the ability of CMP and analogues to act as 
competitive inhibitors of sialyltransferases, (including the polySTs) [112]. 
CMP is the nucleotide portion of the donor substrate, CMP-sialic acid 
(see Figure 1.16).  
 
Figure 1.16.  Chemical structures of CMP, 2-O-methyl CMP, and 5-methyl CMP. 
The C-5 (on the heterocyclic ring of the nucleotide) and the 2’-OH (on the 
sugar) positions of CMP were each methylated to produce 5-methyl CMP 
and 2’-O-methyl CMP respectively (Figure 1.16). Biochemically, It was 
determined that 2’-O-methyl CMP and 5-methyl CMP were capable of 
inhibiting the enzymatic activity of a range of sialyltransferases (α-2,3- 
and α-2,6-sialyltransferase, PST and STX) but with some selectivity for 
polyST. Unmodified CMP, however remained the most effective. 
Moreover, when CHO cells were treated CMP, 5-methyl CMP and 2-O-
methyl CMP (all at 0.5 mM concentrations), PSA-NCAM expression was 
almost equally decreased by all the treatments. Therefore, it was 
suggested that these small molecules might be used to preferentially 
decrease PSA biosynthesis on NCAM through competitive inhibition of 
polySTs [112]. 
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Aims and Objectives 
Neuroblastoma is a paediatric tumour characterised by rapid and highly 
metastatic behaviour. Long-term survival of patients with advanced 
disease is poor despite recent advances in therapy. Therefore, new 
drugs for the treatment of neuroblastoma are needed.  
The hypothesis underlying this work is that the inhibition of polySTs will 
reduce PSA-NCAM expression on the tumour cell surface, thereby 
modulating the events associated with tumour cell dissemination. 
The main aims of the work described in this thesis were to evaluate PSA-
NCAM expression in clinical neuroblastoma samples, and to identify and 
utilise cell-based models to pharmacologically investigate novel polyST 
inhibitors. 
These aims were achieved through the following objectives: 
1.  To characterise PSA-NCAM expression in clinical neuroblastoma 
samples and to identify relationships between PSA-NCAM expression 
and molecules involved in NCAM signalling. 
 2. To select a panel of suitable cell lines for the development of cell-
based assays to investigate the effects of PSA-NCAM inhibition.  
3.  To develop and validate appropriate cell-based assays to investigate 
the effects of PSA-NCAM inhibition  
4. To evaluate the pharmacological properties of novel polyST inhibitors.  
68 
 
2. General Materials and Methods 
2.1.  Materials 
All general chemicals, media and media supplements were obtained 
from Sigma-Aldrich (Poole, UK) unless otherwise specified. 
2.2.  Antibodies and associated materials 
The mouse anti-PSA-NCAM monoclonal antibody (clone: 2-2B) which 
recognises α-2,8-linked sialic acid residues with a degree of 
polymerization (DP) of greater than 10 residues,  and the rabbit anti-
NCAM polyclonal antibody which recognizes all NCAM isoforms were 
purchased from Chemicon-Millipore (Watford, UK). The mouse anti PSA-
NCAM monoclonal antibody (clone: 735) was a kind gift from Professor 
Rita Gerardy-Schahn (Hannover Medical School, Hannover, Germany). 
The goat anti-phosphorylated FGFR1 polyclonal (clone: C-15), rabbit 
anti-phosphorylated TrkB polyclonal (clone: H-181) and rabbit anti-
phosphorylated ERK1/2 monoclonal (clone: E337) antibodies were 
obtained from Insight Biotechnology (Middlesex, UK). The PSA-NCAM 
binding fluorescent fusion protein endoneuraminidase N-GFP (EndoN-
GFP) was synthesised by Dr. Anne Jokilammi, and kindly donated by 
Prof. Jukka Finne (University of Helsinki, Helsinki, Finland). 
Endoneuraminidase N (EndoN), which specifically cleaves α-2,8-linked 
sialic acid residues in polysialic acid (PSA), was obtained from Abcys 
(Paris, France). EndoNF and EndoNF-mutant were both kind gifts from 
Prof. Rita Gerardy-Schahn. Colominic acid, a bacterial homopolymer of 
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α-2,8 linked sialic acid, was obtained from Sigma. The biotinylated horse 
anti-mouse, biotinylated goat anti-rabbit, and biotinylated rabbit anti-goat 
polyclonal secondary antibodies, normal horse serum, normal goat 
serum, normal rabbit serum, vectastain avidin-biotin complex (ABC), 3,3-
diaminobenzidine tetrahydrochloride (DAB) chromogen, mouse-on-
mouse (M.O.M) immunodetection basic kit, and Vectashield hardset 
fluorescent mounting medium with and without4',6-diamidino-2-
phenylindole (DAPI) were all obtained from Vector Laboratories Ltd 
(Peterborough, UK). TRITC-conjugated rabbit anti-mouse secondary 
antibody and FITC-conjugated goat anti-rabbit were from Dako 
(Cambridgeshire). 
2.3. Cell culture 
2.3.1. Cell lines and culture media 
The human neuroblastoma cell lines IMR32 and SK-N-SH were a gift 
from Professor Sue Burchill (University of Leeds, Leeds, UK). IMR32 and 
SK-N-SH cells were maintained in Minimum Essential Medium (MEM) 
supplemented by 10% FCS, 2 mM L-glutamine, and 1 mM sodium 
pyruvate to 500mL of incomplete medium. The rat C6-WT glioma cell line 
and C6-STX transfected cell line were gifts from Professor Minoru 
Fukuda (Sanford-Burnham Institute, San Diego, USA). Both C6-STX and 
C6-WT cell lines were grown in alpha MEM medium (VWR, 
Leicestershire, UK) supplemented with 10% FCS. The human colorectal 
cancer cell line DLD-1 was obtained from ATCC (Manassas, USA), and 
was maintained in Roswell Park Memorial Institute (RPMI) 1640 medium 
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supplemented with 10% Foetal Calf Serum (FCS), 2 mM L-glutamine, 
and 1 mM sodium pyruvate.  
2.3.2. Cell maintenance 
All cell lines except IMR-32 were routinely maintained as monolayer 
cultures in  75cm2 cell culture treated flasks (T75 flask) (Corning, 
Amsterdam, Netherlands) in complete media and incubated at 37C in a 
humidified atmosphere of 5% CO₂. The IMR-32 cell line was maintained 
as monolayer cultures in 90 mm Petri dishes (Corning) in complete 
media and incubated at 37C in a 5% CO₂ humidified atmosphere. When 
cultures reached 70-90% confluence, they were passaged by washing 
twice with Hanks Balanced Salt Solution, prior to trypsinisation using a 
0.25% trypsin-EDTA solution (3mL) and incubation at 37C for 2-5 
minutes. When cells became detached from the flask, media containing 
FCS was added to deactivate the action of trypsin/EDTA. The trypsinised 
cells were then centrifuged for 5 minutes at 1000rpm. The resulting 
supernatant was discarded and the cell pellet was re-suspended in 10 
mL of fresh complete culture medium. Cells were then counted using a 
Neubauer Haemocytometer and the required amount of cell suspension 
was then seeded into new vessels containing the appropriate amount of 
comple 
2.3.3. Characterisation of cell growth 
For the determination of cell proliferation and survival, a quantitative 
MTT-based assay was performed [113]. This assay relies on 
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mitochondrial succinate dehydrogenase reduction of the yellow water-
soluble tetrazolium salt, MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium bromide) to a purple, water-insoluble formazan salt. 
The salt is then dissolved in dimethyl sulfoxide (DMSO) and measured 
on a multi-well scanning spectrophotometer [113]. 
2.3.3.1. Evaluation of the reproducibility for specific cell lines 
The reliability of the MTT assay to accurately reflect viable cell number 
was assessed using a couple of the cell lines under investigation. Cells 
were trypsinized, counted and seeded in 96-well plates at dilutions 
ranging from 100 to 1x105 cells/mL (4 wells per dilution, 180 µL/well). 
Wells in one lane of the plate served as an experimental blank and were 
filled only with medium. 20 µL of MTT solution (5mg/mL, 100 mg of MTT 
in 20mL of H₂O) was then added to each well followed by incubation of 
the plate for 4 hours in the dark at 37C in a 5% CO₂ humidified 
atmosphere. Following incubation, the plate was centrifuged at 1000rpm 
for 5 minutes. The supernatant was removed carefully and 150 µL of 
DMSO added with vigorous mixing in the pipettor to dissolve the 
formazan crystals. The absorbance of the formazan solution was 
determined immediately at 540 nm using a Thermo Lab-systems 
Multiscan Plus spectrophotometer (Lab-systems Group, UK). Mean 
absorbance for each cell concentration was calculated by subtracting the 
mean background absorbance (average of the blank wells) from the 
average absorbance of the test wells. To validate the results, mean 
values were plotted against cell number and the linear regression was 
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calculated by the Least Squares Method using Microsoft Office Excel 
(2007) software. 
2.3.3.2. Assessment of cell growth using the MTT assay 
Cells were grown in T75 flasks until they reached approximately 70% 
confluency. Cells were then harvested as described previously (section 
2.3.2). They were then seeded in 96-well plates (4 wells per dilution, 200 
µL/well) at concentrations ranging from 1x102 to 1x105 cells/mL. A 
medium blank was prepared as above. The plates were incubated at 
37C in a 5% CO₂ humidified atmosphere. At various time intervals, the 
increases in cell number were determined using the MTT assay. For day 
0 only, the plate was processed as described in the previous section. For 
other time points, plates were taken from the incubator, the supernatant 
was removed and 200 µL of MTT stock solution (5 mg/mL) was added to 
each well. Plates were then incubated in the dark for 4h at 37oC, the 
supernatant carefully removed and 150 µL of DMSO was added to 
dissolve the formazan crystals. The absorbance of the formazan solution 
was determined and mean absorbance was calculated as described in 
the previous section (2.3.3.1). Growth curves were established from 
mean ±SD values for three independent experiments. 
2.3.4. Evaluation of chemosensitivity using the MTT assay  
The chemosensitivity of compounds used in these studies was assessed 
using the MTT assay. On reaching approximately 70% confluence, cells 
were detached and cell suspensions were prepared at a concentration of 
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1x104cell/mL. Cells were seeded in 96-well plates (180 µL/well) and 
incubated overnight at 37C in a 5% CO₂ humidified atmosphere. A 
medium blank was prepared as above. Once cells adhered, 20 µL of test 
(inhibitor) or control (medium) solution was added to each well followed 
by incubation of plates for 96 hours in the dark at 37C in a 5% CO₂ 
humidified atmosphere. Following treatment, the supernatant was 
removed and 200 µL of MTT stock solution (5mg/mL) was added to each 
well. Plates were then incubated in the dark for 4 h at 37oC to allow for 
the formation of formazan crystals. The supernatant was carefully 
removed and 150 µL of DMSO was added to dissolve formazan crystals. 
The mean absorbance of the formazan solutions was determined as 
described previously in section 2.3.3.1. The chemosensitivity data were 
calculated from the mean ±SD values of three independent experiments. 
2.3.5. Human tumour xenografts 
Human tumour cell lines were xenografted in mice according to 
UKCCCR guidelines [114] under the jurisdiction of a project licence 
issued by the UK Home Office. Male Balb/C OlaHsd-Foxn1nu mice aged 
6-12 weeks (Harlan, Loughborough, UK) were used. They were housed 
in cages in an air-conditioned room with regular alternating cycles of light 
and darkness, and were fed with Teklad 2018 diet (Harlan) and water ad 
libitum. Under brief general inhalation anaesthesia 2-3 mm3 fragments of 
IMR32 and SK-N-SH tumour were implanted subcutaneously in the left 
and right abdominal flanks of each mouse using a trocar. Tumour growth 
and any deleterious effects were monitored frequently and once tumours 
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had reached approximately 500 mm3 as measured by callipers, the mice 
were sacrificed and the tumours removed. The tumours were either 
further processed for paraffin-embedding (section 2.4.1) or snap-frozen 
in liquid nitrogen and stored at -80C until required. 
2.4. Histology 
2.4.1. Tissue fixation and embedding 
Following removal, the xenograft tumour material was immediately 
immersed in neutral buffered 10% formalin for 24-48 h before being 
transferred to 70% ethanol where it was stored until further processing. 
Tissues were processed with an automatic tissue processor (Leica TP 
1020, Leica Microsystems, Nussloch, Germany). The process of tissue 
embedding was achieved by consecutive incubation of tissues in 70% 
ethanol for 1 hour, 80% ethanol for 1 hour, 95% ethanol for 1 hour, 100% 
ethanol for 1 hour (twice in different tanks), 100% ethanol for 2 hours, 
histoclear for 1 hour (twice in different tanks), histoclear for 2 hours and 
paraffin wax for 2.50 hours (twice in different tanks). 
Finally, the tissues were placed in labelled plastic moulds (Polysciences, 
Warrington, USA) which then were filled with molten paraffin wax and left 
to set on a refrigerated surface. Once set, the wax blocks were kept at 
room temperature until required for sectioning. 
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2.4.2. Slide coating 
To increase the adhesion between the tissue sections and glass slides, 
slides were coated with the adhesive compound 3-
aminopropyltriethoxysilane (APES). Slides were first washed with 
acetone for 3 minutes after which they were immersed in a freshly 
prepared 4% solution of APES (Sigma-Aldrich, Poole, UK) in acetone for 
2 minutes. They were then washed under running tap water for 2 minutes 
and left to dry at room temperature before storage in a dust-free 
environment. 
2.4.3. Wax sectioning 
Wax blocks containing tumour tissues were kept at -20°C for at least 30 
minutes in order to increase wax rigidity before sectioning. 5µm thick 
sections were taken using a Leitz rotary microtome (Leica RM2155, 
Leica Microsystems, Nussloch, Germany) with disposable stainless steel 
blades. The sections were then collected in sequence, placed on labelled 
APES coated slides, and stored at room temperature prior to staining. 
2.4.4. Haematoxylin and Eosin staining (H&E) 
The sections were deparaffinised and rehydrated prior to staining. All 
steps were performed at room temperature. Slides were sequentially 
immersed in 100% xylene for 5 minutes (twice in different tanks), 50% 
xylene/ethanol for 5 minutes, 100% ethanol for 5 minutes (twice in 
different tanks), 90% ethanol for 5 minutes and 70% ethanol for 5 
minutes. Slides were then stained in Harris’s Haematoxylin solution 
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(Sigma Aldrich) for 10 minutes and washed under running tap water. 
Following washing, the haematoxylin staining was differentiated by briefly 
immersing the slides in acidic alcohol (0.25% hydrochloric acid in 70% 
ethanol) for 5 seconds in order to remove the excess haematoxylin and 
therefore leaving only the nuclei strongly stained but not the cytoplasm. 
Sections were then washed briefly using tap water before ‘blueing’ in a 
strongly alkaline solution, Scott’s tap water (STW, 3.5 g sodium 
bicarbonate and 20g magnesium sulphate dissolved in 1000 mL H₂O) for 
2 minutes. After that, sections were counterstained with 1% aqueous 
Eosin for 1 minute and washed briefly with running tap water before 
draining excess water for 1 minute. Once the sections were stained, they 
were then dehydrated by sequential immersions in absolute ethanol for 4 
minutes, 50% xylene/ethanol for 3 minutes and 100% xylene for 3 
minutes (twice in different tanks). Finally, the sections were mounted with 
coverslips using DPX medium (VWR international Ltd. Poole, England). 
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2.5. Immunohistochemistry 
2.5.1. Immunohistochemistry protocol for paraffin-embedded 
human clinical and tumour xenograft sections 
2.5.1.1.  Sample preparation 
Five µm-thick formalin-fixed and paraffin-embedded (FFPE) tissue 
sections were mounted on APES coated slides. The sections were 
deparaffinised and rehydrated by transferring them through xylene and 
serial dilutions of alcohol.  Slides were consecutively incubated in 100% 
xylene for 10 minutes (twice in different tanks), 50% xylene/ethanol for 5 
minutes, absolute ethanol for 5 minutes (twice in different tanks), 90% 
ethanol for 5 minutes, 70% ethanol for 5 minutes and distilled water for 5 
minutes. To block endogenous peroxidase activity, the sections were 
treated for 30 minutes with 1% hydrogen peroxide (H₂O₂) and were then 
washed 3 times in PBS (Phosphate Buffered Saline) for 3 minutes each. 
2.5.1.2. Antigen retrieval 
Antigen retrieval was performed by microwaving the slides in citrate 
buffer. The slides were placed in a plastic microwavable container 
containing citrate buffer (10 mM citrate buffer, pH 6.0). The container 
was then covered with punctured cling film and heated in a microwave at 
medium-high power (600W) for different time cycles (5 minutes per 
cycle) with the citrate buffer topped up where appropriate after every 
cycle. Following microwaving, the slides were allowed to cool for 30 
minutes in citrate buffer followed by 3 washes in PBS for 3 minutes each. 
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2.5.1.3. Antibody incubations 
Prior to antibody incubation, the non-specific binding of the antibodies 
was blocked by incubating the sections for 20 minutes at room 
temperature with 1.5% normal serum (diluted in PBS) of the species in 
which the secondary antibody was raised. Following treatment with 
blocking serum, the sections were incubated in a humid chamber with 
the primary antibody. The sections were then washed 3 times in PBS for 
3 minutes. The negative controls were incubated with normal serum for 
the same period of time. Following primary antibody treatment, each 
section was incubated with appropriate secondary antibodies (7.5 µg/mL 
in PBS) for 30 minutes at room temperature and washed 3 times in PBS 
for 3 minutes. After washing, the sections were then incubated with 
peroxidase-labelled streptavidin (Vector Laboratories Ltd, Peterborough, 
UK) for 30 minutes at room temperature and were then washed 3 times 
in PBS for 3 minutes. 
2.5.1.4. Visualisation of immunolocalisation 
Immunoreactivity was visualised by incubating sections with DAB 
chromogen (Vector Laboratories Ltd, Peterborough, UK) solution for 3-5 
minutes. Following colour development, sections were then washed in 
distilled water for 5 minutes before being counterstained in Harris’s 
haematoxylin solution for 20 seconds and washed thoroughly under 
running tap water. After washing, the slides were incubated in Scott’s tap 
water for 2 minutes. After blueing, the sections were dehydrated and 
cleared by successive incubation in 70% ethanol for 3 minutes, 90% 
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ethanol for 3 minutes, absolute ethanol for 3 minutes (twice in different 
tanks), 50% xylene/ethanol for 3 minutes and 100% xylene for 5 minutes 
(twice in different tanks). Finally, the sections were mounted with 
coverslips using DPX medium. The resulting slides were viewed as 
described in section 2.5.4.  
2.5.2. M.O.M Kit Staining Protocol for Paraffin Sections 
Where it was not possible to obtain clear immunolocalisation for primary 
mouse antibodies using the protocols described above, a kit (M.O.M kit, 
Vector Laboratories Ltd, Peterborough, UK) that is specially designed to 
localise primary antibodies on mouse tissues and consequently eliminate 
background staining in mouse tissue was utilised. 
2.5.2.1. Sample preparation 
Five µm-thick FFPE tissue sections were de-waxed and rehydrated as 
previously stated in section 2.5.1.1. Following rehydration, the sections 
were treated with 3% of hydrogen peroxide (H₂O₂) in order to block 
endogenous peroxidase activity and then washed twice in PBS for 2 
minutes. 
2.5.2.2. Preparation of M.O.M kit working solutions 
The mouse Ig blocking reagent was prepared by adding 2 drops of stock 
solution to 2.5mL of PBS. The diluent solution was prepared by diluting 
600 µL of protein concentrate stock solution to 7.5mL of PBS. The 
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Biotinylated anti-mouse IgG reagent was prepared by mixing 10 µL of 
stock solution with 2.5 mL of diluent solution prepared above. 
2.5.2.3. Antibody incubations 
Before antibody incubation, non-specific staining was blocked by treating 
the sections with working solution of M.O.M mouse Ig blocking reagent 
for 1 hour. The sections were then washed twice in PBS for 2 minutes 
and were then incubated with working solution of M.O.M diluent for 5 
minutes. After removing excess M.O.M diluents, the sections were 
incubated in a humid chamber with anti-PSA-NCAM mouse monoclonal 
antibody IgM (clone: 735). To confirm the specificity of staining, one 
section was treated with the EndoNF. Negative controls were incubated 
with M.O.M mouse blocking solution for the same period of time. The 
sections were then washed twice in PBS for 2 minutes and were then 
treated with M.O.M biotinylated anti-mouse IgG reagent for 10 minutes 
and washed twice in PBS for 2 minutes. After washing, the sections were 
incubated with peroxidase-labelled streptavidin for 30 minutes at room 
temperature and then washed twice in PBS for 2 minutes. The 
visualisation of immunoreactivity, counterstaining, dehydration and 
mounting were performed as previously described in section 2.5.1.4. The 
resulting slides were viewed as described in section 2.5.4.  
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2.5.3. PSA-NCAM detection using fluorescent fusion protein 
(EndoN-GFP) 
EndoN-GFP was used for the detection of PSA-NCAM expression in 
FFPE tissues. EndoN-GFP is a molecular tool that offers a very specific, 
effective and fast single-step protocol for detecting PSA-NCAM [115]. 
Five µm-thick FFPE tissue sections were de-waxed and rehydrated as 
previously stated in section (2.5.1.1) and were then washed in PBS for 
15 minutes. Prior to EndoN-GFP incubation the sections were incubated 
with normal horse serum (15:1000, diluted in PBS) for 1 hour at room 
temperature. After blocking, they were then incubated with 25 µg/mL 
EndoN-GFP for 1 hour in the dark. Following incubation, the sections 
were them rinsed and washed twice in PBS for 10 minutes. The slides 
were then mounted with cover slips using Vectashield hardset 
fluorescent mounting medium without DAPI (Vector Laboratories Ltd, 
Peterborough, UK). The slides were then stored at 4C until analysis. 
The resulting slides were viewed as described in section 2.5.4. 
2.5.4. Microscopy 
All the immunohistochemical analysis was performed by using a Leica 
DMRB microscope (Leica DMRB, Wetzlar, Germany) with the images 
digitally captured and processed using a Leica MPS52 camera (Q 
Imaging, Germany) and the AcQuis imaging capture system (Synoptics, 
Cambridge, UK) respectively. 
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2.6. Immunocytochemistry 
Cells were detached and counted as described previously in section 
2.3.2.  They were then seeded at 1x104 cells/mL onto autoclaved 22×22 
glass cover slips in 2mL of medium in a 6-well plate and the plates were 
then incubated at 37C overnight. Once cells adhered, the medium was 
removed and the cover slips were washed twice with HBSS. The cells 
were then fixed with ice cold methanol at -20°C for 30 minutes. After air-
drying, the cells were hydrated with PBS for 15 minutes (three washes of 
5 minutes each) before being stained at room temperature. The cells 
were blocked for non-specific binding of antibodies by being incubated 
for 10 minutes at room temperature with 1.5% normal serum prepared in 
PBS of the species in which the secondary antibody was raised. In case 
of EndoN-GFP, the cells were blocked with 1.5% normal horse serum 
prepared in PBS for 1hour. After removal of serum, the cells were 
incubated in a humid chamber with either primary antibodies or EndoN-
GFP.  Controls included were the omission of primary antibody and 
treatment with EndoNF. The cells were then washed 3 times in PBS for 5 
minutes followed by incubation with the respective secondary antibodies. 
Cover slips were washed 3 times in PBS for 5 minutes and then mounted 
with Vectashield hardset fluorescent mounting medium containing DAPI.  
The resulting slides were stored in the dark at 4C until analysis. The  
cells were analysed either with a confocal system (Zeiss LSM510) 
equipped with an Axiovert 200M inverted microscope using LSM510 
software (Zeiss, Welwyn Garden City, UK) or a Leica DMRB microscope 
83 
 
with images digital captured by a Leica MPS52 camera  and processed 
by the AcQuis imaging capture system.   
2.7. Flow cytometry 
All the protocol steps were performed at room temperature except for the 
fixation step. Once the cells had reached approximately 70% confluency, 
treatment was carried out where required and cells were then detached 
to produce single cell suspension as described previously in section 
2.3.2. The cells were then centrifuged for 5 minutes at 1000rpm and 
pellets were re-suspended in 5mL of HBSS/medium (2% FCS). After 
spinning for 5 minutes at 1000 rpm, cells were fixed with 1mL of 70% ice 
cold ethanol in PBS at -20oC for 30 minutes followed by addition of 
0.5mL PBS. Cells were then centrifuged at 1000rpm for 5 minutes and 
the ethanol/PBS layers were removed. Cell pellets were re-suspended in 
75 µL of 10 µg/mL of EndoN-GFP for 60 minutes in dark. After 
centrifugation for 5 minutes at 1000rpm, the cells were washed twice with 
PBS to remove excess EndoN-GFP followed by centrifugation for 5 
minutes at 1000rpm. Cell pellets were re-suspended in 500 μL of PBS 
and the samples were analysed using a BD FACS calibur flow cytometer 
operated by Cellquest™ software (Becton Dickinson, Oxford, UK). At 
least 10000 events were analysed per sample.  
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3. Characterisation of PSA-NCAM expression in 
neuroblastoma 
3.1. Introduction 
As previously described, PSA-NCAM is aberrantly found to be re-
expressed in many tumours including neuroblastoma [71-75]. In patients 
with neuroblastoma, PSA-NCAM expression has been associated with 
progressive disease and it has been put forward as a prognostic marker 
for metastatic neuroblastoma [71-73].  
Several lines of evidence support the notion that besides the physical 
effects on PSA on NCAM function, PSA decoration on NCAM is involved 
in modulating cellular signalling that contributes to tumour malignancy 
[93, 95]. However, the mechanisms of these effects remain largely 
elusive. PSA decoration of NCAM is thought to modulate cellular 
signalling by modifying the signalling of growth factor receptors and 
appearing to crosstalk with FGFR signalling machinery contributing to 
tumour metastasis [93, 116]. PSA was shown to facilitate activation of 
the FGFR signalling pathway, mediating subsequent activation of ERK 
1/2, and thereby promoting neoplastic cell migration [93].  
One of most important effects of PSA modification of NCAM in tumour 
malignancy is the interplay with neurotrophin signalling. It appears to be 
required for proper neurotrophin signalling in tumours but the mechanism 
of this effect remains poorly understood [92, 117]. PSA modification of 
NCAM was shown to promote the growth and survival of neuroblastoma 
cells by modulating BDNF-TrKB signalling [92] with PSA shown to 
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increase cell response to BDNF through the formation of large 
complexes of PSA-BDNF at the cell surface. These large complexes act 
as a reservoir for BDNF that delays the diffusion of BDNF away from the 
cell surface, retaining sufficient concentrations to enhance activation of 
TrKB receptors [92, 117]. Concordant with this, BDNF and TrKB were 
found to be over-expressed in aggressive neuroblastomas where their 
expression was associated with poor prognosis [25, 118, 119].  
Whilst there have been some studies evaluating PSA-NCAM in clinical 
tumours [61, 65, 66, 71-75, 78], none have attempted to explore the 
relationship between expression of PSA-NCAM and that of proteins 
involved in NCAM signalling.  
3.1.1. Aims 
The aims were to evaluate the expression of PSA-NCAM and the key 
proteins involved in NCAM signalling.  NCAM, FGFR, TrkB and ERK 1/2 
were analysed in archival clinical samples using immunohistochemical 
techniques in order to identify any correlations between PSA expression 
and the proteins involved in NCAM signalling. Given the limited material 
available for the clinical samples, these techniques were initially 
optimised using human tumour xenograft material. 
 
 
 
86 
 
3.2. Materials and methods 
3.2.1. Antibodies and associated materials 
All antibodies and associated materials used in this chapter were 
previously described in Chapter 2 (section 2.2). 
3.2.2. Human tumour xenografts 
Human tumour xenografts were obtained as described in Chapter 2 
(section 2.3.5). 
3.2.3. Clinical specimens 
All patient samples used in this study were obtained from St James’s 
University Hospital, Leeds. Ethical approval was obtained from the 
corresponding Research Ethics Committees before collecting the 
samples (Licence No. 07/H1306/98). 
FFPE material was obtained from 17 patients diagnosed with different 
types and stages of neuroblastoma. 10 patients were diagnosed with 
neuroblastoma, 6 with ganglioneuroblastoma and one patient with 
ganglioneuroma (Table 3.1). 
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Table 3.1. Patient number sex, age, histology, INPC classification and tumour 
stage.  
Number Sex Age Histology INPC Stage 
ET-3204 male 1 month Neuroblastoma Favourable 4S 
ET-3205 female 7 years Ganglioneuroblastoma Favourable 2 
ET-3206 female 5 years Ganglioneuroblastoma Favourable 
 
ET-3207 female 13 months Neuroblastoma Favourable 2b 
ET-3208 male 5 months Neuroblastoma Favourable 2 
ET-3209 female 6 years Ganglioneuroma Favourable 
 
ET-3210 male 5 months Neuroblastoma Favourable 1 
ET-3211 female 4 years Ganglioneuroblastoma Favourable 3 
ET-3212 female 4 years Ganglioneuroblastoma Favourable 
 
ET-3213 female 12 years Ganglioneuroblastoma Favourable 
 
ET-3214 female 3 months Neuroblastoma Favourable 1 
ET-3215 male 9 months Neuroblastoma Unfavourable IV 
ET-3216 male 15 months Neuroblastoma Favourable 3 
ET-3217 female 8 years Neuroblastoma Unfavourable I 
ET-3218 male 11 years Ganglioneuroblastoma Favourable 
 
ET-3219 female 19 months Neuroblastoma Unfavourable 4 
ET-3220 male 2 years Neuroblastoma Unfavourable 
 
INPC: International neuroblastoma pathology classification 
3.2.4. H&E staining 
Haematoxylin and eosin staining for clinical specimens was performed as 
previously stated in Chapter 2 (section 2.4.4). 
3.2.5. M.O.M. kit labelling protocol for detection of PSA-NCAM in 
paraffin sections 
3.2.5.1. Sample preparation 
Five µm-thick FFPE tissue sections were prepared for immunostaining as 
previously stated in Chapter 2 (section 2.5.2.1).  
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3.2.5.2. Preparation of M.O.M. kit working solutions 
The M.O.M working solutions were prepared as previously described in 
Chapter 2 (section 2.5.2.2). 
3.2.5.3. Antibody incubations 
Before antibody incubation, non-specific staining was blocked by treating 
the sections with working solution of M.O.M. mouse Ig blocking reagent 
for 1 hour. Sections were then washed twice in PBS for 2 minutes. 
Following washing, the sections were incubated with working solution of 
M.O.M. diluent for 5 minutes. After removing excess M.O.M. diluents, 
they were incubated in a humid chamber with 25 µg/mL anti-PSA-NCAM 
mouse monoclonal antibody IgM (clone: 735) for 1 hour at room 
temperature. To confirm the specificity of staining, one section was 
treated with EndoNF (1 µg/mL) to remove PSA-NCAM and thereby 
abolish immunolabelling. Negative controls were incubated with M.O.M. 
mouse blocking solution for the same period of time. The sections were 
then washed twice in PBS for 2 minutes and then treated with M.O.M 
biotinylated anti-mouse IgG reagent for 10 minutes and washed further 
twice in PBS for 2 minutes. After washing, sections were then incubated 
with peroxidase-labelled streptavidin for 30 minutes at room temperature 
and then washed twice in PBS for 2 minutes.  
The visualisation of immunoreactivity, counterstaining, dehydration and 
mounting were performed as previously described in Chapter 2 (section 
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2.5.1.4). The resulting slides were viewed as described in Chapter 2 
(section 2.5.4).  
3.2.6. IHC protocol for NCAM, FGFR1, TrKB and ERK1/2 in 
paraffin-embedded human clinical and tumour xenograft 
sections. 
3.2.6.1.  Sample preparation 
Five µm-thick FFPE tissue sections were prepared for 
immunohistochemistry as previously stated in Chapter 2 (section 
2.5.1.1). 
3.2.6.2. Antigen retrieval 
Antigen retrieval was performed for NCAM, FGFR1 and TrKB 
immunodetection (none was required for ERK1/2) by microwaving the 
slides in a citrate buffer. The slides were placed in a plastic 
microwavable container containing citrate buffer (10 mM citrate buffer, 
pH 6.0). The container was covered with punctured cling film and heated 
in a microwave at medium-high power (600W) for 20 minutes (5 minutes 
per cycle) with the citrate buffer topped up where appropriate after every 
cycle.  Following microwaving, slides were allowed to cool for 30 minutes 
in citrate buffer followed by 3 washes in PBS for 3 minutes each. 
3.2.6.3. Antibody incubations 
Prior to antibody incubation, the non-specific binding of antibodies was 
blocked by incubating the sections for 20 minutes at room temperature 
90 
 
with normal serum (15:1000, diluted in PBS) of the species in which the 
secondary antibody was raised. Following treatment with blocking serum, 
sections were incubated in a humid chamber with either rabbit anti-
NCAM (1 µg/mL), goat anti-FGFR1 (4 µg/mL), rabbit anti-TrkB (4 µg/mL) 
or rabbit anti-ERK1/2 (2 µg/mL) antibodies and left overnight at 4 oC. 
Sections were then washed 3 times in PBS for 3 minutes. The negative 
controls were incubated with normal serum for the same period of time. 
Depending on primary antibody type, each section was incubated with 
secondary antibodies (7.5 µg/mL in PBS) of either biotinylated goat anti-
rabbit or biotinylated rabbit anti-goat for 30 minutes at room temperature 
and washed 3 times in PBS for 3 minutes. After washing, the sections 
were then incubated with peroxidase-labelled streptavidin (Vector 
Laboratories Ltd, Peterborough, UK) for 30 minutes at room temperature 
and were then washed 3 times in PBS for 3 minutes. 
The visualisation of immunoreactivity, counterstaining, dehydration and 
mounting were performed as previously described in Chapter 2 (section 
2.5.1.4). The resulting slides were viewed as described in Chapter 2 
(section 2.5.4).  
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3.2.7. Scoring of immunohistochemical labelling of neuroblastoma 
clinical samples 
The scoring system used to analyse immunohistochemical labelling of 
neuroblastoma clinical samples was based on previously published 
studies [71, 72, 120]. Criteria for identification of cell type classification 
were finalised after discussion with consultant histopathologists Dr. 
Catherine Cullinane and Dr. Jens Stahlschmidt (Oncology Unit, St 
James’s University Hospital, Leeds). The cell types observed were 
classified as neuroblastic, ganglionic or Schwannic cells (Figure 3.1). For 
PSA-NCAM and NCAM expression, cells were considered positive if they 
demonstrated clear membranous immunolabelling. For FGFR1 
expression, cells were considered positive if they demonstrated clear 
membranous and/or cytoplasmic immunolabelling. For TRKB expression, 
cells demonstrating clear cytoplasmic and/or nuclear immunolabelling 
were considered positive. For ERK1/2 expression, cells were considered 
positive if they demonstrated clear nuclear immunolabelling (Figure 3.2). 
The scoring results were calculated as percentage of cells showing 
positive expression as opposed to strength of staining in an individual 
cell. The scoring results of each immunolabelling of specific cell types 
were presented as: none (-), weak (+), medium (++) and high (+++). The 
score ‘none’ indicated an absence of expression. Sections were 
allocated a score of ‘weak’ when less than 33% of cells had expression. 
A score of ‘medium’ was applied to cells which had expression on 33% to 
66% of the section whilst the score ‘high’ represented sections which had 
expression on more than 67% of the cells. 
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Figure 3.1. Cellular heterogeneity of neuroblastoma (black arrows). a 
Neuroblastic cells, b Ganglionic Cells and c Schwann Cells. Scale bar = 50 µm. 
a 
b 
c 
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Figure 3.2. Immunolabelling pattern of PSA-NCAM, NCAM, p-FGFR, p-TrKB and p-
ERK1/2 in neuroblastic cells (white arrows). Clear, specific PSA-NCAM labelling 
localised to the cell membrane (a). NCAM exhibited a similar membranous labelling 
pattern as the PSA-NCAM (b). p-FGFR1 labelling localized to the cell membrane and/or 
cytoplasm (c). p-TrKB labelling localised to the cell cytoplasm and/or nucleus (d). p-
ERK1/2 labelling localised to the cell nucleus (e). Scale bar = 30 µm. 
3.2.8. Statistical analysis 
The data was appropriately coded and subjected to analysis using the 
Fisher’s Exact Test and to linear regression using Stata 9 software 
(College Station, Texas, USA). 
a 
d c 
b 
e 
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3.3. Results 
3.3.1. Optimisation of immunohistochemistry (IHC) in FFPE 
xenograft sections 
3.3.1.1. IHC of PSA-NCAM  
In order to optimise IHC for PSA-NCAM immunodetection in FFPE 
sections of human tumour xenograft, several variables were considered. 
These variables included antigen retrieval, antibody incubation time and 
concentration, and use of the M.O.M. basic immunodetection kit. 
Initially, PSA-NCAM positive IMR-32 (neuroblastoma) and PSA-NCAM 
negative HCT-116 (Colorectal carcinoma) xenografts were assessed. 
Here, tissue sections were subjected to heat-induced antigen retrieval to 
recover the tissue antigenicity which may have been adversely altered by 
formalin fixation. The optimisation of the antigen retrieval process was 
performed by microwaving the IMR-32 and HCT-116 sections for 
different time periods: 0, 10 minutes (2x5 minutes cycle) and 20 minutes 
(4x5 minutes cycle). The primary antibody was used at a concentration of 
50 µg/mL and was incubated for 1 hour at room temperature. 
Immunoreactivity was visualised by incubating the sections with DAB for 
5 minutes. Whilst high background staining was observed in sections 
without antigen retrieval, no immunolabelling or background staining was 
seen where antigen retrieval was used (Figure 3.3 a-h).  
The optimisation of the PSA-NCAM immunodetection method was 
continued with the aim of optimising immunoreactivity and eliminating 
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background staining. This was achieved by assessing different 
concentrations of primary antibody (5, 10, 25 and 50 µg/mL) for different 
incubation times (for 1 hour at room temperature or overnight at 4C). 
However, all attempts were unsuccessful as specific immunoreactivity 
obscured by high background staining was seen in IMR-32 tissues and 
diffuse staining was seen for HCT-116 (Figure 3.3 e and g). Therefore, 
the next step was to use the M.O.M immunodetection kit to see if this 
would eliminate background staining. This kit is specially designed to 
localize mouse primary antibodies on mouse tissues and consequently 
eliminates background staining [121]. 
3.3.1.2. M.O.M. immunodetection of PSA-NCAM 
The M.O.M. method was optimised using IMR-32 and HCT-116 tissue 
sections, at the optimum conditions of 25 µg/mL concentration of primary 
antibody for one hour at room temperature. The IMR-32 tissue sections 
displayed definitive cell-surface associated immunoreactivity. The 
staining was predominantly localised to the membranes of tumour cells 
without any significant staining noted in the cytoplasm, giving a 
distinctive ‘honeycomb’ pattern to areas of immunolabelled cells. In 
contrast, HCT-116 tissue sections showed no immunoreactivity or diffuse 
non-specific labelling (Figure 3.3 i-l).  
In order to validate the results obtained at that point, PSA-NCAM 
expression was evaluated across a large panel of xenografts such as 
predicted PSA-NCAM positive tumours including SK-N-SH 
neuroblastoma, and predicted negative tumours including HT1080 
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fibrosarcoma, HT-29 colon adenocarcinoma and EJ-138 bladder 
carcinoma. Consequently, similar results were obtained for IMR-32 
confirming PSA-NCAM immunoreactivity in SK-N-SH neuroblastoma 
tissue sections. To confirm the specificity of immunolabelling, treating 
IMR-32 tissue with EndoNF to remove PSA-NCAM resulted in a lack of 
immunoreactivity suggesting the specificity of the PSA-NCAM antibody. 
As expected, no specific immunolabelling was seen for the other tumour 
xenografts (Figure 3.4).  
 
97 
 
 IMR-32 HCT-116 
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Figure 3.3. Optimisation of IHC to detect PSA-NCAM expression in human xenograft tissues. No specific immunoreactivity seen for IMR-32 (a) and 
HCT-116 (c) with antigen retrieval. No specific immunoreactivity was seen without antigen retrieval, with high non-specific background staining (e and g). 
Clear, specific PSA-NCAM labelling localised to the cell membrane seen for IMR-32 using the M.O.M. kit (i), with no immunopositivity seen for HCT-116 (k), 
For all experiments, negative controls where no primary antibody was administered show no immunopositivity (b, d, f, h, j and l). Scale bar = 50 µm.  
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d c 
j i 
h 
l k 
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Figure 3.4. Evaluation of PSA-NCAM expression in a panel of tumour xenografts 
using M.O.M. Clear, specific PSA-NCAM labelling localised to the cell membrane seen 
for IMR-32 (a) and SK-N-SH (b). No immunopositivity seen in IMR-32 treated with the 
EndoNF (c). No specific immunoreactivity above background seen for HT-29 (d), HCT-
116 (e), HT1080 (f) and EJ-138 (g). No immunopositivity was seen in the IMR-32 
negative control where no primary antibody was administered (h). Scale bar = 50 µm. 
a 
d c 
b 
h g 
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3.3.1.3. PSA-NCAM detection using EndoN-GFP 
To further confirm the specificity of the immunolabelling seen with the 
antibody, PSA-NCAM expression was also investigated in paraffin 
embedded tissues using EndoN-GFP. IMR-32 and HCT-116 tissue 
sections were incubated with 25 µg/mL of EndoN-GFP for one hour at 
room temperature. A similar ‘honeycomb’ labelling pattern was seen in 
the antibody for IMR-32 however no labelling was seen in any of the 
negative controls (Figure 3.5).  
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Figure 3.5. Labelling with EndoN-GFP gives a similar labelling pattern to the anti-
PSA-NCAM antibody when used in human xenograft tissues. Clear, specific PSA-
NCAM labelling localised to the cell membrane seen for IMR-32 (c), with no labelling 
seen for HCT-116 (d). No immunopositivity seen in IMR-32 (a) and HCT-116 (b) 
negative controls where no endoN-GFP was administered. Scale bar = 50 µm. 
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3.3.1.4. IHC for NCAM, p-FGFR1, p-TrkB and p-ERK1/2 in xenograft 
sections 
Immunodetection of NCAM, p-FGFR1, p-TrKB and p-ERK1/2 FFPE 
xenograft sections was optimised by manipulating several variables 
including antigen retrieval and antibody incubations. Table 3.2 
summarises the optimised conditions for immunodetection of these 
molecules. 
Table 3.2. Optimum conditions for immunodetection of NCAM, FGFR1, TrKB and 
ERK1/2. 
 Antigen retrieval 
(minutes) 
Concentration of primary 
antibody (µg/mL) 
Incubation time of 
primary antibody 
NCAM 20 1 overnight at 4 
o
C 
p-FGFR1 20 4 overnight at 4 
o
C 
p-TrKB 20 4 overnight at 4 
o
C 
p-ERK1/2 - 2 overnight at 4 
o
C 
 
Figure 3.6 shows the labelling pattern seen for each antibody in IMR-32 
(PSA-NCAM positive) and HT-29 (PSA-NCAM negative) xenografts. 
NCAM exhibited a similar membranous ‘honeycomb’ labelling pattern as 
the PSA-NCAM. p-FGFR1 expression was seen at the cell membrane 
and/or in the cytoplasm whilst p-TrKB expression was seen in the 
cytoplasm and/or the nucleus. p-ERK1/2 expression was seen clearly in 
the nucleus. 
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Figure 3.6. Optimised IHC for the detection of NCAM, p-FGFR1, p-TrKB and p-
ERK1/2 expression in xenograft tissues (arrows). Clear, specific NCAM labelling 
localised to the cell membrane was seen for IMR-32 (a), with no immunopositivity seen 
for HT-29 (b). p-FGFR1 labelling localized to the cell membrane and/or cytoplasm seen 
for IMR-32 (c). p-TrKB labelling localised to the cell cytoplasm and/or nucleus seen for 
IMR-32 (d).p- ERK1/2 labelling localised to the cell nucleus seen for IMR-32 (e). Scale 
bar = 50 µm. 
3.3.2. IHC on clinical samples 
Following the optimisation of protocols for immunodetection of PSA-
NCAM, NCAM, FGFR1, TrKB and ERK1/2 on xenograft tissues, these 
protocols were used in the FFPE neuroblastoma clinical samples.  Table 
a 
d c 
b 
e 
102 
 
3.3 summarises the scores for immunolabelling for the antibody panel 
against the clinical samples, with further breakdown into specific cell 
type. Representative images for the panel are shown in Figure 3.7. 
Table 3.3. Cell type-based IHC analysis for the antibody panel in the clinical 
neuroblastoma material. 
 
N: Neuroblastic, G: Ganglionic, S: Schwannic cells, (-) = None, (+) = (<33%), (++) = (>33%) and (+++) = 
(>67%).
Number Histology Cell type % PSA-NCAM NCAM TrkB FGFR1 ERK1/2
ET-3204 Neuroblastoma N 100 +++ +++ ++ ++ ++
G
S
ET-3205 Ganglioneuroblastoma N
G 6 ++ +++ +++ ++ ++
S 94 +++ ++ + ++ +++
ET-3206 Ganglioneuroblastoma N
G 1 + +++ +++ + +++
S 99 ++ +++ + +++ +++
ET-3207 Neuroblastoma N 100 +++ +++ ++ ++ +
G
S
ET-3208 Neuroblastoma N 100 +++ +++ + + +
G
S
ET-3209 Ganglioneuroma N
G 3 + +++ + + +++
S 97 + +++ + +++ +++
ET-3210 Neuroblastoma N 91 +++ +++ ++ + ++
G
S 9 +++ +++ - - ++
ET-3211 'Ganglioneuroblastom N
G 4 ++ +++ +++ +++ +++
S 96 +++ +++ + + ++
ET-3212 Ganglioneuroblastoma N
G 7 +++ +++ +++ ++ ++
S 93 ++ +++ + + +
ET-3213 Ganglioneuroblastoma N
G 17 +++ +++ + ++ +++
S 83 ++ ++ + + +++
ET-3214 Neuroblastoma N 97 +++ +++ ++ + +
G
S 3 + + + + ++
ET-3215 Neuroblastoma N 76 +++ +++ ++ + +
G
S 24 + + ++ + +
ET-3216 Neuroblastoma N 73 +++ +++ + + +
G
S 27 ++ ++ + + ++
ET-3217 Neuroblastoma N 74 +++ +++ ++ + +
G
S 26 ++ ++ + - +++
ET-3218 Ganglioneuroblastoma N
G 3 +++ +++ ++ ++ +
S 97 +++ +++ + - ++
ET-3219 Neuroblastoma N 64 +++ +++ ++ ++ +
G 1 +++ +++ ++ ++ ++
S 35 ++ ++ + + ++
ET-3220 Neuroblastoma N 85 +++ +++ ++ + -
G
S 15 + ++ ++ + ++
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Figure 3.7. Representative images for positive labelling for the panel of antibodies (arrows).  Distinct PSA-NCAM labelling of the cell membrane seen for 
neuroblastic (a), ganglionic (b) and Schwannic cells (c) cells, with lymph node tissue showing no labelling in (a). NCAM exhibited a similar membranous labelling 
pattern as the PSA-NCAM for neuroblastic (d), ganglionic (e) and Schwannic cells (f), with lymph node tissue showing no labelling in (d). Weak p-TrkB labelling of 
cell cytoplasm and/or nucleus seen for neuroblastic (g), and Schwannic cells (i) while strong labelling seen for ganglionic cells (h). Weak p-FGFR1 labelling of cell 
membrane and/or cytoplasm seen for neuroblastic (j), and Schwannic cells (l) while strong labelling seen for ganglionic cells (k). Weak p-ERK1/2 labelling of cell 
nucleus seen for neuroblastic (m) while strong labelling seen for ganglionic cells (n) and Schwannic cells (o). Scale bar = 50 µm.   
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3.3.2.1. Statistical Analysis 
Initial analysis of the data was attempted based on the overall 
histopathological diagnosis of the patient material. Of the 17 patients, 10 
patients were diagnosed with neuroblastoma, 6 with 
ganglioneuroblastoma and one patient with ganglioneuroma.  
Analysis revealed that PSA-NCAM was expressed more in the 
neuroblastoma diagnosed patients than those diagnosed with 
ganglioneuroblastoma and ganglioneuroma, although this was not 
statistically significant. Moreover, there were no significant differences 
observed for NCAM expression across the different tumour histologies. 
Likewise, p-FGFR1 was also widely expressed in the different tumour 
histologies, with no significant differences. Unlike the other molecules, 
expression of both p-TrkB and p-ERK1/2 exhibited differential 
expression. TrkB was more highly expressed in the neuroblastoma than 
in the ganglioneuroblastoma and ganglioneuroma types. Conversely p-
ERK1/2 was more frequently expressed in ganglioneuroblastoma and 
ganglioneuroma than in neuroblastoma (Table 3.4). However, PSA-
NCAM expression correlations were not measurable due to the small 
sample size. 
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Table 3.4. Fisher’s Exact analysis results for each of the biomarkers when 
compared against overall histopathological diagnosis, with the p value denoting 
significance of expression between the 3 different cell types examined. (*) not 
significant at the 95% level. 
MARKER p VALUE 
PSA-NCAM 0.343* 
NCAM 0.569* 
p-Trkb 0.006 
p-Fgfr1 0.064* 
p-Erk1/2 0.007 
 
As cellular heterogeneity is characteristic for neuroblastoma, the 
expression of biomarkers was further analysed at the cellular level. PSA-
NCAM was more frequently expressed in neuroblastic than in other cell 
types but the p value did not reach statistical significance (0.052). A 
statistically significant difference was however seen for NCAM 
expression, with higher expression seen for neuroblastic and ganglionic 
cells compared to Schwannic cells. p-TrkB expression also showed 
statistically significant differential expression in the same manner. In 
contrast, p-ERK1/2 expression was significantly higher in Schwannic 
cells than in ganglionic and neuroblastic cells.  Although not significant 
(0.056), p-FGFR1 had higher expression in neuroblastic cells than in the 
other cell types (Table 3.5). 
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Table 3.5. Fisher’s Exact analysis results for each of the biomarkers with the p 
value denoting significance of expression between the 3 different cell types 
examined. (*) not significant at the 95% level. 
MARKER p VALUE 
PSA-NCAM 0.052* 
NCAM 0.003 
p-Trkb 0.015 
p-Fgfr1 0.056* 
p-ERK1/2 0.011 
 
Using linear regression analysis, all 5 biomarkers were also evaluated to 
detect for statistical evidence of any relationship between co-expression, 
sex, age, histology, INPC classification, tumour stage and cell type. 
Unfortunately, however, no statistically significant relationships were 
identified. This is likely to be due to the small sample size of this pilot 
study.  
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3.4. Discussion 
Several lines of evidence indicate the importance of PSA-NCAM 
expression in malignant tumours where it is increasingly recognized as a 
potential modulator of tumour invasion and metastasis including in 
neuroblastoma [59-61, 69, 78, 85]. The overall survival for patients with 
high risk neuroblastoma is poor despite recent advances in 
neuroblastoma therapy [14]. A potential new therapeutic approach which 
may be beneficial for the treatment of neuroblastoma is associated with 
the presence of PSA-NCAM. Besides its physical properties, there is 
growing evidence to support the potential impact of PSA decoration on 
NCAM signalling that contributes to malignancy. PSA modification 
promotes malignancy through masking NCAM signalling and crosstalk 
with other signalling receptors and pathways, such as FGFR [93, 95, 
116], TrKB [92] and ERK1/2 [87, 93]. Therefore, the overall aims of this 
part of the study were to characterize PSA-NCAM expression as a drug 
target in neuroblastoma and to look at co-expression of PSA-NCAM and 
other molecules such as FGFR1, TrKB and ERK1/2 involved in NCAM 
signalling. 
The initial objectives were to develop methodologies to characterise 
expression of PSA-NCAM and other molecules in clinical neuroblastoma 
samples. Since PSA-NCAM is expressed in minute quantities, detection 
by chemical methods is made difficult. Anti-PSA-NCAM antibodies and 
EndoN-GFP have been developed as powerful probes in localising and 
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elucidating the functional roles of PSA-NCAM with 
immunohistochemistry.   
PSA-NCAM expression was initially investigated in paraffin-embedded 
xenograft tissues using both an antibody-based detection method and 
EndoN-GFP in order to optimise these techniques, before embarking on 
the studies in precious clinical material. The antibody-based detection of 
PSA-NCAM expression was performed using a mouse anti-PSA-NCAM 
monoclonal antibody (clone: 735) [122], which has already been used 
widely for detection of PSA-NCAM on the surface of tumour cells [86, 87, 
123]. It recognizes the specific helical structure within the internal region 
of polysialic acid chains formed by a minimum 10 residues of α-2,8-linked 
sialic acid [124]. Moreover, PSA-NCAM expression was further 
investigated in paraffin-embedded xenograft tissues by using EndoN-
GFP. This protein is an inactive endosialidase fused with green 
fluorescent protein (GFP). EndoN-GFP efficiently and specifically binds 
to PSA without degrading it. EndoN-GFP recognises polysialic acid 
chains formed by a minimum 4 residues of the α-2,8 linked sialic acid 
and offers advantages over conventional antibodies in a way that it is 
very specific, effective and fast single-step protocol for detecting PSA-
NCAM [115]. As PSA-NCAM is expressed on the membrane of tumour 
cells, a clear membranous reaction would be exhibited by both methods 
of detection. 
Consistent with other studies, the resulting pattern of PSA-NCAM 
immunoreactivity was similar to that previously described, indicating the 
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specificity of primary antibody [61-63, 66, 67, 77]. Moreover, the intensity 
of PSA-NCAM immunoreactivity was heterogeneous across the tumour 
tissue. This heterogeneity is probably due to the wide variety of degrees 
of polymerisation seen for the PSA-NCAM homopolymer such that areas 
of cells where low polymerisation is present may not be detected as 
strongly positive [61, 66].  
Unfortunately, the sample size of this study was too small to permit 
robust statistically significant correlations to be made between PSA-
NCAM expression and the identified signalling molecules. However, 
some clear trends were apparent, particularly between expression of 
individual signalling molecules and cell types.  
Although not statistically significant, PSA-NCAM was more highly 
expressed in the histopathologically diagnosed neuroblastoma 
phenotype compared to ganglioneuroblastoma and ganglioneuroma. 
These results are consistent with other studies where PSA-NCAM 
expression strongly correlated with tumour histology [73, 75]. PSA-
NCAM was seen to be highly expressed in aggressive neuroblastomas 
and lower in less aggressive and benign tumours such as 
ganglioneuroblastoma and ganglioneuroma [73, 75]. Whilst this 
differential expression has been reported for PSA-NCAM, the lack of 
differential expression for NCAM seen here also concurs with previous 
studies [75].  
Given the cellular heterogeneity that exists in neuroblastoma, the results 
were also analysed for each case looking at expression for each of the 3 
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main cell phenotypes seen. Again, although the sample size was too 
small to permit statistically significant correlations to be made regarding 
molecule expression, some clear trends were apparent. Within each 
tumour sample, PSA-NCAM expression was highly expressed in 
neuroblastic cells compared to the other cell phenotypes. Since the 
undifferentiated neuroblastic phenotype is the most aggressive in terms 
of potential for tumour dissemination [13, 14], it further supports the 
linkage between high PSA-NCAM expression and tumour 
aggressiveness in neuroblastoma.  
Although there was no difference in NCAM expression in the gross 
pathology analysis, NCAM expression was significantly associated with 
cell phenotype (on a cell phenotype basis), following a similar pattern to 
PSA-NCAM expression. This supports other studies [37] suggesting that 
NCAM acts as the sole carrier of PSA. 
As reported previously, there are several lines of evidence suggested for 
the interplay between polysialylation of NCAM and FGFR signalling 
machinery [93]. Due to the small sample size it was not possible here to 
determine an association between FGFR1 and PSA-NCAM, and thus a 
larger sample size would be required to explore this further. The fact that 
analysis revealed that there was no difference in FGFR1 expression 
across all tumour histologies and in different cell phenotypes would 
suggest that there may be other factors at play in controlling FGFR1 
signalling as well as PSA-NCAM.  
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Phosphorylated ERK1/2 was seen to be highly expressed in 
ganglioneuroblastoma and ganglioneuroma compared to the 
neuroblastoma diagnosis, and likewise at cellular level the most 
differentiated cell types, the Schwannic cells showed the highest ERK1/2 
expression. These statistically significant results suggest that activation 
of ERK1/2 promotes tumour differentiation, and concurs with a previous 
study which suggested that activation of ERK1/2 enhances the survival 
and differentiation of neuroblastoma cells [87].  
As the over-expression of TrkB and its ligand BDNF in neuroblastoma is 
often associated with unfavourable prognosis [25, 118], TrkB expression 
was also studied. In agreement with the literature, TrkB was seen to be 
more highly expressed in the neuroblastoma phenotype compared to 
ganglioneuroblastoma and ganglioneuroma, and also in the neuroblastic 
cell phenotype.   
In conclusion, following optimisation of IHC protocols, the antibody panel 
was used to evaluate the expression of PSA-NCAM and key proteins 
involved in NCAM signalling in archival neuroblastoma clinical samples. 
Whilst the sample size was too small to confirm any statistically 
significant relationships, trends were evident throughout the samples 
which backed up previous findings in the literature for neuroblastoma. 
Most important was the association between high PSA-NCAM 
expression and tumour aggressiveness. This highlights the potential of 
PSA-NCAM as a novel therapeutic opportunity for the development of a 
new therapeutic strategy for the treatment of neuroblastoma. 
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4. Assembly of a cell line panel for in vitro 
pharmacological studies  
4.1. Introduction 
From the previous chapter, it is evident that PSA-NCAM is over-
expressed in neuroblastoma xenograft and clinical tissues. This, in 
addition to published literature [71-75], supports the potential for the 
development of therapeutics in this area. Therefore, this chapter 
examines the selection of suitable cell lines that would serve as models 
for future development and optimisation in cell-based assays for the 
pharmacological screening of novel polyST inhibitors.  
There are many characteristics required of a cell line suitable for use in 
such models. The cell line should ideally be from a human source, and 
positive cell lines should stably and naturally express NCAM, PSA-
NCAM and the polySTs. The cells should ideally grow as adherent cell 
monolayers, to enable use in functional assays. Two cell lines meeting 
these criteria are IMR-32 and SK-N-SH. These cell lines have been 
reported to express NCAM, PSA-NCAM and polySTs [84, 89, 90]. Both 
cell lines also grow as adherent monolayers.  
Isogenic cell lines are an extremely useful tool in evaluating agents to a 
specific target. Such cell lines are engineered to over-express a given 
enzyme or receptor. The only difference between the engineered cell line 
and the wild type is expression of the target of interest. In this case a cell 
line selectively expressing polySTs (and therefore PSA-NCAM) would be 
highly useful. In this project, a pair of C6 rat glioma cell lines were used, 
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one of which was engineered to over-express STX (C6-STX) whilst wild 
type cells (C6-WT) (which expresses only naked NCAM) served as the 
control. This unique isogenic cellular model was originally established by 
Suzuki and co-workers. It was developed by transfecting C6 cells with 
either pcDNA3 encoding a full length human STX or lacking cDNA 
(mock). Cells transfected with STX enzyme expressed PSA-NCAM, while 
no PSA-NCAM expression was observed in mock transfected or wild 
type cells [78]. 
Another useful approach would be to select a cell line that does not 
express both NCAM and PSA-NCAM to confirm specificity of any effect 
seen with polyST inhibitors. The human colorectal DLD-1 cell line was 
characterised since this cell line has been reported to fit this criteria [84]. 
4.1.1. Aims 
The aims of the work described in this chapter were to assemble a panel 
of cell lines for the development of cell-based assays to investigate the 
effects of PSA inhibition, to characterise the growth patterns of these cell 
lines, and characterise PSA-NCAM and NCAM expression using 
immunocytochemical techniques. In addition, quantification of this 
expression by flow cytometry was performed in the case of the IMR-32 
cell line. 
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4.2. Methods 
4.2.1. Characterisation of cell growth 
4.2.1.1. Evaluation of the reproducibility for specific cell lines 
The reliability of the MTT assay to accurately reflect viable cell number 
was evaluated as previously described in Chapter 2 (section 2.3.3.1) 
using two of the cell lines under investigation, C6-STX and IMR-32.  
4.2.1.2. Assessment of cell growth using the MTT assay 
The growth of C6-STX, C6-WT, IMR-32 and SK-N-SH cell lines was 
observed as previously described in Chapter 2 (section 2.3.3.2)   using 
the MTT assay. 
4.2.2. Immunocytochemistry of PSA-NCAM 
4.2.2.1. PSA-NCAM detection by using anti-PSA-NCAM antibody 
PSA-NCAM expression and morphological localisation were evaluated 
across a panel of cell lines using the antibody-based method as 
described previously in Chapter 2 (section 2.6). C6-STX, C6-WT, IMR-
32, SK-N-SH and DLD-1 cells on coverslips were blocked with 1.5% 
normal rabbit serum prepared in PBS (NRS-PBS) for 10 minutes. After 
removal of serum, cells were immunolabelled with mouse anti-PSA-
NCAM monoclonal antibody (clone: 735, 15 µg/mL) prepared in 1.5% 
NRS-PBS for 30 minutes at room temperature. Cover slips were then 
washed 3 times in PBS for 5 minutes followed by incubation with TRITC-
conjugated rabbit anti-mouse (Dako, Cambridgeshire) secondary 
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antibody prepared in PBS for 30 minutes in darkness. As a negative 
control, C6-STX cells were treated with EndoNF (0.5 µg/mL) to remove 
PSA-NCAM. Cover slips were washed 3 times in PBS for 5 minutes and 
then mounted with Vectashield hardset fluorescent mounting medium 
containing DAPI. 
4.2.2.2. PSA-NCAM detection using EndoN-GFP 
PSA-NCAM expression was further investigated in the C6-WT, C6-STX, 
IMR-32, SK-N-SH and DLD-1 cells using EndoN-GFP as previously 
described in Chapter 2 (section 2.6). Cells were blocked with 1.5% 
normal horse serum prepared in PBS for 1 hour. After removal of serum, 
cells were incubated with EndoN-GFP (10 µg/mL) for 1 hour in darkness 
at room temperature. As a negative control, C6-STX cells were treated 
with EndoNF (0.5 µg/mL) to remove PSA-NCAM. The cover slips were 
washed 3 times in PBS for 10 minutes and then mounted with 
Vectashield hardset fluorescent mounting medium containing DAPI. 
4.2.3. Immunocytochemistry of NCAM 
NCAM expression was characterised as described previously in Chapter 
2 (section 2.6). The C6-STX, C6-WT, IMR-32, SK-N-SH and DLD-1 cells 
were incubated with rabbit anti-NCAM polyclonal antibody (2 µg/mL) 
prepared in PBS for 30 minutes at room temperature followed bybeing 
washed 3 times in PBS for 5 minutes. Cells were then incubated with 
FITC-conjugated goat anti-rabbit secondary antibody prepared in PBS for 
30 minutes in darkness. As a control, C6-STX cells were treated with 
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EndoNF (0.5 µg/mL) to remove PSA from NCAM. Cover slips were then 
mounted with Vectashield hardset fluorescent mounting medium 
containing DAPI. 
4.2.4. PSA-NCAM and NCAM dual labelling 
Dual labelling was performed to evaluate the spatial localisation of PSA-
NCAM and NCAM on the surface of cells. The C6-STX and IMR-32 cells 
were incubated with a mixture of mouse anti-PSA-NCAM monoclonal 
antibody (clone: 735, 15 µg/mL) and rabbit anti-NCAM polyclonal 
antibody (2 µg/mL) prepared in PBS for 30 minutes at room temperature. 
Cells were then washed 3 times in PBS for 5 minutes followed by 
incubation with a mixture of TRITC-conjugated rabbit anti-mouse and 
FITC-conjugated goat anti-rabbit secondary antibodies for 30 minutes in 
darkness. Cover slips were washed 3 times in PBS for 5 minutes and 
then mounted with Vectashield hardset fluorescent mounting medium 
containing DAPI. 
4.2.5. Quantitative analysis of PSA-NCAM by flow cytometry 
PSA-NCAM expression was quantitatively analysed in IMR-32 cells by 
flow cytometry as previously described in Chapter 2 (section 2.2.7). 
Briefly, IMR-32 cells were detached to produce a single cell suspension 
followed by fixation of cells with 70% ice-cold ethanol prepared in PBS at 
-20oC for 30 minutes. Following washing in PBS and centrifugation, cell 
pellets were then re-suspended in 75 µL of 10 µg/mL of EndoN-GFP for 
60 minutes in darkness at room temperature. Controls included omission 
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of EndoN-GFP labelling and EndoNF treatment (0.5 µg/mL) for 24 hours. 
After two further washes with PBS, cell pellets were re-suspended in 500 
µL of PBS and samples were stored at 4°C before subsequent analysis 
by a BD FACS calibur flow cytometer operated by Cellquest™ software 
(Becton Dickinson, Oxford, UK). At least 10000 events were analysed 
per sample.  
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4.3. Results 
4.3.1.  Characterisation of cell growth  
4.3.1.1. Evaluation of the reproducibility for specific cell lines 
The reliability of the MTT assay to measure cell growth and cell 
cytotoxicity depends on the linear relationship between cell number and 
absorbance of reduced MTT. This relationship was validated here using 
C6-STX and IMR-32 cells. As shown in figure 4.1, the absorbance 
readings obtained correlate strongly with the number of C6-STX and 
IMR-32 cells with regression coefficients of 0.992 and 0.993 respectively.  
 
 
 
R² = 0.992 
0
0.1
0.2
0.3
0.4
0.5
0.6
0 1 2 3 4 5 6 7 8 9 10 11
A
b
s
o
rb
a
n
c
e
 (
5
4
0
 n
m
) 
Cell number (103 cells) 
A. 
119 
 
 
Figure 4.1. Calibration curve of C6-STX (A) and IMR-32 (B) cell numbers versus 
MTT absorbance at 540 nm. C6-STX and IMR-32 cell numbers strongly correlated 
with MTT absorbance with regression coefficients of r²= 0.992 and 0.993 respectively. 
4.3.1.2. Assessment of growth using the MTT assay 
The growth of C6-STX, C6-WT, IMR-32 and SK-N-SH was characterised 
using the MTT assay. For the C6-STX and C6-WT cell lines, a cell 
concentration of 5×103 cell/mL had a lag phase of less than two days and 
an exponential phase of up to four days (Figure 4.2 A and B). In case of 
IMR-32 and SK-N-SH cell lines, a 5×104 cell/mL cell concentration had a 
lag phase of less than two days and an exponential phase of up to four 
days (Figure 4.2 C and D). From these curves, the optimum cell 
concentrations in the log phase for particular assay time were 
determined and used in further studies (Figure 4.3).   
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Figure 4.2. Growth curves of C6-WT (A), C6-STX (B), IMR-32 (C) and SK-N-SH (D) 
cell lines at different cell concentrations. Data are expressed as mean ± SD of three 
independent experiments. 
 
 
Figure 4.3. Comparison of the growth at optimum cell concentration for C6-WT and 
C6-STX (5 ×103 cell/mL) as well as IMR-32 and SK-N-SH (5 ×104 cell/mL).  
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4.3.2. PSA-NCAM immunocytochemistry  
4.3.2.1. PSA-NCAM detection by anti-PSA-NCAM antibody 
In the C6 model, C6-STX cells showed strong membranous 
immunoreactivity indicating PSA-NCAM expression, with an absence of 
expression observed on C6-WT cells. The IMR-32 and SK-N-SH 
neuroblastoma cells exhibited PSA-NCAM immunoreactivity at the cell 
surface whereas DLD-1 colorectal cells did not display any 
immunoreactivity, confirming that they do not express PSA-NCAM. To 
confirm the specificity of immunolabelling in a negative control, C6-STX 
cells treated with EndoNF (0.5 µg/mL) did not show any PSA-NCAM 
immunoreactivity (Figure 4.4).   
4.3.2.2. PSA-NCAM detection by using EndoN-GFP 
To further confirm the results obtained above, PSA-NCAM expression on 
the cell surface was detected by using EndoN-GFP. This fusion protein 
specifically and effectively recognises PSA expression on NCAM [115]. 
In agreement with the above results, C6-STX, IMR-32 and SK-N-SH cells 
displayed membranous immunoreactivity similar to that obtained with the 
antibody indicating PSA-NCAM expression. Simultaneously, C6-WT and 
DLD-1 cells did not demonstrate PSA-NCAM expression. C6-STX cells 
treated with EndoNF (0.5 µg/mL) indicated an absence of PSA-NCAM 
confirming the EndoN-GFP specificity (Figure 4.4).   
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4.3.3. NCAM immunocytochemistry  
NCAM expression was characterised in cells by immunolabelling with 
rabbit anti-NCAM polyclonal antibody. A membranous pattern of 
immunoreactivity was observed in C6-STX, C6-WT, IMR32 and SK-N-SH 
cells indicating NCAM expression. The immunoreactivity was intense and 
uniformly distributed at the cell surface of all NCAM expressing cell lines. 
DLD-1 did not show any reactivity confirming absence of NCAM. 
Following EndoNF treatment, the C6-STX cells continued to exhibit 
NCAM immunoreactivity confirming that EndoNF treatment did not affect 
NCAM expression (Figure 4.4). 
4.3.4. PSA-NCAM and NCAM dual labelling  
Dual labelling of C6-STX and IMR32 cells with anti-PSA-NCAM and anti-
NCAM revealed that all NCAM immunoreactive cells were also fully 
immunoreactive for PSA-NCAM as denoted by the uniform co-
localisation (Figure 4.5). 
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Figure 4.4. Immunofluorescence detection of PSA-NCAM and NCAM expression in C6-STX, C6-WT, IMR-32, SK-N-SH, DLD-1 and C6-STX EndoNF 
treated cells. For PSA-NCAM detection by PSA-NCAM antibody (735) and EndoN-GFP, C6-STX, IMR-32, and SK-N-SH showed membranous 
immunoreactivity while nothing was observed in C6-WT and DLD-1 cells. For NCAM immunodetection by rabbit anti-NCAM polyclonal antibody, C6-STX, 
C6-WT, IMR-32, and SK-N-SH displayed cell surface associated immunoreactivity while nothing was observed in DLD-1 cells. When the C6-STX cells were 
treated with the EndoNF, the PSA-NCAM labelling exhibited by 735 antibody and EndoN-GFP was abolished. No effect was observed on NCAM 
immuolabelling confirming the specificity of PSA-NCAM immunolabelling. Images were taken using confocal microscopy.  Scale bar = 50 µm. 
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Figure 4.5. Dual labelling of PSA-NCAM and NCAM in C6-STX and IMR-32 cells. C6-STX and IMR-32 cells were immunolabelled 
simultaneously with mouse anti- PSA-NCAM (735) and rabbit anti-NCAM followed by labelling with anti-mouse TRITC and anti-rabbit FITC 
conjugated secondary antibodies. The PSA-NCAM and NCAM staining was co-expressed at the surface of C6-STX and IMR-32 cells. Images 
were taken using confocal microscopy. Scale bar = 50 µm. 
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4.3.5. Quantitative analysis of PSA-NCAM expression by flow 
cytometry 
Flow cytometry was used to quantitatively analyse PSA-NCAM 
expression in IMR-32 cells by EndoN-GFP (10 µg/mL) (Figure 4.6). The 
viable IMR-32 cell population was gated according to their forward and 
side scatter properties. As shown, PSA-NCAM expression was detected 
in 95.4% of gated IMR-32 cells (EndoNF (-)), in contrast to only 6.2% of 
control cells (without EndoN-GFP). When cells were treated with EndoNF 
(0.5 µg/mL), only 7.7% of cells were polysialylated. On this basis, the 
EndoNF treatment led to an almost complete removal of PSA-NCAM 
expression suggesting the usage of EndoNF as a treatment control for 
future analysis of novel polyST inhibitors. Moreover, these results 
suggest the utility of flow cytometry to quantitatively detect changes in 
PSA-NCAM expression in IMR-32 cells labelled with EndoN-GFP. 
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Figure 4.6. Flow cytometry histogram for IMR-32 cells using EndoN-GFP labelling. 
EndoN-GFP labelled IMR-32 cells showed high PSA-NCAM expression (EndoNF (-)) 
compared to control (without EndoN-GFP) and EndoNF treated cells (EndoNF (+)). 
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EndoNF (+) 
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4.4.  Discussion 
Since the aim of the work outlined in this chapter was to assemble 
suitable cell lines necessary for the development of methods to screen 
novel polyST inhibitors, PSA-NCAM and NCAM expression were 
investigated across a panel of cell lines. This panel included the C6-STX, 
C6-WT, IMR-32, SK-N-SH and DLD-1 cell lines.  
The C6 cell model was used in this project because it represents a pair 
of isogenic cell lines. The only difference between the two cell lines is the 
engineered over-expression of STX and resulting expression of PSA-
NCAM as previously described, making it an ideal model to assess 
polyST inhibitors [78].  
The C6-cell model was established by Suzuki and co-workers [78]. No 
difference in growth rate was observed in vitro between the C6-STX 
(PSA-NCAM positive) and C6-WT (PSA-NCAM negative) cell lines [78]. 
This was also true in the studies performed here. Moreover, the growth 
of IMR-32 and SK-N-SH neuroblastoma cell lines was consistent with 
previous reports where high cell concentrations of both cell lines were 
attained at plateau growth phase [125, 126]. This in part, validates the 
use of these cell lines for the development of models necessary for the 
pharmacological screening of novel polyST inhibitors. 
PSA-NCAM expression was characterised in these cell lines using both 
an antibody-based detection method and EndoN-GFP. The antibody 
based detection of PSA-NCAM expression was performed by using a 
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mouse anti-PSA-NCAM monoclonal antibody (clone: 735) [122]. EndoN-
GFP was used to efficiently and specifically bind PSA on tumour cells 
[115]. As PSA-NCAM is expressed at the membrane of tumour cells, 
clear membranous labelling was expected using both methods of 
detection. 
On characterisation of PSA-NCAM expression in the cell lines by both 
methods, the C6-STX, IMR-32 and SK-N-SH cells were found to exhibit 
PSA-NCAM expression. PSA-NCAM expression was detected with clear 
membranous immunoreactivity without significant labelling in the 
cytoplasm of cells. In contrast, C6-WT and DLD-1 cells showed an 
absence of PSA-NCAM expression, as predicted. For NCAM 
characterisation, all cell lines showed cell surface-associated 
immunoreactivity indicating NCAM expression, except in DLD-1 cells. 
When the C6-STX and IMR-32 cells were dual-labelled for PSA-NCAM 
and NCAM, both were found to be co-expressed on the surface of cells. 
The intensity of immunolabelling was perhaps lower than expected. This 
may have been due to the secondary antibodies cross reacting with each 
other. On treatment with EndoNF, the PSA-NCAM reactivity of antibody 
and EndoN-GFP was eliminated; while no effect on NCAM 
immunolabelling was seen, suggesting the PSA-NCAM labelling 
specificity. 
The status of PSA-NCAM and NCAM expression in the above cell lines 
was in agreement with previous studies. Suzuki described how the STX-
transfected C6 cells showed a heavy polysialylation of NCAM compared 
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to naked NCAM on C6-WT cells [78]. In addition, and as expected, 
neither PSA-NCAM nor NCAM were expressed in the DLD-1 cell line 
[84]. In neuroblastoma, several reports have demonstrated PSA 
decoration of NCAM at the surface of IMR-32 and SK-N-SH cells [84, 86, 
89, 90]. However, a very recent study has suggested that the SK-N-SH 
cell line expresses neither PSA-NCAM nor NCAM. This is in contrast to 
previous reports including those by the same research group [85].  
This contradictory result as to the status of PSA-NCAM in SK-N-SH cells 
demonstrates in part the cellular heterogeneity of all neuroblastoma cell 
lines but especially SK-N-SH [126-128]. The SK-N-SH cell line consists 
of three cell phenotypes with different malignant potentials and includes 
neuroblastic (N), intermediate (I) and substrate adherent (S) cells. The N-
type cells are malignant small rounded cells with short neuritic processes 
while the S-type cells are non-malignant large flattened substrate 
adherent cells that show contact-cell growth inhibition [126]. The I-type 
cells are highly malignant round cells with or without neuritic extensions, 
showing mixed characteristics of N- and S-types cells and capable of 
spontaneous trans-differentiation to N- or S-type cells. Moreover, the I-
type cells are moderately substrate adherent cells while the N-type cells 
are very weakly adherent to substrates and to other cell types (Figure 
4.7) [127, 128].  
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Figure 4.7. SK-N-SH cellular heterogeneity. Images shows three different cellular 
phenotypes neuroblastic (N), intermediate (I) and substrate adherent (S) cells (arrows). 
Image obtained via personal communication with Dr. Elio Messi, University of Milano, 
Italy. 
Based on our investigations with the SK-N-SH cell line, it is clear that 
both N- and I-type cells express PSA-NCAM and NCAM whereas S-type 
cells are negative for both. This is often the case in first passages 
following the receipt of cells from the main source (for example, ATCC). 
With these facts in mind, it is possible to explain this contradictory issue 
as a shift in the equilibrium of cellular phenotypes in SK-N-SH during 
routine culturing. In other words, when the SK-N-SH culture becomes 
over-confluent or old, I-type cells undergo phenotypic interconversion to 
either N- or S-type cells [129]. Furthermore, N-type cells are also lost 
during the trypsinization process as these cells are easily detached and 
float in the medium due to naturally being poorly attached to the 
substrate and to I and S cell phenotypes [127, 128].  Consequently, this 
creates a bias in the equilibrium of cellular phenotypes of the SK-N-SH 
cell line toward a culture enriched with PSA-NCAM negative S-type cells. 
Such a problem was encountered in this project. For this reason, SK-N-
SH was not use as a model in subsequent studies. 
N 
I 
S 
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The IMR-32 cell line was selected for flow cytometric analysis because it 
offers great advantages over the other cell lines tested here. IMR-32 is a 
naturally high PSA-NCAM-expressing cell line containing both PST and 
STX enzymes [84, 130], and does not have the multiple phenotype 
issues like the SK-N-SH. Moreover, and unlike C6-STX cells, the small 
tear-drop shaped cells morphology of IMR-32 cells facilitated flow 
cytometry [125], and upon cell dissociation from one Petri dish give a 
considerable cell number for analysis. In contrast, the morphology of C6-
STX cells impeded flow cytometry analysis as they are large flattened 
fibroblast-like cells and upon cell dissociation, large numbers of T75cm2 
flasks were required to give a considerable cell number for analysis. Flow 
cytometry results revealed that in a given IMR-32 population, PSA-
NCAM was expressed in 95.4% of gated cells as compared to 6.2% of 
control cells (without EndoN-GFP). When the IMR-32 cells were treated 
with EndoNF, PSA-NCAM was expressed only in 7.7% of cells. These 
results suggest the applicability of EndoN-GFP and IMR-32 cells as tools 
for future flow cytometry analysis of the effects of novel polyST inhibitors.  
PSA-NCAM expression was therefore quantitatively analysed in IMR-32 
cells by flow cytometry using EndoN-GFP. This reagent has been 
successfully used by others to quantify PSA-NCAM expression by flow 
cytometry in bone marrow cells and SH-SY5Y neuroblastoma cells [75], 
as well as in STX-transfected NIH-3T3 cells (mouse embryonic fibroblast 
cells) and Cos-7 (African Green Monkey kidney) cells [93].  
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In conclusion, PSA-NCAM and NCAM expression was successfully 
characterised in a panel of cell lines (see Table 4.1 for a summary of 
expression). All NCAM expressing-cell lines were positive for PSA-
NCAM expression except the C6-WT cell line. Neither PSA-NCAM nor 
NCAM was expressed in the DLD-1 cell line and quantitative analysis of 
PSA-NCAM by flow cytometry was achieved using IMR-32 labelled with 
EndoN-GFP. In the light of these results, IMR-32, C6-STX, C6-WT and 
DLD-1 cell lines were selected as suitable models. These appropriate 
models would be used for future development and optimisation in cell-
based screens described in next chapter. The SK-N-SH cell line was not 
used as a model for subsequent studies. 
       Table 4.1. PSA-NCAM and NCAM expression in selected cell lines 
Cell line Origin PSA-NCAM NCAM 
C6-STX Rat glioma transfected 
with STX enzyme 
+ + 
C6-WT Rat glioma wild-type - + 
IMR-32 Human neuroblastoma + + 
SK-N-SH Human neuroblastoma + + 
DLD-1 Human colorectal 
cancer 
- - 
Key: ‘+’= positive expression, ‘-’= negative expression. 
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5. Development of compound screening 
methodologies and validation using CMP 
5.1.  Introduction 
One of the main aims of the work described in this thesis was to identify 
novel polyST inhibitors. In order to do this, a screening cascade needed 
to be established, part of which involved cell-based screens. The 
questions that needed to be addressed in a developing cascade were the 
issues of cytotoxicity, inhibition of PSA-NCAM and functional effects of 
PSA-NCAM inhibition. This cascade could be developed as follows 
(Figure 5.1). 
Therefore suitable cell-based screening assays that would cover these 
aspects were developed and optimised using the previously assembled 
panel of cell lines. On assessing the effects of inhibiting polySTs on PSA-
NCAM expression, flow cytometry was employed to quantitatively 
measure the effects of novel polyST inhibitors on NCAM polysialylation. 
Alongside flow cytometry, and to assess the effects of compound 
inhibition on PSA-NCAM re-expression in cells, a PSA-NCAM recovery 
assay was established. This assay was modified from one originally 
developed by Kiss and co-workers [131] and provided a model to 
investigate the effect of polyST inhibitors on the cell surface PSA-NCAM 
recovery following EndoN treatment.  
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Figure 5.1.  Diagram showing the flow of polyST inhibitors screening cascade. 
This cascade assesses the compound chemosensitivity, inhibition of PSA-NCAM and 
functional role of PSA-NCAM inhibition. 
Alongside the above assays, and in order to evaluate the effects of PSA-
NCAM modulation by novel polyST inhibitors on cell migration, 
pharmacologically relevant migration assays were developed: a wound 
healing assay and a radius cell migration assay. The concept of these 
assays is based on creating an artificial wound or ‘scratch’ in a confluent 
monolayer of cells and monitoring wound healing over time [132] (Figure 
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5.2 A). The radius cell migration assay was originally developed to 
overcome some of the limitations of the traditional wound healing assay 
such as inconsistency of scratch perimeter [133]. An example of this is 
the Oris Cell Migration assay kit (Platypus Technologies, Madison, USA). 
This assay uses silicon inserts as stoppers that firmly seal the bottom of 
a 96-well plate. When cells are seeded through the side ports of inserts, 
they are allowed to adhere and grow forming a confluent monolayer in 
the presence of inserts. Upon removal of these inserts, circular cell free 
zones (2mm in diameter) at the centre of the wells are formed into which 
cell migration may occur (Figure 5.2 B) [134]. 
 
 
 
 
 
 
 
Confluent 
monolayer of cells 
Wounding of 
monolayer 
Initial 
perimeter  
Cells migrate into 
wound space  
A. 
Cells seeded and 
adhered to plate 
 
Stoppers removed to 
create detection zone 
 
Cells migrated 
into the detection 
zone 
 
Empty spaces analyzed 
within detection zone 
 
B. 
137 
 
Figure 5.2. Schematic diagram of the wound healing assay (A) the radius cell 
migration assay (B).  The radius assay overcomes some of limitations of traditional 
wound healing assay such as inconsistency of scratch perimeter and challenges to 
screen large numbers of compounds.  Adapted from [134]. 
In the absence of standardised established methods for testing novel 
polyST inhibitors, the fitness and reliability of any pharmacological 
assays should be determined, ideally using a molecule with known 
polyST inhibitory activity. As described in Chapter 1, CMP is a nucleotide 
that reduces the synthesis of PSA on NCAM through competitive polyST 
inhibition [112]. Moreover, preliminary studies in-house have 
demonstrated the ability of CMP to block the polysialylation of NCAM 
through polyST in an enzyme-based (cell-free) assay. CMP strongly 
inhibited polyST enzymatic activity at a concentration of 1 mM, whereas 
complete inhibition was achieved at 5 mM. CMP treatment did not affect 
NCAM expression. The effects of CMP on tumour cell function are 
unknown. CMP was therefore utilised here as a tool to develop and 
validate the pharmacological assays.  
5.1.1. Aims 
The aims of the work outlined in this chapter were to develop and 
validate cell-based assays to be used to evaluate novel polyST inhibitors 
using the cell models characterised in the previous chapter. The known 
natural polyST inhibitor CMP was used as a positive control compound to 
validate the assays. This included an evaluation of the cytotoxicity of 
CMP. A quantitative assessment of the effects of CMP on (i) NCAM 
polysialylation by flow cytometry, (ii) PSA-NCAM mobilisation by a PSA-
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NCAM recovery assay and (iii) in neoplastic cell migration was carried 
out. 
 
5.2. Methods 
5.2.1. Compounds 
CMP, cisplatin and colominic acid were purchased from Sigma-Aldrich 
(Dorset, UK). CMP and colominic acid were dissolved in medium while 
cisplatin was dissolved in DMSO. 
5.2.2. Evaluation of chemosensitivity using the MTT assay  
The chemosensitivity of CMP was measured using the MTT assay as 
previously described in Chapter 2 (section 2.3.4). C6-STX, C6-WT, DLD-
1 and IMR-32 cells were incubated with CMP concentrations varying 
from 0.01 to 30 mM for 96 hours continuous drug exposure. As an 
example of a cytotoxic standard agent control, cisplatin was used. This 
was evaluated over a range of concentrations (0.01-30 µM) against the 
C6-STX and C6-WT cell lines.  Dose response curves were constructed 
and the IC50 values for CMP and cisplatin were calculated for each cell 
line as described in Chapter 2 (section 2.3.3.2). 
5.2.3.  Flow cytometry 
The effect of CMP treatment on PSA-NCAM expression was 
quantitatively analysed in IMR-32 cells labelled with EndoN-GFP. IMR-32 
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cells were incubated with a range of CMP concentrations (0.5-7 mM) for 
24 hours. Controls included untreated cells labelled with EndoN-GFP and 
treatment of cells with EndoNF (0.5 µg/mL) for 24 hours. Samples were 
then prepared and analysed by flow cytometry as previously described in 
Chapter 2 (section 2.7). 
5.2.4. PSA-NCAM recovery assay 
The concept of this assay was based on a model system developed by 
Kiss and co-workers [131]. This model monitors PSA-NCAM recovery at 
the cell surface following removal by EndoN. Cells harvested as 
described previously Chapter 2 (section 2.3.2) were seeded at 1x104 
cells/mL onto autoclaved cover slips in a 6-well plate in 2mL of medium 
followed by incubation overnight at 37C in a 5% CO₂ humidified 
atmosphere. Once cells had adhered to cover slips, they were treated 
with different types of EndoN (see section 5.3.3) using a range of 
enzyme concentrations and exposure times in order to optimise assay 
conditions. Following EndoN treatment, cultures were carefully washed 
with HBSS (two washes) and all cultures were then processed in parallel. 
Controls for the experiment were cultures fixed directly with ice cold 
methanol at   -20°C for 30 minutes following EndoN treatment, to confirm 
PSA removal, and cultures that were further incubated with culture 
medium at 37C to allow PSA recovery. Other cultures were incubated 
with medium containing CMP at different concentrations to determine the 
effect of CMP on PSA recovery. Following these treatments, the cultures 
were rinsed twice with HBSS and fixed with ice cold methanol at -20°C 
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for 30 minutes. After air drying, they were stored at -20°C or immediately 
processed for immunocytochemistry as previously described in Chapter 
4 (section 4.2.2). The resulting slides were analysed by counting the 
number of positive cells and results were arbitrarily normalised to the 
untreated control (100%) and expressed as the mean ±SD of three 
independent experiments. 
5.2.5. Migration assays 
5.2.5.1. Wound healing assay  
Cells were maintained as described previously in Chapter 2 (section 
2.3.2). Cells were seeded into six-well plates at different concentrations. 
Plates were then incubated overnight at 37C. Once a confluent 
monolayer had formed, a straight wound of approximately 1 cm in length 
and 800±160um in thickness was created in the centre of the well using 
a sterile P200 pipette tip. After scratching, the media was slowly 
aspirated and discarded, and wells were washed with growth medium 
(1mL) to remove debris and to smooth the edge of the scratch. After 
washing, fresh medium was added to the cells with or without compound. 
The plates were then incubated at 37C in 5% CO₂ for up to 24 hours.  
During incubation, plates were periodically monitored using phase- 
contrast microscopy to determine the time required for the migrating cells 
to fully close the wound. Measurement of the wound was achieved by 
measuring the gap width at five points in the centre of the wound using 
an eyepiece graticule with a micrometer scale (Figure 5.3). After 24 
hours, the cells were washed twice with Hanks Balanced Salt Solution 
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(HBSS) and fixed with ice cold methanol (100%) at -20°C for 30 minutes. 
After fixation, the cells were then hydrated by two washes in PBS and 
counterstained with Harris’s Haematoxylin solution. They were then 
washed briefly under running tap water, before the excess water was 
drained for 1 minute and left to dry at room temperature. 
 
Figure 5.3. Example of wound perimeter measurement at five points of the 
wound. 
Before using this assay to measure cell migration, several experimental 
conditions required optimisation. As the wound healing assay is 
dependent on the cell density per well leading to confluence before 
scratching, the C6-STX, C6-WT and DLD-1 cells were each seeded into 
six-well plates at concentrations ranging from 1x105 to 1x106 cell/mL. 
Cell concentrations of 3x105 cell/mL (C6-STX and C6-WT) and 1x106 
cell/mL (DLD-1) were found to be optimum, as confluent cell monolayers 
formed within 24 hours of incubation.  
The resulting plates were viewed under a Nikon dissecting microscope 
(Nikon, C-D55230, Japan) and digital images were acquired for each 
sample. The extent of cell migration, expressed as percentage migration, 
was calculated as follows: 
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Migration (%) = [Average of S0 - Average of S1] × 100% 
                                                        Average S1 
 
Where S0: is the width of initial perimeter;   S1: is the width of wound at 
time of sampling. 
Data were expressed as means ± S.D of three independent experiments.  
5.2.5.2. Radius assay 
Cells were trypsinised and counted as described previously in Chapter 2 
(section 2.3.2). Cell seeding stoppers were then inserted into each well 
of the 96-well plate where they formed a tight seal to the base of plate. 
Cells were then seeded at a range of concentrations into each well by 
adding 100 µL of cell suspension through the side ports of stoppers. The 
microplate was then incubated at 37C in a humidified atmosphere of 5% 
CO₂ overnight to allow cell adherence. Once a confluent monolayer 
formed around the inserts, the stoppers were gently removed followed by 
careful washing with HBSS to remove any detached cells. For pre-
migration controls (t0), the stoppers were left in the wells until the day of 
fixation. After washing, 100 µL of fresh medium was added to the wells 
followed by incubation at 37C in a 5% CO₂ humidified atmosphere for up 
to 72 hours to allow cell migration. Where required, compound was 
added to the medium. During incubation, plates were periodically 
monitored using phase-contrast microscopy to examine the progression 
of cell migration. After repopulation of the detection zone, the stoppers 
were removed from the controls (pre-migration t0) and all cultures were 
rinsed twice with HBSS and fixed with ice cold methanol at -20°C for 30 
143 
 
minutes. After fixation, cells were then hydrated by two washes in PBS 
and counterstained with Harris’s Haematoxylin solution (Figure 5.4). 
Before using this assay to measure cell migration, several assay 
conditions were optimised. For the C6 cell model, the C6-STX and C6-
WT cells were seeded at concentrations ranging from 1x105 to 5x105 
cell/mL. The cell concentration 2x105 cell/mL was found to be optimum 
where confluent monolayers were formed around the cell stoppers within 
an overnight incubation period. For DLD-1, cells were seeded in different 
concentrations ranging from 5x105 to 1x106 cell/mL and a concentration 
of 8x105 cell/mL was found to be optimum. Following formation of 
confluent monolayers around the stoppers, inserts were removed and 
cells were allowed to migrate into the cell-free zone (2 mm in diameter) 
(Figure 5.4).  
The resulting plates were viewed under a Nikon dissecting microscope 
(Nikon, C-D55230, Japan) and digital images were acquired for each 
sample. The images were analysed by counting the empty spaces in the 
detection zone using a 432 point grid. Percentage migration was 
calculated as follows: 
Migration (%) = [Average of S0 - Average of S1] × 100% 
             Average of S0 
Where: 
S0: numbers of empty grid spaces in the detection zone at pre-migration 
t0. 
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S1: number of empty grid spaces in the detection zone at t1 (post-
migration: 24 h, 48 h, etc). 
Data were expressed as mean ± S.D of three independent experiments. 
               
Figure 5.4. Examples of radius cell migration assay. a shows the initial perimeter of 
the detection zone (pre-migration, t0) while b shows the migration of cells in detection 
zone (post-migration, t1). 
 
5.2.6. Statistics 
For both migration assays, data shown was expressed as mean ± S.D of 
independent experiments. The number of independent experiments 
performed is stated in the respective table or figure legend. Images 
shown are representatives of independent experiments. Statistical 
analysis was performed using the student’s t-test for statistical 
significance using Microsoft Office Excel (2007) software. 
 
 
 
 
a 
 
b 
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5.3. Results 
5.3.1. Evaluation of CMP in chemosensitivity assay  
Using the MTT assay, the cytotoxicity of CMP against C6-STX, C6-WT, 
DLD-1 and IMR-32 cells was assessed over a range of different 
concentrations for 96h continuous drug exposure given the high 
concentrations utilised in these studies. As shown in figure 5.5 and table 
5.1, all cell lines responded to CMP treatment in a concentration-
dependent manner. When C6-STX, C6-WT, IMR-32, and DLD-1 cells 
treated with CMP, there was no significant difference in cell viability (P> 
0.05) (Figure 5.5) and all cell lines responded to CMP treatment with IC50 
values ranging from 13.9 to 14.8 mM. In the case of cisplatin, there was 
no significant difference in cell viability between C6-STX and C6-WT 
cells (P>0.05) with IC50 values of 1.81 and 1.73 µM respectively 
suggesting that C6 cell lines respond to cytotoxic drugs similarly (Figure 
5.6 and Table 5.1).  
Table 5.1. IC50 values for CMP and cisplatin on cell lines. ND= not determined 
Cell line 
CMP 
IC50 (mM) 
Cisplatin 
IC50 (µM) 
C6-STX 14.8 1.81 
C6-WT 14 1.73 
DLD-1 14.5 ND 
IMR-32 13.9 ND 
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Figure 5.5. MTT chemosensitivity assay for CMP concentrations against C6-STX, 
C6-WT, DLD-1 and IMR-32 cells for 96 h. Responses of all cell lines increased in a 
similar concentration-dependent manner. Results are expressed as mean ± SD of three 
independent experiments. 
 
 
Figure 5.6. MTT chemosensitivity assay for cisplatin against C6-STX and C6-WT 
cell lines for 96 h. No significant difference in cell viability was observed between C6-
STX and C6-WT cells with IC50 values of 1.81 and 1.73 µM respectively. Results are 
expressed as mean ± SD of three independent experiments. 
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5.3.2. Quantitative analysis of CMP treatment on PSA-NCAM 
expression 
The effect of CMP treatment on PSA-NCAM expression was 
quantitatively analysed in IMR-32 cells. IMR-32 cells were cultured with a 
range of CMP concentrations (0.5, 1, 3, 5 and 7 mM) and EndoNF (0.5 
µg/ml) for 24 hours. Cells were then labelled with EndoN-GFP and 
analysed by flow cytometry. As shown in figure 5.7, CMP treatment at all 
concentrations led to a significant reduction in PSA-NCAM levels in 
compared to the control (P<0.01). This inhibitory effect was 
concentration-dependent where the maximal inhibition was seen at the 7 
mM concentration of CMP (48.4±6.8%). When cells were treated with 
EndoNF (0.5 µg/ml), PSA-NCAM levels were highly decreased compared 
to the control (10.8±1.8%).  
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Figure 5.7. A. Flow cytometry analysis of CMP effects on PSA-NCAM expression 
in IMR-32 cells. B. Relative median fluorescence intensities (MFI) of CMP 
concentrations and EndoNF.  CMP treatment significantly reduced PSA-NCAM levels 
in a concentration-dependent manner. EndoNF treatment significantly reduced PSA-
NCAM expression. Values are relative to control and expressed as mean ± SD of three 
independent experiments (* P<0.01, ** P<0.001). 
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5.3.3. Optimisation of the PSA-NCAM recovery assay 
The effect of CMP treatment on cell surface PSA-NCAM expression was 
investigated modifying a model system developed by Kiss and co-
workers [131]. This model was used to examine PSA-NCAM re-
expression following PSA-NCAM removal by EndoN and to examine the 
effect of CMP treatment on PSA-NCAM recovery. Before using this 
assay, several experimental conditions were optimised. 
As this assay relies on PSA-NCAM removal, it was imperative that PSA-
NCAM could be removed efficiently and reliably using EndoN. Equally 
important was having confidence that PSA-NCAM expression re-
established following the recovery period. Differences were observed in 
the recovery of cell surface PSA-NCAM expression depending on the 
EndoN used; hence it was necessary to explore different types of EndoN 
(see section 5.3.3.2). EndoNF was evaluated first. After observing a lack 
of PSA-NCAM recovery, a mutant version of this enzyme (EndoNF-
mutant) was evaluated in an attempt to understand this issue. Finally 
EndoNK was assessed. 
5.3.3.1. Optimisation of Endoneuraminidase conditions (EndoN) 
In the case of EndoNF (Figure 5.8), IMR-32 was used for initial 
optimisation. Complete removal of PSA-NCAM was seen at 
concentrations of 0.5 and 1 µg/mL after 24 hours exposure. 0.5 µg/mL 
was determined as the optimum concentration. The EndoNF-mutant 
demonstrated similar activity. 
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To confirm PSA-NCAM removal was equally effective in another PSA-
NCAM-expressing cell line, C6-STX cells were treated with 0.5 µg/mL of 
EndoNF and EndoNF-mutant. Complete PSA-NCAM removal was 
observed, and 0.5 µg/mL was also found to be the optimum 
concentration (Figure 5.9).  
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Figure 5.8. PSA-NCAM Immunofluorescence of IMR-32 cells treated with EndoNF (upper row) and EndoNF-mutant (lower row). IMR-32 cells 
were treated with EndoNF and EndoNF-mutant for 24 hours, and immunolabelled with anti-PSA-NCAM antibody (735) followed by incubation with 
TRITC- conjugated secondary antibody. (a and g) cells without anti-PSA-NCAM antibody (negative control). (b and h) strong PSA-NCAM expression in 
untreated IMR-32 cells. (c and d) show cells treated with EndoNF at concentrations of  0.05 and  0.1 µg/mL respectively still showing  immunoreactivity 
for PSA-NCAM. (e and f)  complete removal of PSA-NCAM immunorectivity in cells treated  at concentrations of  0.5 and 1 µg/mL respectively. Scale bar 
= 50 µm. 
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Figure 5.9. PSA-NCAM Immunofluorescence of C6-STX cells treated with EndoNF 
and EndoNF-mutant. C6-STX cells were treated with EndoNF and EndoNF-mutant for 
24 hours, and immunolabelled with anti-PSA-NCAM antibody (735) followed by 
incubation with TRITC- conjugated secondary antibody. (a) cells without anti-PSA-
NCAM antibody (negative control). (b) PSA-NCAM expression in untreated C6-STX 
cells. (c) complete removal of PSA-NCAM in cells treated with EndoNF at concentration 
of 0.5 µg/mL. (d) complete removal of PSA-NCAM in cells treated with EndoNF-mutant 
at concentrations of 0.5 µg/mL. Scale bar = 50 µm. 
 
Following the difficulties experienced using EndoNF in terms of PSA-
NCAM recovery (see section 5.3.3.2), an alternative EndoN was 
evaluated. EndoNK was selected. For EndoNK, both IMR-32 and C6-
STX cells were incubated with 0.075, 0.15, 0.3, 0.5 µg/mL for 24 hours. 
Consequently, the treatments at 0.075 and 0.15 µg/mL of EndoNK were 
ineffective in removing PSA-NCAM, while treatment with high 
concentrations (0.3 and 0.5 µg/mL) were effective (Figure 5.10). To 
confirm the effectiveness of PSA-NCAM removal by EndoNK (0.3 
µg/mL), IMR-32 and C6-STX cells were treated for 24 hours and labelled 
with PSA-NCAM antibody (735) or EndoN-GFP. As a result, all samples 
treated with EndoNK (0.3 µg/mL) demonstrated an absence of labelling 
both with antibody and EndoN-GFP confirming PSA-NCAM removal from 
the cell surface (Figure 5.11). Therefore, the EndoNK concentration of 
0.3 µg/mL was found to be optimal for further experiments.
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Figure 5.10. PSA-NCAM Immunofluorescence of IMR-32 (a-f) and C6-STX (g-l) cells treated with EndoNK. IMR-32 and C6-STX cells were treated with 
EndoNK for 24 h, and immunolabelled with anti-PSA-NCAM antibody (735) followed by incubation with TRITC- conjugated secondary antibody. (a and g) 
IMR-32 and C6-STX cells without anti-PSA-NCAM antibody respectively (negative control). (b and h)  PSA-NCAM expression in IMR-32 and C6-STX cells. 
(c and i) PSA-NCAM immunoreactivity in IMR-32 and C6-STX cells treated at concentrations of 0.075 µg/mL respectively. (d and j) weak PSA-NCAM 
immunolabelling in IMR-32 and C6-STX cells at EndoNK concentrations of 0.15 µg/mL respectively. (e and f)  PSA-NCAM immunolabelling was absent in 
IMR-32 cells at EndoNK concentrations of 0.3 and 0.5 µg/mL respectively. (k and l) PSA-NCAM immunolabelling was absent in C6-STX cells at 
concentrations of 0.3 and 0.5 µg/mL respectively. Scale bar = 50 µm. 
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Figure 5.11. Effect of EndoNK treatment on PSA-NCAM expression in C6-STX and IMR-32 cells as exhibited by anti-PSA-NCAM antibody (735) and 
EndoN-GFP. C6-STX and IMR-32 cells were treated with EndoNK (0.3 µg/mL), and immunolabelled with anti-PSA-NCAM antibody (735) and EndoN-GFP. 
All cell lines tested showed PSA-NCAM labelling with either the antibody or EndoN-GFP. Cells treated with EndoNK (0.3 µg/mL) showed an absence of 
labelling for both antibody and EndoN-GFP confirming PSA-NCAM removal. Scale bar = 50 µm. 
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5.3.3.2.  Optimisation of PSA-NCAM mobilisation  
Once the optimum EndoN concentrations for PSA-NCAM removal were 
determined, the necessary conditions for PSA-NCAM recovery at the cell 
surface following EndoN treatment were optimised. Here, IMR-32, SK-N-
SH and C6-STX cells were employed.  
In the case of EndoNF, no PSA-NCAM recovery was observed at any 
time point in IMR-32 cells (Figure 5.12 A). A similar result was obtained 
when using C6-STX cells (Figure 5.13). In an attempt to encourage PSA-
NCAM recovery, and following the treatment of IMR-32 cells with 
EndoNF, cells were incubated with 1mg/mL colominic acid (a 
homopolymer of α-2,8 linked N-acetylneuraminic acid derived from 
bacteria) for 20 minutes at 37°C. This was an attempt to remove EndoN 
by competitive displacement should it be tightly bound to remnant PSA 
chains on NCAM, and to therefore allow PSA-NCAM recovery in normal 
medium for 24 hours [135]. Cells were consistently unable to mobilise 
PSA-NCAM to the cell surface (Figure 5.14). 
To test the hypothesis that EndoNF remains tightly bound to remnant 
PSA chains on NCAM, a mutant version of the enzyme was evaluated. 
This enzyme lacks part of the binding domain, but retains its catalytic 
activity [136]. Unfortunately PSA-NCAM recovery was not observed in 
IMR-32 cells (Figure 5.12 B), or in C6-STX cells (Figure 5.13). Colominic 
acid treatment had no effect on these results (Figure 5.14). 
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Conversely, PSA-NCAM expression recovered in all cell lines treated 
with EndoNK. The naturally expressing cell line IMR-32 exhibited 
abundant re-expression of PSA-NCAM on the cell surface 6 hours post 
treatment (Figure 5.15). For C6-STX cells, the initial recovery of PSA-
NCAM on the cell surface started at 2 hours post-treatment and recovery 
was abundant at 6 hours (Figure 5.15). On this basis, EndoNK was 
selected for further experiments and 6 hours was selected as the optimal 
recovery time for all the cell lines. 
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Figure 5.12. Recovery of PSA-NCAM immunoreactivity after EndoNF (A) and 
EndoNF-mutant (B) treatments in IMR-32 cells. IMR-32 cells were treated with 
EndoNF and EndoNF-mutant, and immunolabelled with anti-PSA-NCAM antibody (735) 
followed by incubation with TRITC-conjugated secondary antibody. For A and B, (a) 
Cells without anti-PSA-NCAM antibody (negative control). (b) strong PSA-NCAM 
expression in untreated IMR-32 cells. (c) complete removal of PSA-NCAM 
immunoreactivity following the treatment of 0.5 µg/mL EndoNF (A) and treatment of 0.5 
µg/mL EndoNF-mutant (B). (d-h) PSA-NCAM immunoreactivity was not recovered after 
2, 4, 6, 8 and 24 hours respectively. Scale bar = 50 µm. 
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Figure 5.13. Recovery of PSA-NCAM immunoreactivity after EndoNF and EndoNF-
mutant treatments in C6-STX cells. C6-STX cells were treated with EndoNF and 
EndoNF-mutant, and immunolabelled with anti-PSA-NCAM antibody (735) followed by 
incubation with TRITC- conjugated secondary antibody. (a) Cells without anti-PSA-
NCAM antibody (negative control). (b) PSA-NCAM expression in untreated C6-STX 
cells. Complete removal of PSA-NCAM immunoreactivity after treatment with 0.5 µg/mL 
EndoNF (c) and 0.5 µg/mL Endo-N F mutant (d). No PSA-NCAM recovery was seen in 
C6-STX cells following 24 h of treatment with EndoNF (e) and EndoNF mutant (f). Scale 
bar = 50 µm. 
 
 
 
 
 
 
 
 
 
Figure 5.14.  Effect of colominic acid on PSA-NCAM recovery after EndoNF and 
EndoNF-mutant treatments in IMR-32 cells. (a) Cells without anti-PSA-NCAM 
antibody (negative control). (b) PSA-NCAM expression in untreated IMR-32 cells. 
Complete removal of PSA-NCAM immunoreactivity after treatment with 0.5 µg/mL 
EndoNF (c) and 0.5 µg/mL EndoNF-mutant (d). No PSA-NCAM recovery was seen in 
colominic acid treated IMR-32 cells following 24 hours of treatment with EndoNF (e) and 
EndoNF-mutant (f). Scale bar = 50 µm. 
   
   
   
 
   
 
a c 
b d 
e 
f 
a c 
b d 
e 
f 
159 
 
 Negative control Control EndoNK 2 hours recovery 4 hours recovery 6 hours recovery 8 hours recovery 24 hours recovery 
IM
R
-3
2
 
        
C
6
-S
T
X
 
        
Figure 5.15. Recovery of PSA-NCAM immunoreactivity following EndoNK treatment in IMR-32 and C6-STX cells. IMR-32 and C6-STX cells were 
treated with EndoNk (0.3 µg/mL) and immunolabelled with anti-PSA-NCAM antibody (735) followed by incubation with TRITC-conjugated secondary antibody. 
(a and i) Cells without anti-PSA-NCAM antibody (negative control). (b and j) PSA-NCAM expression in untreated IMR-32 and C6-STX cells. (c and k) 
Complete removal of PSA-NCAM immunoreactivity following treatment with 0.3 µg/mL EndoNk. (d) PSA-NCAM did not recover on the surface of IMR-32 cells 
after 2 hours while weak immunoreactvity was seen after 4 hours of treatment (e). (f, g and h) PSA-NCAM was clearly re-expressed on the cell surface 
following 6, 8 and 24 hours post treatment respectively. (l) PSA-NCAM started to recover on the cell surface after 2 hours and weak immunoreactivity was 
seen after 4 hours post treatment (m). PSA-NCAM was abundantly re-expressed on the cell surface 6 (n), 8 (o) and 24 hours post treatment (p).  Scale bar = 
50 µm. 
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5.3.3.3. Effect of CMP on PSA-NCAM recovery 
Once all the experimental conditions were optimised, the model was 
used to examine the effect of CMP on PSA-NCAM mobilisation. C6-STX 
and IMR-32 cells were treated with 0.3 µg/mL EndoNK to remove 
existing PSA-NCAM followed by incubation with culture medium 
containing 0.5, 1, 3, 5, 7, and 10 mM CMP for 6 hours. EndoNK 
treatment completely removed existing PSA-NCAM on the surface of C6-
STX and IMR-32 cells whilst C6-STX and IMR-32 cells were able to 
highly mobilise PSA-NCAM to the cell surface within 6 hours in the 
absence of CMP (Figure 5.16 and 5.17). 
When C6-STX and IMR-32 cells were incubated with CMP during the 
recovery period (6 hours), the activity of PSA-NCAM mobilisation was 
gradually decreased in both cell lines upon increasing concentrations of 
CMP (Figure 5.16 and 5.17). This decrease in PSA-NCAM mobilisation 
was reflected by the reduction in fluorescence labelling intensity upon 
CMP treatments. CMP concentrations of 0.5, 1 and 3 mM produced no 
difference in fluorescence labelling intensity between the treated cells 
and controls in both cell lines. At high CMP concentrations (>5 mM), the 
fluorescence labelling intensity of PSA-NCAM decreased. That reduction 
was concentration-dependent where the maximum reduction was seen at 
10 mM treatment in both cell lines. Moreover, CMP treatment exerted a 
greater inhibitory effect on mobilisation of PSA-NCAM in IMR-32 
(19±4%) than in C6-STX (45±7%) cells especially at high concentrations. 
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However, complete removal of fluorescence labelling was not observed, 
even at high concentrations in both cell lines.  
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Figure 5.16. The effect of CMP on PSA-NCAM mobilisation in IMR-32 cells. IMR-32 cells immunolabelled with anti-PSA-NCAM antibody (735) followed 
by incubation with TRITC-conjugated secondary antibody. (a) Cells without anti-PSA-NCAM antibody (negative control). (b) PSA-NCAM expression in 
untreated IMR-32 cells. (c) Complete removal of PSA-NCAM immunoreactivity by treatment with 0.3 µg/mL EndoNk. (d) PSA-NCAM immnuoreactivity was 
clearly recovered on the cell surface within 6 h of cells incubation in medium. (e) PSA-NCAM immunolabelling recovery was not affected by 0.5 mM CMP 
treatment while moderate patchy labelling was seen at 1 mM (f) and 3 mM (g). (h) Low patchy labelling was seen at 5 mM CMP treatment and the 
immunolabelling became fainter with 7 mM (i) and more fainter with 10 mM CMP treatment (j). Scale bar = 50.  
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Figure 5.17. The effect of CMP on PSA-NCAM mobilisation in C6-STX cells. C6-STX cells immunolabelled with anti-PSA-NCAM antibody (735) followed 
by incubation with TRITC-conjugated secondary antibody. (a) Cells without anti-PSA-NCAM antibody (negative control). (b) A uniform and intense PSA-
NCAM expression in untreated cells. (c) Complete removal of PSA-NCAM immunoreactivity by treatment with 0.3 µg/mL EndoNk. (d) PSA-NCAM 
immnuoreactivity was clearly recovered on the cell surface within 6 h of cells incubation in medium. PSA-NCAM immunolabelling recovery was not affected 
with CMP treatment at concentration of 0.5 mM (e), 1 mM (f) and 3 mM (g). (h) Low patchy labelling was seen at 5 mM CMP treatment and the 
immunolabelling became fainter with 7 mM (i) and more fainter with 10 mM CMP treatment (j). Scale bar = 50 µm. 
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5.3.4. PSA-NCAM and cell migration 
Initially, the role of PSA-NCAM in cell migration was assessed using 
the wound healing assay with C6-STX and C6-WT cells. Evaluation of 
wound closure was carried out at time 0, 4, 8 and 24 hours. 
Quantitative analysis showed that the C6-STX cells migrated more 
rapidly into the cell-free scratch region than C6-WT cells over the time 
course of the experiment (Figure 5.18 and 5.19) (P<0.01).  
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Figure 5.18. Degree of wound healing for C6-STX and C6-WT cell lines at 24 
hours as assessed by the wound healing assay. Scratched confluent cell 
monolayers were incubated with fresh complete medium and wound closure was 
measured as described. C6-STX cells migrated more rapidly than C6-WT cells. 
Values shown are means ± S.D based on three independent experiments. * P<0.01 
compared with C6-WT. 
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Figure 5.19. Migration of C6-STX and C6-WT cell lines as assessed by the 
wound healing assay. Scratched confluent cell monolayers were incubated with 
fresh complete medium and wound closure was measured as described. C6-STX 
cells migrated faster than C6-WT cells. Results shown are means ± S.D based on 
three independent experiments. * P<0.01 compared with C6-WT. 
 
Additionally, the role of PSA-NCAM expression in modulating the 
migratory capabilities of C6-STX cells over C6-WT cells was further 
confirmed using the radius assay. In agreement with the results 
described above, C6-STX cells more rapidly populated the cell-free 
zone than C6-WT cells (Figure 5.20 and 5.21). The optimal incubation 
time for the C6-STX cell line to repopulate the cell-free zone was 
approximately 60 hours whilst the C6-WT cell line required more than 
72 hours. In general, the migratory potential of C6-STX cells was 
significantly higher than C6-WT cells (Figure 20). In the case of DLD-1 
cells, the cell-free zone was repopulated by cells after 120 hours 
(Figure 5.22 h). 
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Figure 5.20. Degree of migration of C6-STX and C6-WT cell lines at 60 hours as 
assessed by the radius assay. Confluent cell monolayers were incubated with fresh 
complete medium and migration of cells was monitored as described. C6-STX cells 
more quickly repopulated the cell-free zones than C6-WT cells.  
 
Figure 5.21. Degree of cellular migration of C6-STX and C6-WT cell lines at 60 
hours as assessed by the radius assay. The migratory capacity of C6-STX cells 
was significantly higher than C6-WT cells. Values shown are means ± S.D based on 
three independent experiments (P<0.001). Values shown are expressed as means ± 
S.D of three independent experiments. 
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To test the hypothesis that; PSA-NCAM expression is critical for 
migration, C6-STX and C6-WT monolayers were treated with EndoNF 
(12 µg/mL) for 60 and 72 hours respectively. Under these conditions 
PSA-NCAM is efficiently removed from the cell surface (see section 
5.3.3.1). EndoNF treatment led to a significant decrease in the 
migration of C6-STX cells (P<0.01). In contrast, EndoNF treatment did 
not affect the migration of C6-WT cells (Figure 5.22 and 5.23). This 
reduction in the migration of C6-STX cells (16.8%) over C6-WT cells 
(99.4%) further confirms the role of PSA-NCAM expression in 
enhancing cell migration. As a further control, DLD-1 monolayers were 
similarly treated with EndoNF, but for 120 hours. The migration 
capacity of DLD-1 cells was not changed compared to the untreated 
monolayers (Figure 5.22 and 5.23).  
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Figure 5.22. The effect of EndoNF treatment on cellular migration of C6-STX (60 
hours), C6-WT (72 hours) and DLD-1 (120 hours) cells as assessed by radius 
assay. EndoNF treatment significantly reduced the migration of C6-STX cells while 
no effect was observed on the migration of C6-WT and DLD-1 cells (P<0.001).  
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Figure 5.23. The effect EndoNF treatment on cellular migration of C6-STX, C6-
WT and DLD-1 cells as assessed by radius assay. The migration of C6-STX cells 
was almost completely inhibited by the treatment of EndoNF while no effect was 
seen on the migration of C6-WT and DLD-1 cells. Values shown are relative to 
control and expressed as means ± S.D of three independent experiments (** 
P<0.001). 
 
Biological removal of PSA-NCAM therefore modulated cell migration in 
C6-STX cells. We next tested the hypothesis that small molecule 
polyST inhibitors would prevent PSA-NCAM synthesis and therefore 
also modulate cell migration. As previously described, CMP has been 
shown to reduce polysialylation of NCAM through competitive inhibition 
of both STX and PST [112]. Here, C6-STX and C6-WT wounded 
confluent cell monolayers were incubated with 0.5, 1, 3, 5 and 7 mM 
concentrations of CMP (previously shown to be non-toxic) for 24 hours. 
Results indicated that the addition of different concentrations of CMP 
to C6-STX wounded monolayers led to a significant concentration-
dependent reduction in cell migration during wound healing compared 
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to C6-WT (P<0.01) (Figure 5.24 and 5.25). This inhibitory effect was 
concentration-dependent where the maximal inhibition was seen at 7 
mM. When C6-WT wounded monolayers were treated with CMP, no 
significant reduction in cell migration over controls (untreated) (P>0.05) 
was observed. In comparing the inhibitory effects of CMP treatments, 
migration of C6-STX cells was decreased significantly more than C6-
WT cells during wound healing at all CMP concentrations. This 
reduction in the migratory potential of C6-STX cells (19%) over C6-WT 
cells (77.5%) was clearly evident with CMP treatment at 7 mM 
(P<0.01) (Figure 5.24 and 5.25).  
As a further control, wounded DLD-1 (PSA-NCAM and NCAM 
negative) monolayers were treated with CMP at various concentrations 
ranging from 0.5-7 mM for 24 hours. The results showed that CMP 
treatment at concentrations of 0.5, 1 and 3 mM had no effect on 
migration (Figure 24 and 25). When cells were treated with 5 and 7 
mM of CMP, the migration capacity of DLD-1 cells was modulated 
slightly compared to controls (untreated). This, however was 
determined to be statistically insignificant (P>0.05). The effects of CMP 
treatment on C6-WT and DLD-1 cells were seen to be equally 
insignificant (P>0.05) (Figure 5.24 and 5.25). 
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Figure 5.24. The effect of CMP on cellular migration for C6-STX (upper row), C6-WT (middle row) and DLD-1 (lower row) cell monolayers as assessed by 
scratch assay after 24 hours. (a, h and o) show initial perimeter of scratches in confluent cell monolayers for C6-STX, C6-WT and DLD-1 respectively. (b and i) 
show C6-STX cells migrated faster than C6-WT cells during wound closure. (p) shows the wound healing of DLD-1 after 24h.  CMP treatment at all concentrations 
decreased the migration capacity of C6-STX cells (c-g) but not C6-WT cells (j-n) in a dose dependent manner during the wound closure. In (q-u) CMP treatment at 
all concentrations did not exert any significant effect on migration of DLD-1 cells. 
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Figure 5.25. The effect of CMP treatment on wound healing of C6-STX , C6-WT 
and DLD-1 monolayers for 24 h. CMP treatment at all concentrations decreased the 
migration capacity of C6-STX cells over C6-WT and DLD-1 cells in a concentration 
dependent manner during wound closure. Moreover, CMP treatments insignificantly 
reduced the migration of C6-WT cells and DLD-1 cells even at high concentrations. 
Values shown are relative to control and expressed as means ± S.D of three 
independent experiments (* P<0.01). 
Following assessment in the wound healing assay, the effects of CMP 
were further examined in the radius assay, as described previously. 
Following stopper removal, C6-STX and C6-WT monolayers were 
incubated with 0.5, 1, 3, 5 mM concentrations of CMP for 72 hours. 
These results also indicated a significant concentration-dependent 
decrease in migration of C6-STX cells compared to C6-WT cells upon 
CMP treatment (P<0.01) (Figure 5.26 and 5.27). This concentration-
dependent inhibition in migration of C6-STX cells was clearly evident at 5 
mM. In contrast, CMP treatment of C6-WT monolayers did not affect 
cellular migration at lower concentrations (0.5 and 1 mM) while 3 and 5 
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mM showed an insignificant reduction compared to the controls 
(untreated) (P>0.05). Overall, the inhibitory effect of CMP treatment on 
migration of C6-STX cells was significantly higher than that observed for 
C6-WT cells at all concentrations (Figure 5.27).  
DLD-1 monolayers were incubated with CMP at concentrations of 0.5, 1, 
3, 5 mM for 120 hours (Figure 5.26 and 5.27). Results clearly 
demonstrated that migration of DLD-1 cells was not affected by CMP 
treatment at lower concentrations (P>0.05). A very minor reduction in 
DLD-1 cellular migration was observed at 5 mM CMP but this was 
confirmed as statistically insignificant when compared to that observed in 
untreated monolayers.  
 
 
 
173 
 
 Initial perimeter Control 0.5 mM CMP 1 mM CMP 3 mM CMP 5 mM CMP EndoNF 12 µg/mL 
C
6
-S
T
X
 
       
C
6
-W
T
 
       
D
L
D
-1
 
       
Figure 5.26. The effect of CMP and EndoNF treatments on cellular migration of C6-STX (upper row), C6-WT (middle row) and DLD-1 (lower row) cell lines 
as assessed by radius assay. (a, h and o) initial perimeter of cell-free zones surrounded by confluent monolayers of C6-STX, C6-WT and DLD-1 cells respectively. 
(b, i and p) show the repopulation of C6-STX, C6-WT and DLD-1 cells in cell-free zones respectively.  CMP treatment at all concentrations decreased the migration 
capacity of C6-STX cells (c-f) over C6-WT cells (j-m) in a concentration dependent manner.  When DLD-1 cell were treated with CMP, no significant effect on 
migration was observed (q-t). EndoNF treatment highly reduced the migration of C6-STX cells (g), while no effect was seen on C6-WT (n) and DLD-1 (u) cells. 
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Figure 5.27. The effect of CMP and EndoNF treatments on cellular migration of 
C6-STX, C6-WT and DLD-1 cells as assessed by radius assay. CMP treatment led 
to concentration-dependent reduction in migration capacity of C6-STX cells over C6-WT 
and DLD-1 cells. EndoNF treatment significantly reduced the migration of C6-STX cells 
while no effect was observed on the migration of C6-WT and DLD-1 cells. Moreover, 
CMP treatment showed insignificant decrease on migration of C6-WT cells over DLD-1 
cells at high concentrations, while almost no effect was observed at 0.5 and 1 mM 
treatment of CMP. Values shown are relative to control and expressed as means ± S.D 
of three independent experiments (* P<0.01).  
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5.4. Discussion 
The main aims of the work described in this chapter were to develop cell-
based screening assays to provide a reliable platform for assessing the 
pharmacological effects of novel polyST inhibitors. These assays provide 
valuable insights into the effects of compounds in whole cell systems. 
Compounds demonstrating activity in cells will require cell permeability. 
This information is ultimately useful towards understanding the likely 
effects of compounds in vivo [134].  
In order to confirm that any observed effects on migration by biological 
and chemical intervention were indeed due to modulation of PSA-NCAM 
expression, the PSA-NCAM recovery assay was employed. This assay 
was devised as a model to investigate PSA-NCAM recovery at the 
surface of neurons and endocrine cells following EndoN treatment under 
various conditions of cell activity [131]. On this basis, this assay was 
modified and optimised here to investigate the effect of novel polyST 
inhibitors on tumour cell surface PSA-NCAM recovery following EndoN 
treatment. 
The PSA-NCAM recovery assay depends not only on the efficient 
removal of PSA from cell-surface NCAM but also on the subsequent re-
growth following a recovery period. Different types of EndoN were 
evaluated in the optimisation of the assay. Despite all types of EndoN 
being effective in digesting cell surface PSA-NCAM, differences were 
observed in PSA-NCAM re-expression on the surface of cells. EndoNK 
alone led to successful PSA-NCAM recovery.   
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One possible explanation for these results is that EndoNF is highly 
potent (more potent than EndoNK) with a very strong affinity for PSA 
chains on the surface of cells [136]. Consequently, this enzyme remains 
tightly bound to the remnant PSA chains thereby blocking the binding 
sites for the anti-PSA-NCAM antibody. To test this hypothesis, a mutant 
EndoNF enzyme (EndoNF-mutant) was obtained in which part of the 
binding domain was removed. However, it was observed that the activity 
was identical to EndoNF and that PSA recovery did not occur.  
In contrast, EndoNK may have lower affinity to surface-bound PSA 
chains being easily dissociated from the PSA chains, and therefore 
forming no competition with polySTs.  
In an attempt to encourage PSA-NCAM recovery following treatment with 
EndoNF or EndoNF mutant, cells were incubated with colominic acid in 
an attempt to disrupt the binding of enzyme-PSA complexes which may 
exist. Unfortunately, this proved unsuccessful, in contrast to previous 
reports [135]. On this basis, EndoNK was utilised in the PSA-NCAM 
recovery assay, whilst the other enzymes were used for other 
applications (flow cytometry and radius cell migration assay) where PSA-
NCAM recovery was not required. 
On monitoring PSA-NCAM recovery following EndoNK digestion, C6-
STX and IMR-32 cells were able to abundantly mobilise PSA-NCAM to 
the cell surface within 6 hours following EndoNK treatment. This was in 
agreement with other studies, where naturally PSA-NCAM expressing 
neuroblastoma (LAN-5 and SH-SY5Y) and rhabdomyosarcoma (TE-671) 
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cell lines demonstrated PSA-NCAM recovery within 6 hours following 
Clostridium perfringens neuraminidase treatment [130].  
Several lines of evidence indicate that PSA-NCAM expression in 
malignant tumours is increasingly recognised as a modulator of tumour 
invasion and metastasis [59-61, 69, 78, 85]. As neoplastic cell migration 
is one of the many facets of tumour metastasis [5], the role of PSA-
NCAM expression in cell migration was investigated here by using 
pharmacologically relevant cell migration assays: the wound healing 
assay and radius cell migration assay. The wound healing assay is one 
of the more widely used cell migration assays to study types of cellular 
migration and to identify the anti-migratory effect of compounds [137]. 
This assay depends on creating a defined wound in a confluent 
monolayer of cells by mechanical scratching [132]. This assay has 
gained popularity as it is elegant, simple and inexpensive to perform. 
Furthermore, it is particularly suitable to study the effects of cell 
interactions (cell-cell or cell-extracellular matrix interactions) on cell 
migration. It is also suitable for observing the movement and morphology 
of cells as well as live cell imaging [132].  
Despite these advantages over other cell migration assays, it also has 
some disadvantages [133, 134, 137, 138]. It can be difficult to achieve 
highly reproducible results because of the inconsistency in size and 
shape of wounds between experiments and even between the wells in 
the same experiment. Moreover, cellular migration during wound closure 
is affected by the release of growth and/or apoptotic factors from the 
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damaged or dead cells created during the process of scratching that may 
enhance cellular migration. The process of scratching itself may also 
influence cellular migration due to physical damage of the extracellular 
matrix or plate surface [133, 134, 137, 138]. These factors however, can 
be controlled, to some extent. Additionally, it is challenging to screen 
large numbers of compounds [133].  
As an alternative, the radius assay method was also used to investigate 
the role of PSA-NCAM expression in cell migration. The radius assay 
was originally developed to circumvent many of the disadvantages of 
classical wound healing assay [133, 134]. This assay is based on using 
silicon stoppers as barriers that populate a 96-well plate. These stoppers 
occupy circular areas in the centre of the wells that prevent the cells from 
attaching through the seeding process. Following the removal of these 
stoppers, circular cell-free zones (2 mm in diameter) at the centre of the 
wells are formed, into which cell migration may occur [133, 134]. This 
assay offers great advantages over the wound healing assay and other 
cell migration assays in that damage does not occur to the cells, 
extracellular matrix or plate surface. Moreover, it allows the formation of 
accurately sized and homogenously shaped cell-free zones which 
thereby reduces variability and increases the robustness of results. It 
also generates highly reproducible and quantitative results, making it 
compatible for screening larger numbers of compounds [133, 134, 138].  
Both the wound healing assay and radius assay are unsuitable for non-
adherent cells or where chemotaxis is required for cell migration [134]. 
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Following the establishment of the wound healing assay and radius 
assay methods, the role of the PSA-NCAM expression in cell migration 
was investigated. Here, the isogenic C6-STX and C6-WT cell lines were 
utilised. Attempts to use the IMR-32 cell line in the above migration 
assays proved unsuccessful, as this cell line grows in colonies and forms 
dense focal clumps [125], making it unsuitable for the wound healing 
assay where uniform coverage of the plate is required. 
Results demonstrated that wounding confluent monolayers of C6-STX, 
which sustainably expresses PSA-NCAM, led to fast and strong 
repopulation of cells in the wounded area compared to C6-WT cells. This 
indicates a clear differential in the rate of migration. Concordant with the 
above results, the radius assay also showed that C6-STX cells more 
rapidly repopulated the cell-free zones than C6-WT cells. In both assays, 
forced PSA-NCAM expression enhanced the migration capacity of C6-
STX cells over C6-WT cells. In contrast, when C6-STX and C6-WT 
monolayers were treated with EndoNF, migration of C6-STX cells was 
significantly reduced while the migration of C6-WT cells was not affected. 
Given that only C6-STX and not C6-WT cells express PSA-NCAM, this 
confirms the involvement of PSA-NCAM in the migration of C6-STX cells. 
These results are in agreement with previous studies showing that the 
forced expression of PSA-NCAM significantly enhances the migration of 
STX-transfected cells compared to wild type cells [93, 139-141]. It was 
shown that scratching confluent monolayers of STX transfected Schwann 
cells enhanced the repopulation of cells in the wounded area over 
180 
 
controls [140, 141]. The treatment of scratched monolayers with EndoN 
significantly reduced cell migration and completely inhibited wound 
healing [93, 139, 140].  
In an attempt to elucidate the mechanism by which PSA-NCAM 
enhances tumour invasion and metastasis, Li and co-workers suggested 
that polysialylation of NCAM enhances cell migration in an FGFR-
dependent manner and differentially alters cell adhesion on different 
substrates [93]. It was found that cells transfected with STX stably 
expressed PSA-NCAM and showed an increase in their migratory and 
invasive potential compared to mock transfected cells. Additionally, PSA-
NCAM expression differentially affected cell adhesion to different 
substrates. These effects were readily reversed when the STX 
transfected cells were treated with EndoN. This PSA-NCAM-driven 
migration on different matrices was potentiated by activation of the FGFR 
signalling pathway [93]. 
More recently, it was shown that PSA decoration regulates NCAM 
mediated tumour cell migration and controls focal adhesions in cell-cell 
contacts [95]. The migration of neuroblastoma (SH-SY5Y and Kelly) and 
rhabdomyosarcoma (TE-671) cells was significantly reduced after PSA-
NCAM removal by EndoN. It was proposed that this reduction in cellular 
migration was due to increased focal adhesion through NCAM-
dependent signalling [95]. Together and in line with our results, this 
suggests that PSA-NCAM plays an important role in promoting tumour 
cell migration. 
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Following the development and optimisation of these methods, all assays 
were validated using a naturally occurring polyST inhibitor, CMP [112], 
which is known to significantly reduce PSA-NCAM expression on the cell 
surface. This decrease in PSA-NCAM synthesis was shown to be due to 
competitive inhibition of polyST [112]. Miyazaki et al. investigated this 
using an assay employing radiolabelled substrates. CMP was found to 
be capable of inhibiting the enzymatic activity of a range of 
sialyltransferases, with some selectivity for polyST, thereby decreasing 
polysialylation of NCAM. Moreover, polysialylation of NCAM was 
decreased on the surface of Chinese hamster ovary (CHO) cells by CMP 
treatment as assessed by Western blotting and flow cytometry [112]. The 
lack of selectivity (it inhibits ST3Gal-III, ST3Gal-IV and ST6Gal-I) means 
that it is not an ideal basis for development of a specific polyST inhibitor 
in this context. Moreover, CMP is vitally converted and utilised in many 
human biosynthetic reactions, which when administered exogenously 
may lead to adverse effects [112]. However, as it is an effective inhibitor 
of polyST, CMP was considered a useful probe molecule.  
It was previously shown that exogenously added CMP can be 
incorporated into cells at high concentrations due to its high hydrophilicity 
[142]. Its effects on polysialylation of NCAM were investigated in cultured 
cells where it was shown that exogenously added CMP at 0.5 mM 
reduced PSA-NCAM expression on the surface of CHO cells as 
measured by flow cytometry [112]. In my hands, CMP treatment was 
non-toxic and well tolerated by C6-STX, C6-WT, IMR-32 and DLD-1 cell 
lines with IC50 values ranging from 13.9 to 14.8 mM, well above the 
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effective concentrations used in the assays here. On this basis and by 
flow cytometry, the effects of CMP on polysialylation were quantitatively 
assessed in vitro by incubating IMR-32 cells with different concentrations 
of CMP ranging from 0.5 to 7 mM for 24 hours. CMP treatment led to a 
concentration-dependent inhibition of cell surface PSA-NCAM expression 
where the maximum inhibition was seen at 7 mM. Moreover, PSA-NCAM 
levels were robustly decreased upon EndoNF treatment for 24 hours 
confirming the reliability of the method for quantitative analysis. Based on 
these results, it was concluded that exogenously added CMP is taken up 
into cells and decreases PSA-NCAM expression on the surface of IMR-
32 cells by inhibiting polyST enzymes. 
At the level of individual cell surfaces, the effect of CMP on 
polysialylation of NCAM was studied using the PSA-NCAM recovery 
assay [131]. When the C6-STX and IMR-32 cells were treated with CMP 
directly following the PSA-NCAM digestion by EndoNK, the recovery rate 
of PSA-NCAM was drastically reduced on the surface of both cell lines. 
This delay in mobilisation of PSA-NCAM was concentration-dependent 
with the maximum effect being seen at 10 mM in both cell lines. 
Moreover, CMP treatment had a greater inhibitory effect on recovery of 
PSA-NCAM in IMR-32 cells than in C6-STX cells. A possible explanation 
may perhaps be, that the IMR-32 cell line encodes both STX and PST 
enzymes [84, 130], whilst the C6-STX cell line is only transfected with 
STX. The fact that CMP did not completely inhibit PSA-NCAM recovery 
is supported by the idea that the efficiency of CMP transport to the Golgi 
apparatus may represent a rate-limiting step [112].  On this basis, and 
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after being transported to Golgi apparatus, CMP may exert its inhibitory 
effect by competing with CMP-Neu5Ac in the polyST enzyme active site 
[112]. Therefore, these results indicate that CMP decreases PSA-NCAM 
synthesis by preferential inhibition of polyST activity. 
In an attempt to establish the importance of polyST inhibition by CMP 
and therefore PSA-NCAM synthesis in cell migration, the optimised 
wound healing assay and radius assay methods using the C6 and DLD-1 
cell lines were employed. Experiments showed that CMP caused a 
significant decrease in the migration of C6-STX cells with insignificant 
reduction in migration of C6-WT and DLD-1 cells being observed. This 
pronounced reduction in the migration of C6-STX cells over C6-WT and 
DLD-1 cells was a concentration-dependent effect where the maximum 
inhibition was observed on treatment with highest concentration of CMP 
in both models. There was also a slight, albeit insignificant reduction in 
the migration of C6-WT over DLD-1 cells upon treatment with high 
concentrations of CMP which could be due to inhibition of other 
sialyltransferases (e.g. ST3Gal-III, ST3Gal-IV and ST6Gal-I) by CMP 
[112]. Furthermore, EndoN treatment dramatically reduced migration of 
C6-STX cells but no effect was seen on the migration of C6-WT and 
DLD-1 cells. On this basis, it was substantiated that inhibition of polySTs 
by CMP and therefore PSA-NCAM synthesis, led to reduced migration of 
PSA-NCAM expressing cells. 
In conclusion, in this chapter cell-based assays for the pharmacological 
screening of novel polyST inhibitors were successfully optimised and 
184 
 
validated using CMP. These methods proved reliable and reproducible in 
demonstrating the effects of CMP on the polysialylation of NCAM. CMP 
inhibited polysialylation of NCAM in cells as assessed by flow cytometry 
and the PSA-NCAM recovery assay. Moreover, the wound healing and 
radius assay methods generated robust and reproducible results on the 
migration potential of C6-STX over C6-WT cells, supporting the 
association of polysialylation with increased migratory capacity,  as well 
as the anti-migratory effects of CMP achieved through polyST inhibition. 
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6. Pharmacology of novel polyST inhibitors 
6.1. Introduction 
In the previous chapter the development and validation of cell-based 
methods (using CMP) to evaluate novel polyST inhibitors was described. 
This chapter will discuss how these methods were utilised to assess the 
effects of PSA-NCAM inhibition by novel polyST inhibitors. 
The development of polyST inhibitors at the ICT is based on an iterative 
process of design, synthesis and biological screening using two rational 
approaches explained below. The cell-free screen which was used to 
select compounds for evaluation in the cell-based assay is also 
described here. 
The first rational approach – substrate-inspired inhibitors - focused on the 
substrate (donor) for polysialylation, namely CMP-sialic acid (Figure 6.1). 
It was rationalised that modification of the substrate structure at different 
sites might lead to potential inhibitors. These modifications were intended 
to introduce stability to the glycosidic linkage and to maximise functional 
group interactions within the active site of the polyST enzymes and 
therefore lead to inhibition of catalytic activity. Figure 6.1 outlines 
examples of modifications made to the CMP-sialic acid. The molecule 
can be broadly split into three sections – the sialic acid component, the 
nucleoside component and the phosphate linkage. Compounds tested 
focused principally on the latter two areas (see Table 6.1).   
186 
 
 
Figure 6.1. Possible structural substitutions and/or replacements on the moieties 
of CMP-sialic acid.  
The second rational approach in discovering polyST inhibitors was based 
on computational chemistry and virtual screening. In the absence of a 
crystal structure for the human polyST enzymes, the crystal structure of 
bacterial sialyltransferase CstII (from the human pathogen 
Campylobacter jejuni strain OH4384) was utilised for computer modelling 
studies [143]. All sialyltransferase enzymes (STs) share consensus 
sequences known as the sialyl motifs found in the catalytic sites of all 
mammalian STs. These are known as sialyl motifs L (large; 48 amino 
acids), S (small; 23 amino acids), VS (very small; 6 amino acids) and 
Motif III (4 amino acids) [41]. The use of CstII sialyltransferase was 
significant as it is a bifunctional enzyme, having α2,8-
polysialyltransferase catalytic activity in addition to the α2,3-
sialyltransferase activity normally expected of an enzyme of this type. In 
other words, it catalyzes the initial formation of an α-2,3-sialic residue as 
acceptor substrate onto which it then adds an α-2,8-sialic residue [143]. 
These factors together meant that the CstII crystal structure was a useful 
model to generate polyST inhibitors. 
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Virtual screening is a term used to describe the search for potential 
inhibitors from libraries of chemical structures using computer modelling 
software. The software attempts to automatically orientate and position 
the structure of each molecule in turn into a pre-determined area of the 
enzyme or protein (e.g. the active site) before calculating the binding 
efficiency. The Maybridge database, which contains the structures of 
20,000 compounds with drug-like properties, was used for docking 
studies. These virtual ‘hits’ could then be purchased and evaluated in 
vitro. The ten most promising compounds were identified from the screen 
and evaluated for polyST inhibition in vitro. From these, four were 
selected for evaluation (see Table 6.1).  
Alongside the novel inhibitors, a small number of compounds identified in 
the literature as polyST inhibitors were also studied. CMP, a competitive 
non-selective polyST inhibitor has already been discussed. A second 
group of compounds shown to inhibit polysialylation on NCAM are the N-
acylmannosamines. These compounds have been previously discussed 
in Chapter 1(section 1.5.2). 
Lithocholic acid, a mono-sialyltransferase inhibitor was also included in 
this study (referred to as ICT-3124 here) at each stage as a control. This 
molecule has been shown to decrease terminal sialylation (i.e. 
glycosylation with a single sialic acid residue, via an -2,3/-2,6 linkage) 
in human lung cancer cells both in vitro and in vivo [144]. However, in the 
recently reported study, no assessment was made on its inhibition of 
polyST enzymes. 
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Table 6.1. Summary of the polyST inhibitors evaluated in this study. 
 
Substrate-inspired inhibitors Inhibitors identified from 
virtual screening 
N-acylmannosamines Others 
ICT-2568 ICT-3068 ICT-3147 CMP 
ICT-3004 ICT-3069 ICT-3128  
ICT-3018 ICT-3071   
ICT-3020 ICT-3025   
ICT-3021 ICT-3026   
ICT-3029 ICT-3027   
ICT-3031    
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The potential inhibitors for study in the cell-based assays described in 
Chapter 5 were selected on the basis of inhibitory activity in an enzyme-
based assay. The ability of these compounds to inhibit the polyST 
enzymes and therefore reduce PSA synthesis on NCAM was 
biochemically assessed using a Western blotting method. Briefly, NCAM 
polysialylation was measured in the presence and absence of an 
inhibitor, and the degree of polysialylation was detected on the blot using 
mouse anti-PSA-NCAM monoclonal antibody (clone: 735). Compounds 
that blocked polysialylation of NCAM by inhibiting the STX and PST 
enzymes were identified as polyST inhibitors (by those at the Institute of 
Cancer Therapeutics). 
6.1.1. Aims 
This chapter describes the evaluation of potential polyST inhibitors for 
their pharmacological effects in cellular systems. Evaluation of cellular 
migration using the radius assay and confirmation of the involvement of 
polyST inhibition in the anti-migratory effects using the optimised PSA-
NCAM recovery assay will be described. The most promising compounds 
will then be more extensively evaluated in both the radius and wound-
healing migration assays. 
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6.2. Methods 
6.2.1. Compounds 
“Substrate-inspired” inhibitors were synthesised at the ICT (in the 
laboratory of Dr Falconer). These compounds were: ICT-2568, ICT-3004, 
ICT-3018, ICT-3020, ICT-3021, ICT-3029 and ICT-3031. 
Compounds identified from virtual screening were purchased from the 
Maybridge library (via Fisher Scientific, Loughborough). These 
compounds were: ICT-3068, ICT-3069, ICT-3071 and ICT-3125. 
Following promising results, ICT-3125 was subsequently re-synthesised 
in the ICT in larger quantities, along with an analogue (ICT-3126) and the 
ester prodrug version of ICT-3125 (ICT-3127). 
N-propylmannosamine, ICT-3147, was provided by Prof Rudiger 
Horstkorte (Halle University, Germany). This compound, along with the 
acetylated prodrug version, ICT-3128, was also synthesised at the ICT. 
Lithocholic acid, ICT-3124, was purchased from Sigma-Aldrich (Dorset, 
UK). 
6.2.2. Cell migration 
6.2.2.1. Radius assay  
The radius assay method was performed as previously described in 
Chapter 5 (section 5.2.5.2) using the C6-STX, C6-WT and DLD-1 cell 
lines to assess the pharmacological effects of the compound panel. 
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Initially, C6-STX cells were used to evaluate the 16 compounds over a 
range of concentrations. Moreover, CMP, EndoNF and DMSO (0.4%) 
were also included in the initial screen as treatment controls. For CMP, 
the 5 mM concentration of CMP was used, while EndoNF was used at 
concentrations 3, 6 and 12 µg/mL (based on the optimum concentrations 
determined previously). Following identification of the most interesting 
compounds, further analysis was performed in the C6-WT and DLD1 cell 
lines.  
6.2.2.2. Wound healing assay  
The anti-migratory effects of the candidate polyST inhibitors on cell 
migration was further evaluated by the wound healing assay using the 
C6-STX, C6-WT and DLD-1 cell lines. This was performed as previously 
described in Chapter 5 (section 5.2.5.1). 
6.2.3. PSA-NCAM recovery assay 
The pharmacological effects of compounds that proved promising in the 
radius assay were evaluated using the PSA-NCAM recovery assay as 
previously outlined in Chapter 5 (section 5.2.4) confirming that anti-
migratory effects were due to the absence of PSA. Following the removal 
of PSA-NCAM by EndoN (0.3 µg/ml) treatment, cell-surface PSA-NCAM 
was allowed to recover in either normal medium (control) or in the 
presence of inhibitor. CMP (10 mM) and DMSO (0.1%) were also 
included in the experiments as treatment controls. Initially, compounds 
were screened using C6-STX cells. Promising compounds were then 
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evaluated in a naturally expressing neuroblastoma cell line, IMR-32. The 
results were analysed by counting positive cells with results expressed 
as means ±S.D of the two independent experiments. 
6.2.4. Statistics 
Data shown were expressed as means ±S.D of the independent 
experiments. The number of independent experiments performed is 
stated in the respective table or figure legend. Images shown are 
representatives of independent experiments. Statistical analysis was 
performed using the Student’s t-test for statistical significance.  
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6.3. Results 
6.3.1. Characterisation of the anti-migratory effect of polyST 
inhibitors 
The anti-migratory activity of the panel of compounds was initially 
evaluated in the radius assay using the C6-STX cell line, with 
compounds administered at 1, 10 and 100 µM. Following screening 100 
µM was selected as the cut-off point for selection for compound 
progression.  
The initial screen results demonstrated that treatment with several of the 
compounds led to a significant reduction in the migration of C6-STX 
cells, as indicated by closure of the cell-free zones compared to the 
controls (untreated, CMP and EndoNF) (Table 6.2, Figure 6.2) (P<0.01). 
This significant inhibitory effect was seen at the highest concentration 
examined (100 µM) for 3 compounds (namely ICT-3125, ICT-3126 and 
ICT-3128) while no effect was observed at lower concentrations (1 and 
10 µM). 
Several compounds exhibited toxicity at 100 µM. These compounds were 
re-evaluated at lower concentrations (Table 6.2, Figure 6.2). The highest 
concentration demonstrating an absence of toxicity was utilised for 
assessment of anti-migratory capacity. ICT-3021, ICT-3068 and ICT-
3127 each exhibited cytotoxicity at 100 µM, but significant anti-migratory 
activity at lower concentrations (75 µM, 10 µM and 75 µM respectively) in 
the absence of toxicity. Four compounds, ICT-3020, ICT-3069 and ICT-
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3071 exhibited cytotoxicity at 100 µM but had no effect on cell migration 
at lower concentrations, and therefore were not explored further. 
Sialyltransferase inhibitor ICT-3124 also demonstrated cytotoxicity at 100 
µM and had no effect on cell migration at lower concentrations.  
The migratory capacity of C6-STX cells was not significantly affected at 
any concentration by the following compounds: ICT-2568, ICT-3004, 
ICT-3018, ICT-3029 and ICT-3031. These compounds were also not 
explored further. 
The one exception to our inclusion criteria was ICT-3147 (ManNProp) 
which along with CMP, has been previously reported as a polyST 
inhibitor [109-111, 145]. ICT-3147 is a simple reducing sugar and 
therefore a very hydrophilic molecule (readily dissolved in medium), 
possessing poor membrane permeability characteristics and therefore 
required higher concentrations for an effect than the other more lipophilic 
compounds. In this context, C6-STX monolayers were treated with ICT-
3147 at concentrations of 1, 3 and 5 mM, with a significant reduction in 
the migration of C6-STX cells compared to untreated monolayers 
(P<0.01) seen. Maximal inhibition was observed at 5 mM. 
In addition and as expected, CMP treatment of C6-STX monolayers 
caused a significant reduction in the migration capacity of C6-STX cells. 
Moreover, the degree of cellular migration of C6-STX cells was inhibited 
by EndoNF in a concentration-dependent manner, with almost complete 
inhibition observed at a concentration of 12 µg/mL. DMSO, when 
administered at the highest concentration used for solubilisation (0.4%) 
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did not exert any effect on the migration potential of C6-STX cells (Table 
6.2) and was confirmed as non-toxic (Figure 6.2).  
The selected agents were then evaluated for anti-migratory effects in the 
non-PSA-NCAM expressing C6-WT cells. C6-WT monolayers were 
incubated with 1, 10 and 100 µM concentrations of these compounds 
and the cells were allowed to completely repopulate the cell free-zones. 
In addition, C6-WT monolayers were also treated with CMP (5 mM) and 
EndoNF (12 µg/ml) as treatment controls. The migration of the C6-WT 
cells was not significantly affected by the treatment of any of the tested 
compounds (Table 6.2 and Figure 6.3).  
The compounds (namely ICT-3021, ICT-3068 and ICT-3127) that 
demonstrated C6-STX cytotoxicity also demonstrated cytotoxicity in the 
C6-WT cell line at concentrations of 100 µM. These compounds were 
further examined at the same concentrations identified as non-toxic and 
producing anti-migratory effects in C6-STX cells. All compounds failed to 
significantly modulate migration in C6-WT cells. ICT-3147 did not 
modulate migration in C6-WT cells at all concentrations tested (Table 6.2 
and Figure 6.3). 
Sialyltransferase inhibitor ICT-3124 also demonstrated cytotoxicity at 100 
µM but had no effect on cell migration at lower concentrations.  
CMP treatment did not cause a significant reduction in the migration of 
C6-WT cells. Moreover, the cellular migration of C6-WT cells was not 
affected by treatment with EndoNF (Table 6.2 and Figure 6.3).  
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Table 6.2. Determination of the anti-migratory effect of novel polyST inhibitors on 
C6-STX and C6-WT cells as assessed by the radius cell migration assay. Values 
shown are normalised relative to the untreated control (100%) and expressed as mean 
±S.D of four independent experiments. (*) P<0.01. 
Compound Concentration* Migration (%)# 
C6-STX C6-WT 
Substrate 
inspired 
inhibitors 
ICT-2568 100 µM Nil 
 
ICT-3004 100 µM Nil 
ICT-3018 100 µM Nil 
ICT-3020 100 µM 
50 µM 
toxic 
Nil 
ICT-3021 100 µM 
75 µM 
toxic 
55 ± 9.0 
 
Nil 
ICT-3029 100 µM Nil 
 
ICT-3031 100 µM Nil 
Compounds 
identified 
from virtual 
screening 
ICT-3068 100 µM 
10 µM 
toxic 
63 ± 6.0 
 
Nil 
ICT-3069 100 µM 
25 µM 
toxic 
Nil 
 
ICT-3071 100 µM 
50 µM 
toxic 
Nil 
ICT-3125 100 µM 71 ± 2.7 Nil 
ICT-3126 100 µM 72 ± 8.3 Nil 
ICT-3127 
100 µM 
75 µM 
toxic 
67 ± 8.4 
 
Nil 
N-acyl-
mannosamin
es 
ICT-3147 
100 µM 
1 mM 
Nil 
79 ± 4.2 
 
Nil 
3 mM 70 ± 4.8 Nil 
5 mM 65 ± 5.0 Nil 
ICT-3128 100 µM 62 ± 3.1 Nil 
ST inhibitor ICT-3124 
100 µM 
75 µM 
toxic 
Nil 
 
Controls 
CMP 5 mM 31 ± 6.2 Nil 
EndoNF 
3 µg/mL 71 ± 3.5 Nil 
6 µg/mL 44 ± 4.2  
12 µg/mL 17 ± 4.2  
DMSO 0.4% Nil Nil 
*All compounds were initially screened at a concentration of 100µM. If toxicity was 
observed, the lowest concentration where migration could be measured in the absence 
of toxicity is reported. 
#
Nil means cellular migration was below statistical significance (P 
< 0.01). Toxic refers to observed cytotoxicity. 
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Initial perimeter Control CMP 5 mM DMSO 0.4% 
    
EndoNF 3 µg/mL EndoNF 6 µg/mL EndoNF12 µg/mL ICT-3021 75 µM 
    
ICT-3068 10 µM ICT-3125 100 µM ICT-3126 100 µM ICT-3127 75 µM 
    
ICT-3128 100 µM ICT-3147  1 mM ICT-3147  3 mM ICT-3147 5 mM 
    
 
Figure 6.2. Characterisation of the anti-migratory effect of novel polyST inhibitors 
on C6-STX cells as assessed by radius assay for 60 hours. Results showed that 
migration of C6-STX cells was significantly reduced upon 5 mM treatment of CMP. 
Furthermore, EndoNF treatment led to a concentration-dependent inhibition of migration 
in C6-STX cells. Migration affects and toxicity were not observed following treatment 
with DMSO (0.4%). Moreover, treatment with 10µM ICT-3068 led to a significant 
decrease in the migration of C6-STX cells, while similar effects were observed at 100 
µM ICT-3125, ICT-3126 and ICT-3128. Treatment with 75 µM ICT-3021and ICT-3127 
moderately reduced the migration of C6-STX cells. ICT-3147 treatment showed a 
significant concentration-dependent inhibition in C6-STX cell migration. Images shown 
are representatives of four independent experiments. 
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Initial perimeter Control CMP EndoNF 12 µg/mL 
    
ICT-3021 75 µM ICT-3068 10 µM ICT-3125 100 µM ICT-3126 100 µM  
   
ICT-3127 75 µM ICT-3128 100 µM ICT-3147  1 mM ICT-3147  3 mM 
    
ICT-3147  5 mM    
 
   
 
Figure 6.3. Characterisation of the anti-migratory effect of novel polyST inhibitors 
on C6-WT cells as assessed by radius assay for 72 hours. Compounds that were 
identified from the C6-STX screening were further examined in C6-WT monolayers, with 
the same effective concentrations of inhibitor. Results showed that EndoNF treatment 
did not affect migration of C6-WT cells. Moreover, CMP treatment led to slight reduction 
in the migration of C6-WT cells. All other compounds tested did not result in any 
significant effect on C6-WT cell migration. Images shown are representatives of three 
independent experiments. 
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6.3.2. Effect of novel polyST inhibitors on PSA-NCAM mobilisation  
Following on from the radius assay, the pharmacological effects of 
promising compounds were further evaluated in the PSA-NCAM recovery 
assay. Compounds were initially screened in C6-STX cells and if 
deemed promising, in IMR-32 cells. C6-STX cells were treated with 
EndoNK (0.3 µg/mL) to remove existing PSA-NCAM, followed by a 6 
hours recovery period in culture medium containing the test inhibitor.  
Given the short time frame for the experiment (6 hours) and the inability 
to detect small changes in PSA-NCAM expression in this initial screen, 
concentrations of inhibitors sufficient to substantially remove PSA-NCAM 
were used. C6-STX cells were incubated with the highest achievable 
concentration of compound where the final DMSO level was 0.1%. The 
highly polar nature of ICT-3147 meant that the concentration employed 
was 10 mM. The C6-STX cells were also incubated with DMSO (0.1%) 
and CMP (10 mM) as treatment controls.  
Treatment with EndoNK (0.3 µg/mL) completely and effectively digested 
the PSA-NCAM on the surface of both the C6-STX and IMR-32 cells. 
Moreover, PSA-NCAM was significantly re-expressed on the surface of 
C6-STX and IMR-32 cells within 6 hours (Figures 6.4 and 6.5).  
PSA-NCAM re-expression in C6-STX cells following the 6h recovery 
period was completely suppressed by two compounds: ICT-3125 (500 
µM) and ICT-3128 (250 µM) (Table 6.3 and Figure 6.4). This inhibitory 
effect on the activity of PSA-NCAM mobilisation was indicated by 
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complete abolition of the fluorescence labelling intensity upon ICT-3125 
and ICT-3128 treatment. These higher concentrations were investigated 
in the migration assays in subsequent more detailed studies (see section 
6.3.4). A slight-to-moderate decrease in fluorescence labelling intensity 
was seen upon treatment with ICT-3147 (10 mM). Treatment with ICT-
3021, ICT-3068, ICT-3126 and ICT-3127 did not indicate a significant 
difference in the fluorescence labelling intensity between the treated cells 
and controls at the concentrations examined. CMP treatment (10 mM) 
led to a significant decrease in the fluorescence labelling intensity of 
PSA-NCAM. Sialyltransferase inhibitor ICT-3124 showed no effect on 
polysialylation. It was confirmed that DMSO (0.1%) did not exert any 
effect on PSA-NCAM recovery (Figure 6.4). 
ICT-3125, ICT-3128 and ICT-3147 were therefore selected to progress to 
the next phase. The effect of these compounds on PSA-NCAM 
mobilisation at the surface of IMR-32 cells was assessed (Table 6.3, 
Figure 6.5). CMP, ICT-3124 and DMSO (0.1%) were once again included 
in the screening as treatment controls.  
Consequently and in agreement with the above results, PSA-NCAM 
recovery at the surface of IMR-32 cells was substantially inhibited by 
treatment with ICT-3125 (500 µM) and ICT-3128 (250 µM). ICT-3147 (10 
mM) treatment showed a slight-to moderate reduction in the PSA-NCAM 
fluorescence labelling intensity compared to the untreated controls. 
Moreover, a significant decrease in the fluorescence labelling intensity 
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was observed upon the CMP treatment (10 mM). Neither ICT-3124 nor 
DMSO (0.1%) treatments had any effect (Figure 6.5). 
To summarise, ICT-3125, ICT-3128 and ICT-3147 proved successful in 
preventing PSA-NCAM recovery. ICT-3125 and ICT-3128 proved very 
potent in this regard in both C6-STX and IMR-32 cells, whereas a slight 
to moderate effect was observed with ICT-3147. These studies allowed 
further refinement of the initial panel of 16 compounds, to leave three 
promising candidates. These candidate polyST inhibitors were 
subsequently re-assessed in the migration assays. 
Table 6.3. Effect of promising polyST inhibitors on PSA-NCAM recovery at the 
surface of C6-STX and IMR-32 cells as assessed by PSA-NCAM recovery assay. 
Values shown are normalised to untreated controls (100%) and expressed as means 
±S.D of two independent experiments. (*) P < 0.01. ND: Not Determined. 
Compound Concentration 
PSA-NCAM positive cells (%) 
C6-STX IMR-32 
ICT-3021 100 µM 90.3 ± 5.1 ND 
ICT-3068 100 µM 87.3 ± 6.8 ND 
ICT-3125 500 µM 11.1 ± 4.3* 3.8 ± 1.6* 
ICT-3126 500 µM 95.0 ± 5.6 ND 
ICT-3127 100 µM 95.6 ± 3.7 ND 
ICT-3128 250 µM 0.4 ± 2.3* 2.3 ± 1.7* 
ICT-3147 10 mM 67.5 ± 4.9* 79.0 ± 2.8* 
ICT-3124 100 µM 94.6 ± 3.2 98.9 ± 2.0 
CMP 10 mM 41.8 ± 3.5* 22.0 ± 5.0* 
DMSO 0.1% 98.3 ± 2.4 99.3 ± 2.2 
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EndoNK 0.3 µg/ml PSA-NCAM recovery DMSO 0.1% 
   
CMP 10 mM ICT-3021 100 µM ICT-3068 100 µM 
   
ICT-3124 100 µM ICT-3125 500 µM ICT-3126 500 µM 
   
ICT-3127 100 µM ICT-3128 250 µM ICT-3147 10 mM 
   
 
Figure 6.4. Effect of promising polyST inhibitors on PSA-NCAM recovery at the 
surface of C6-STX cells. C6-STX cells were immunolabelled with anti-PSA-NCAM 
antibody (735) followed by incubation with TRITC-conjugated secondary antibody. 
Results showed the EndoNK treatment had effectively digested PSA-NCAM. Moreover, 
abundantly re-expression of PSA-NCAM was detected within 6 hours. DMSO had no 
effect PSA-NCAM recovery. A significant reduction in PSA-NCAM recovery was exerted 
by CMP treatment. ICT-3125 and ICT-3128 completely inhibited recovery, while a 
slight-to-moderate inhibition was exerted by ICT-3147. Other compounds did not show 
any significant effect on PSA-NCAM recovery compared to controls. Images shown are 
representative of three independent experiments. Scale bare = 50 µm. 
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EndoNK 0.3 µg/ml PSA-NCAM recovery DMSO 0.1% 
   
CMP 10 mM ICT-3124 100 µM ICT-3125 500 µM 
   
ICT-3128 250 µM ICT-3147 10 mM  
   
 
Figure 6.5. Effect of ICT-3125, ICT-3128 and ICT-3147 on PSA-NCAM recovery 
at the surface of IMR-32 cells. IMR-32 cells were immunolabelled with anti-PSA-
NCAM antibody (735) followed by incubation with TRITC-conjugated secondary 
antibody. Results showed EndoNk treatment effectively digested PSA-NCAM at the 
surface of IMR-32 cells. Moreover, abundant re-expression of PSA-NCAM was 
detected within 6 hours. Here, ICT-3124, CMP and DMSO were included as 
treatment controls. DMSO treatment did not affect PSA-NCAM recovery. CMP 
treatment led to a strong inhibition of PSA-NCAM recovery. Complete inhibition of 
PSA-NCAM recovery was observed upon treatment with ICT-3125 and ICT-3128. 
Moreover, ICT-3147 treatment showed a slight-to-moderate inhibition of PSA-NCAM 
recovery. Images shown are representative of three independent experiments. Scale 
bare = 50 µm. 
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6.3.3. Further evaluation of the anti-migratory effects of candidate 
polyST inhibitors 
Following the quantitative measurement of PSA-NCAM inhibition at the 
surface of IMR-32 cells by the selected polyST inhibitors, ICT-3125, ICT-
3128 and ICT-3147, the anti-migratory properties of these compounds 
were extensively assessed by the optimised radius cell migration assay 
and wound healing assay methods, using a wider range of 
concentrations and a further control cell line (DLD-1).  
Using the radius assay, the anti-migratory effects of promising polyST 
inhibitors were examined by treatment of C6-STX, C6-WT and DLD-1 
monolayers with ICT-3125 (100, 250 and 500 µM), ICT-3128 (100 and 
250 µM) and ICT-3147 (5 mM). Moreover, C6-STX, C6-WT and DLD-1 
monolayers were once again treated with ICT-3124 (75 µM) as treatment 
control (Figures 6.6 and 6.7). 
The results showed that the ICT-3124 treatment had no effect on 
migration of C6-STX cells (98%) compared to the untreated control 
(100%). Moreover, migration was significantly decreased by treatment 
with ICT-3125. This inhibition was a concentration-dependent effect 
where significant inhibition was achieved at 500 µM (28%). In the case of 
ICT-3128, migration of C6-STX cells was moderately inhibited at the 
concentration of 100µM, while almost complete inhibition was observed 
at a concentration of 250 µM (17%). In agreement with earlier results, 
treatment of ICT-3147 (5 mM) led to a significant inhibition of the 
migration of C6-STX cells.  
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The migration of C6-WT and DLD-1 cells was not affected by the 
treatment of any inhibitor, with ICT-3125, ICT-3128, ICT-3147 and ICT-
3124 were all ineffective at the concentrations described above (Figures 
6.6 and 6.7).  
Figure 6.6. The effect of selected polyST inhibitors and ICT-3124 on cellular 
migration of C6-STX, C6-WT and DLD1 as assessed by radius assay. ICT-3124 
treatment had no effect on migration of C6-STX, C6-WT and DLD1 cells. ICT-3125 
treatment led to a concentration-dependent reduction in migration of C6-STX cells, with 
near complete inhibition seen at 500 µM. Moreover, ICT-3128 treatment showed a 
moderate decrease in migration of C6-STX cells at concentration of 100 µM and almost 
complete inhibition at a concentration of 250 µM. Furthermore, a significant reduction in 
the migration of C6-STX cells was exhibited by the treatment with ICT-3147. In contrast, 
there was no significant effect on the migration of C6-WT and DLD1 cells upon the 
treatment of any inhibitor. Values are normalized to untreated control (100%) and 
expressed as mean ±SD of three independent experiments (* P<0.01, ** P<0.001). 
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Figure 6.7. Anti-migratory effect of selected polyST inhibitors on C6-STX (60 hours), C6-WT (72 hours) and DLD1 (120 hours) cells as assessed by the 
radius assay. ICT-3124 treatment did not affect the migration of C6-STX, C6-WT and DLD1 cells. A concentration-dependent decrease in migration of C6-STX cells 
was exhibited upon treatment with ICT-3125 where the maximum inhibition was observed at a concentration of 500 µM. Moreover, ICT-3128 treatment led to a 
significant reduction in migration of C6-STX cells at concentration of 100 µM and an almost complete inhibition at 250 µM. ICT-3147 treatment led to a moderate 
decrease in the migration of C6-STX cells. In contrast, all inhibitors exerted no significant effect on the migration of C6-WT and DLD1 cells. Images shown are 
representative of three independent experiments. 
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In parallel, these polyST inhibitors were further evaluated by the 
optimised wound healing assay (Figures 6.8 and 6.9). Here, C6-STX, 
C6-WT and DLD1 monolayers were wounded and incubated with 
medium containing ICT-3125 (500 µM), ICT-3128 (250 µM) and ICT-
3147 (1 mM) for 24 hours. The results confirmed that the 500 µM 
treatment of ICT-3125 led to significant reduction in the migration of C6-
STX cells compared to the controls. Moreover, when C6-STX cells were 
treated with ICT-3128 (250 µM), migration of C6-STX cells was strongly 
inhibited compared to the untreated controls. Furthermore, a slight-to-
moderate decrease in the migration of C6-STX cells was exerted by the 
treatment of ICT-3147 (5 mM). In contrast, the treatments with ICT-3125, 
ICT-3128 and ICT-3147 did not have any significant effect on the 
migration of the C6-WT or DLD1 cells (Figures 6.8 and 6.9).   
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Figure 6.8. The effect of selected polyST inhibitors on cellular migration of C6-
STX, C6-WT and DLD1 as assessed by wound healing assay. The results show that 
treatment with ICT-3128 (250 µM) led to a robust decrease in the migration of C6-STX 
cells compared to untreated controls. Moreover, a moderate inhibition of migration was 
effected by treatment with ICT-3125. ICT-3147 treatment significantly reduced migration 
of C6-STX cells. In contrast, there was no significant effect on the migration of C6-WT 
and DLD1 cells with the treatment of all inhibitors. Values are normalized to untreated 
controls (100%) and expressed as mean ±SD of three independent experiments (* 
P<0.01, ** P<0.001). 
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Figure 6.9. Anti-migratory effect of selected polyST inhibitors on the C6-STX, C6-WT and DLD1 cells as assessed by the wound healing 
assay. The results demonstrated that the C6-STX cells more rapidly repopulated the scratch wound than the C6-WT cells. Moreover, when the C6-
STX cells were treated with selected polyST inhibitors, the migration of C6-STX cells was strongly inhibited by ICT-3128 and moderately inhibited by 
ICT-3125. Furthermore, the ICT-3147 treatment significantly reduced the migration of C6-STX cells. In contrast, the migration of C6-WT and DLD1 
cells was not affected upon the treatment with any polyST inhibitor. Images shown are representative images from two experiments. 
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6.4. Discussion 
The main aim of the work described in this chapter was to utilise a cell-
based screening cascade to assess the pharmacological effects of novel 
polyST inhibitors. The first phase of this screening cascade consisted of 
testing the pharmacological effects of novel polyST inhibitors on cell 
migration.  
In the previous chapter, we saw that the radius assay provided a robust 
model for studying the effects of agents on cell migration, as 
demonstrated by biological (EndoN) and chemical means (CMP). The 
small molecule inhibitor approach was therefore deemed promising and 
worthy of further study. On this basis, small molecule polyST inhibitors 
were hypothesised to decrease cell-surface PSA-NCAM biosynthesis 
and thereby modulate cell migration.  
From the initial panel of 16 compounds evaluated in the migration assay, 
7 compounds demonstrated an ability to reduce the migration of C6-STX 
cells, namely ICT-3021, ICT-3068, ICT-3125, ICT-3126, ICT-3127, ICT-
3128 and ICT-3147. Moreover, the behaviour of the controls (CMP, 
EndoNF and DMSO) suggests the reliability and reproducibility of radius 
assay method for screening of novel polyST inhibitors.  
In terms of the different sub-classes of compounds of the six substrate-
inspired inhibitors, ICT-3021 emerged as promising, demonstrating a 
significant reduction in migration (55% migration of control) at 75 μM.  
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The success of the cell-free screening process to identify promising 
compounds was proven when the compounds identified from virtual 
screening were evaluated. Four compounds were originally selected 
representing two of the most promising (ICT-3068, ICT-3125), one 
intermediate (ICT-3071) and one rejected compound (ICT-3069) from the 
in vitro enzyme inhibition assay and were tested blind. ICT-3069 and 
ICT-3071 did not show significant anti-migratory activity. ICT-3068 
demonstrated toxicity at 100 μM, but on reducing the concentration to 10 
μM, showed promise (migration 63% of control). ICT-3125 was non-toxic, 
more water soluble, and demonstrated inhibition at 100 μM (migration 
71% of control).  
Given the promise seen for ICT-3125 in the cell-free screen, two 
analogues ICT-3126 and ICT-3127 were also evaluated. ICT-3126 is a 
structural analogue, whereas ICT-3127 is a prodrug of ICT-3125 in which 
a carboxyl group is esterified to mask its negative charge and facilitate 
membrane permeability (see Table 6.1 for structures). ICT-3126 
produced activity similar to that observed with ICT-3125, also at 100 μM. 
The ester prodrug ICT-3127 however, showed a slight increase in 
potency with similar effects to ICT-3125 (100 μM) being observed at 75 
μM. However, ICT-3127 suffered from poor aqueous solubility (discussed 
later). 
The N-acylmannosamines ICT-3147 and ICT-3128 also proved 
interesting, demonstrating effective inhibition of migration in the C6 
model. The permissiveness (capability to accept modified substrates) of 
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polySTs has been previously exploited in a number of studies [109-111, 
145], as described previously in Chapter 1 (section 1.5.2).  
Given the lack of reported polyST inhibitors in literature, this class of 
compound was explored along with CMP, to demonstrate the potential of 
this approach. In this context, ManNProp (ICT-3147) and its acetylated 
derivative (ICT-3128) were utilised in the work described in this chapter. 
ICT-3147 proved completely ineffective at 100 μM. Given the hydrophilic 
nature of the compound, this was to be expected. Very high 
concentrations were required to produce significant anti-migratory effects 
(in the mM range). However, despite the high concentrations no toxicity 
was observed, which is consistent with the compounds being sugar 
molecules with minor modifications. The acetylated version of 
ManNProp, ICT-3128, proved highly potent in comparison. In agreement 
with the inhibition data previously discussed, this compound achieved 
similar anti-migratory effects to ICT-3147 at 100 μM. Acetylation of this 
molecule improved its potency by more than 50-fold in this assay.   
Since several inhibitors proved promising in modulating the migration of 
C6-STX cells, it was necessary to confirm that these effects were indeed 
due to a reduction in PSA-NCAM through polyST inhibition and not 
through another mechanism. Our first approach was to evaluate these 
compounds at similar concentrations in the C6-WT cell line. This cell line 
is identical to C6-STX, except for an absence of the polyST enzymes. All 
compounds demonstrated no inhibition of migration, including controls 
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CMP and EndoNF. This is sound evidence that the observed effects 
were polyST (STX)-related.  
Further proof that effects of inhibitors were due to polyST inhibition was 
sought using the PSA-NCAM recovery assay. This assay was described 
in the literature as very effective in assessing PSA-NCAM recovery at the 
surface of neurons and endocrine cells upon various conditions of cell 
activity [131]. Moreover, and as described in the previous chapter, CMP 
effectively delayed PSA-NCAM recovery at the surface of C6-STX and 
IMR-32 cells.  
The time-frame of this experiment was short (6 hours) compared to the 
migration assay so higher concentrations were employed in order to 
maximise the opportunity to detect retardation in PSA-NCAM re-
expression (these higher concentrations were subsequently used in later 
migration assay studies). Consequently, PSA-NCAM recovery on the 
surface of C6-STX cells was significantly reduced following ICT-3147 (10 
mM) treatment and was completely inhibited by the ICT-3125 (500 µM) 
and ICT-3128 (250 µM) treatments. These results were further validated 
in the IMR-32 cell line that encodes both the STX and PST enzymes [84, 
130]. At similar concentrations, treatment with ICT-3147 led to a 
significant decrease in PSA-NCAM recovery at the surface of IMR-32 
cells while complete inhibition was observed for ICT-3125 and ICT-3128.  
ICT-3124 (lithocholic acid) was included in the screening process as it is 
reported as an α-2,3-sialyltransferase inhibitor and therefore represented 
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a negative treatment control [144]. Neither ICT-3124 nor DMSO had any 
effect on the cell migration and PSA-NCAM recovery. 
The concentrations of several agents were insufficient to observe a 
measurable response (ICT-3021, ICT-3068 and ICT-3127). Unfortunately 
these agents had insufficient aqueous solubility to allow further analysis. 
Further structural modifications would be required to improve solubility 
and potentially efficacy. ICT-3126, a structural analogue of ICT-3125, 
showed no significant PSA-NCAM inhibition at 500 μM. ICT-3125 and 
ICT-3128 both produced a very significant reduction in PSA-NCAM 
expression at the concentrations tested.  
The acetylated derivative of N-proponylmannasomine (ICT-3128) proved 
to be a very potent inhibitor of PSA-NCAM recovery compared to parent 
compound N-proponylmannasomine (ICT-3147). This was in agreement 
with previous studies demonstrating that acetylated N-
proponylmannasomine (ICT-3128) was more potent in inhibiting PSA-
NCAM synthesis by at least 30 fold [109] compared to a slight to 
moderate reduction exerted by the parent compound N-
proponylmannasomine [109, 110, 146]. Acetylation increased the 
lipophilicity of N-proponylmannasomine,  which in turn increased passive 
diffusion through the cell membrane, thereby increasing potency [109].  
In a more pharmacologically extensive assessment of cell migration, the 
anti-migratory effects of ICT-3125, ICT-3128 and ICT-3147 were further 
characterised in both migration assays, incorporating the higher 
concentrations used in the recovery assay. The radius assay analysis 
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showed that a concentration dependent inhibition of migration of C6-STX 
cells was exerted by ICT-3125 treatment. Moreover, a nearly complete 
inhibition of the migration of C6-STX cells was exhibited by ICT-3128 
(250 µM), whilst a moderate inhibition was exerted with parent compound 
ICT-3147 (5 mM). Furthermore, ICT-3125 (500 µM) and ICT-3128 (250 
µM) treatments showed comparable inhibition to that obtained by the 
EndoNF treatment, where almost complete inhibition was achieved. 
These higher concentrations, previously shown to significantly reduce 
PSA-NCAM expression in the recovery assay showed the enhanced 
effects on cell migration consistent with this. As anticipated, the 
treatment control ICT-3124 (mono-ST inhibitor) had no effect on the 
migration of C6-STX, C6-WT and DLD1 cells. None of the above 
treatments had any effect on the migration of C6-WT and DLD1 cells 
neither of which expresses either the polyST enzymes or PSA-NCAM.  
In line with results above, the wound healing assay analysis 
demonstrated that all compounds exhibited inhibitory effects on the 
migration of C6-STX cells whilst no effect was observed on the migration 
of C6-WT and DLD1 cells. However, the anti-migratory effects of 
inhibitors suggested lower compound potency, compared to that 
exhibited by the inhibitors at the same concentrations in the radius 
assay. 
These results may be explained by the treatment time - polyST inhibitor 
treatment in the radius assay was longer (72 hours) than in the wound 
healing assay (24 hours). This was in line with many studies in the 
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literature, where cells under investigation were incubated with unnatural 
sugars for at least 72 hours allowing the cellular sialylation machinery to 
readily synthesise the respective N-acyl sialosides [109, 110, 146]. 
Consequently, longer treatment times allow the cells to readily take up 
the polyST inhibitors and therefore block the PSA-NCAM biosynthesis 
more efficiently. 
In summary, a screening cascade was successfully established, allowing 
effective assessment of novel polyST inhibitors. These data strongly 
support the hypothesis that small molecule inhibitors of polySTs lead to 
modulation of PSA-NCAM on the tumour cell surface, as exemplified in 
the C6 glioma and neuroblastoma cell lines. Reduction in PSA-NCAM 
leads to a reduction in cell migration as evidenced by the cell-based 
assays. From 16 compounds identified in an in vitro screen of polyST 
inhibition, three compounds emerged from this work as promising. These 
compounds were ICT-3125 (identified from virtual screening) and N-
acylmannosamine compounds ICT-3147 and ICT-3128. Other 
compounds were also potentially interesting but their utility was limited by 
poor aqueous solubility and further structural modification is required to 
improve their effectiveness. 
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7. General discussion and future perspectives 
The key rationale for this study addresses the poor therapeutic options 
currently available for the treatment of neuroblastoma. Neuroblastoma is 
a highly aggressive and invasive tumour, and despite recent advances in 
disease management, mortality is still high due to uncontrolled metastatic 
disease [147]. Furthermore, current treatments for neuroblastoma are not 
satisfactory due to drug-resistant residual disease, long term toxicities 
and reduced survival [13, 147]. Therefore new strategic approaches to 
neuroblastoma treatment are needed. 
Research has begun to focus on alternative targets for therapy including 
angiogenesis, invasion, migration and metastasis. The success of 
therapeutics in these areas has yet to be realised, with toxicities being 
observed. With this in mind, the focus of the research described in this 
thesis is the polyST enzymes responsible for the biosynthesis of 
polysialic acid, which has an important role in the tumour dissemination 
process. 
The polyST enzymes that synthesise PSA-NCAM represent an extremely 
attractive drug target.  PSA-NCAM is aberrantly re-expressed on the cell 
surface of many tumours, including neuroblastoma [71-75]. The fact that 
PSA-NCAM expression disappears elsewhere in the body soon after 
birth, and is only detected in certain areas of the brain in adulthood 
suggests that the polySTs are selective targets for the development of a 
new therapeutic strategy for neuroblastoma.  
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On this basis, the hypothesis that was formulated was that interfering 
with PSA-NCAM biosynthesis by designing small molecules that 
selectively inhibit polySTs would lead to a decrease in PSA-NCAM 
expression on the surface of tumour cells, thereby altering the processes 
associated with tumour cell dissemination.  
Although several studies have reported high PSA-NCAM expression in 
neuroblastoma [71-75], this study is the first to attempt to link expression 
of PSA-NCAM with other proteins involved in NCAM signalling. 
Moreover, it is also the first study to examine PSA-NCAM expression in 
the different cell phenotypes seen in neuroblastoma as a result of its 
heterogeneity. Prior to evaluation in clinical samples, PSA-NCAM 
expression was initially investigated in human xenografts. The 
methodologies were optimised successfully. PSA-NCAM was widely 
expressed in neuroblastoma while other tumour types (colorectal 
carcinoma, fibrosarcoma and bladder cancer) were negative for PSA-
NCAM expression. This was consistent with previous findings of PSA-
NCAM overexpression in neuroblastoma human xenografts [85]. 
These results were promising and encouraged evaluation of PSA-NCAM 
co-expression with other proteins involved in NCAM signalling in clinical 
samples. I was very fortunate to have access to a panel of 17 
neuroblastoma patient samples through our collaboration with St. James’ 
Hospital in Leeds. This was a precious resource given the scarcity of 
such clinical material and the difficulties in obtaining it. This meant I was 
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able to use the methodology that was optimised in the xenograft studies 
to investigate expression in clinical tissues. 
Whereas promising trends were evident in differential expression of PSA-
NCAM and other molecules including NCAM, FGFR, TrkB and ERK 1/2 
across all patient samples tested, caution should be exercised given that 
these were preliminary studies: the sample size was small and 
consequently the results were not statistically significant. Furthermore, 
and unfortunately, statistically significant correlations between PSA-
NCAM expression and presence of signalling molecules could not be 
established. However, some interesting findings did emerge. 
Higher PSA-NCAM expression was found in neuroblastoma than in 
ganglioneuroblastoma and ganglioneuroma. This indicated that PSA-
NCAM was more frequently expressed in more aggressive tumours 
(neuroblastoma) than in benign tumours (ganglioneuroma). These results 
were further supported by the fact that high PSA-NCAM expression was 
found in neuroblastic cells than in other cell phenotypes. This suggests 
that PSA-NCAM expression facilitates tumour dissemination by 
promoting tumour invasion and metastasis, and supports our hypothesis.  
Given the promising trends seen for this small patient cohort, it is clear 
that further evaluation is required. A larger sample of neuroblastoma 
patients is warranted to generate sufficient data to strengthen statistical 
analysis. As well as examining the relationships carried out here, the 
study would also investigate relationships between co-expression of 
PSA-NCAM and sex, age, histology, INPC classification and tumour 
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stage. These correlations will give further biological insights into the 
prognostic and therapeutic value of PSA-NCAM as well as the influence 
of PSA-NCAM expression on the FGFR, TrkB and ERK1/2 signalling 
pathways, all thought to be very important in PSA-NCAM signalling. In 
order to obtain a more quantitative evaluation of expression, the co-
expression of PSA-NCAM, FGFR, TrkB and ERK1/2 could be studied in 
fresh tissue. This would enable a more quantitative measure of 
expression than immunohistochemical evaluation of archival paraffin 
material permits. 
As cellular heterogeneity is a characteristic for neuroblastoma-derived 
cell lines [126-128], it was important to assemble a panel of cell lines with 
a range of PSA-NCAM expression types suitable to screen novel polyST 
inhibitors. 
Whilst the variety in PSA-NCAM expression seen for the lines in this 
panel makes it ideal as a screening tool, the cellular heterogeneity seen 
with time in culture for the neuroblastoma cell lines is something that 
would be interesting for further investigation. Other neuroblastoma lines 
(such as SH-SY5Y, SK-N-BE, SMS-KCN, SMS-KCNR, LAN-I and LA-N-
5) have similar issues with cellular heterogeneity [148] and these should 
also be characterised to see if they can add value in terms of their 
expression patterns compared to the lines in the panel. These cell lines 
should ideally grow as adherent cell monolayers to enable use in 
adhesion, invasion and migration assays. Moreover, it would be more 
interesting to make use of this panel of cell lines as models to investigate 
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the impact of PSA decoration on NCAM signalling and associated effects 
on the tumour cell proliferation and differentiation. This investigation 
would be beneficial in assessing the effects of polyST inhibitors on 
tumour cell proliferation and differentiation. Specifically, it would be 
interesting to assess the role of NCAM polysialylation on FGFR, TrkB 
and ERK1/2 signalling pathways in these cell models. This would further 
support results of the clinical study and give more biological insights in 
evaluating the effects of polyST inhibitors on the PSA-NCAM signalling 
partners. 
In this project, several cell-based screens for pharmacological testing of 
novel polyST inhibitors have been successfully optimised. These screens 
represent reliable and reproducible practical approaches to investigate 
the functional effects of PSA-NCAM inhibition. It was demonstrated that 
PSA-NCAM expression promotes tumour cell migration. This was 
validated by biological removal of PSA-NCAM using endoN. Moreover, it 
was demonstrated that CMP effectively reduces PSA-NCAM expression 
on the surface of tumour cells and that directly decreases cell migration. 
Reduction of PSA-NCAM expression through inhibition of polySTs has 
been achieved previously (using CMP and N-acylmannosamines, as has 
been discussed) but this is the first example of a small molecule leading 
to a reduction in PSA-NCAM-mediated cell migration. 
Beyond cell migration, the next step would be to examine the role of 
PSA-NCAM in other facets of the tumour dissemination process such as 
adhesion and invasion. This would enable a better understanding of the 
222 
 
elements of the metastatic process before ultimately progressing to in 
vivo models. The role of PSA-NCAM in these areas would be validated in 
relevant assays by biological (endoN) and chemical interventions. 
Moreover, assays evaluating these facets of tumour dissemination 
process would also be utilised as screening platforms for novel polyST 
inhibitors.  
To gain further insight into the biological and pharmacological role of 
PSA-NCAM expression in the tumour dissemination process, genetic 
manipulation techniques to knockdown polySTs and therefore PSA-
NCAM expression on the surface of tumour cells could also be utilised. 
Although the endoN enzyme removes PSA-NCAM expression, which I 
have confirmed to modulate cell migration, there is still the question as to 
whether any small molecule inhibitor is selective for the polyST enzymes, 
or additionally acts by alternative pathways. The evidence for selectivity 
is strong – the compounds had no effect on C6-WT cells – but 
experiments that knock-down the target (e.g. using siRNA) would enable 
further confirmation of compound selectivity for the polyST enzymes. It 
would also allow investigation into whether the toxicity seen with some 
agents is polyST-related, which would determine if polyST inhibition also 
has anti-proliferative potential.  
As has been established, the inhibition of polySTs to modulate PSA-
NCAM synthesis as a therapeutic opportunity is a novel approach. There 
has been a limited work in this area focusing on the use of CMP-based 
sialyltransferase inhibitors and N-acylmannosamines to target PSA-
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NCAM synthesis on the surface of cells (previously discussed in section 
1.5.2) [108-112]. However, there are no reports for selective inhibitors of 
polySTs in literature so far. On this basis, this is the first example of a 
study exploring rationally designed inhibitors of polySTs.  
The discovery of these novel inhibitors was based on a “substrate-
inspired” approach and virtual screening. These inhibitors were 
effectively and successfully assessed in well validated cell-based 
screens. From the 16 compounds identified in an in vitro screen of 
polyST inhibition, three compounds were identified as promising. These 
were ICT-3125 (identified from virtual screening) and N-
acylmannosamine compounds ICT-3147 and ICT-3128. Other 
compounds were also interesting; however measurable responses were 
not observed due to insufficient aqueous solubility. Taken together, this 
is the first example of compounds directly affecting the polysialylation of 
NCAM and subsequently the migration of tumour cells. These novel 
findings strongly support further analysis and development of these 
promising inhibitors.  
Of the three compounds, the most promising is ICT-3125. This is a novel 
polyST inhibitor that was successfully identified through virtual screening, 
thus contains a drug-like pharmacophore and has satisfactory solubility 
in aqueous media meaning its properties are most likely to be favourable 
for drug development. As well as its inhibitory activity, encouragingly this 
molecule did not exert any cytotoxic effect on cells, even at high 
concentrations.   
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Compounds ICT-3147 and ICT-3128 are less promising as leads for drug 
development. These compounds are N-acetylmannosamine analogues 
(i.e. they are sugars) and therefore need to progress through all steps of 
the sialic acid pathway in order to generate the corresponding metabolic 
counterpart to exert their action. These compounds are very hydrophilic 
in nature and therefore have poor cell membrane permeability. 
Furthermore, since these compounds are carbohydrate derivatives, they 
are likely to possess poor pharmacokinetic properties and one would 
expect them to be rapidly eliminated from the body [149]. 
The next phase for ICT-3125 would be to focus on structural refinement, 
to explore areas of the molecule that are important for activity, potency 
and selectivity, in other words to generate a structure-activity 
relationship. Any modifications to the structure would need to maintain 
the balance between sufficient aqueous solubility to enable dissolution 
and lipophilicity and enable membrane transport and therefore passage 
into the cell. 
Of the compounds that proved less interesting with some suffering from 
poor aqueous solubility, structural modifications to improve solubility are 
still warranted, as it may be that this would lead to promising polyST 
inhibitory activity.   
As has been discussed, changes in cell adhesion are characteristic for 
neuroblastoma tumour development and are directly associated with the 
processes of tumour cell invasion, migration and metastasis. These 
steps are necessary for neuroblastoma tumour dissemination [150]. Thus 
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by targeting these processes, tumour burden would be reduced. On this 
basis, as well as assessing migration, the effects of these novel polyST 
inhibitors should also be assessed in assays addressing other facets of 
the tumour dissemination process, such as adhesion and invasion. This 
should give further guidance on where in the process inhibition of polyST 
has a role in control of neuroblastoma and will help to shape the 
strategies for treatment. 
The results outlined in this thesis represent a very positive start for the 
development of polyST inhibitors as a potential therapy for 
neuroblastoma. However, much work still needs to be done as discussed 
above before a candidate molecule is selected for progression to 
evaluation in animal models. This will be potentially very challenging. The 
in vivo activity of cytotoxic molecules is usually assessed by monitoring 
tumour shrinkage in xenograft models [101]. Molecules that act on the 
metastatic process will not necessarily have direct effects on tumour 
growth and therefore alternative models are required to investigate this.  
Promisingly, a number of metastatic models already exist where PSA-
NCAM-expressing cell lines have been utilised, for example the 
production of liver metastases following intrasplenic injection of 
neuroblastoma cells in immunodeficient mice [151]. Other examples 
include a rhabdomyosarcoma [69], and a pituitary tumour model [59]. In 
the rhabdomyosarcoma model, lung and liver metastases were formed 
following the intravenous, intramuscular and intraperitoneal injections of 
naturally PSA-NCAM expressing human rhabdomyosarcoma cells [69], 
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whilst in the pituitary model, kidney invasion and metastatic nodules were 
observed following the transplantation of high PSA-NCAM expressing rat 
pituitary tumour cells under the kidney capsule and subcutaneously [59]. 
The incorporation of non-invasive imaging techniques will permit real-
time monitoring of tumour progression, metastasis and the longitudinal 
effects of drug therapy and importantly will reduce and refine the number 
of animals used [152]. 
Alongside these studies in metastatic models in vivo, candidate 
agents would need to be assessed and optimised to ensure the 
molecules possess efficient pharmacokinetic and metabolic profiles. It 
may be that this type of therapeutic would be need to be administered 
continually to suppress metastasis, in which case an oral dosage 
form would be preferable. In addition, an investigation into any 
off-target effects – e.g. cardiotoxicity, neurotoxicity and effects on blood 
composition would be required. 
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7.1. Conclusion 
It is clear that the current therapeutic options for treatment of 
neuroblastoma are poor and that there is a pressing need for the 
identification of a therapeutic strategy that can improve patient survival.  
In this thesis, strong in vitro evidence that supports the potential of one 
such new strategy, namely the targeting of the polyST enzymes, is 
presented. This work strongly supports the hypothesis that inhibition of 
the polyST enzymes reduces PSA-NCAM expression, thereby 
modulating tumour dissemination. This target therefore presents an 
opportunity to reduce metastatic burden in neuroblastoma, and thus 
overcome the main problem with the lack of success of current therapies 
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